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Background: Collaborative care is effective for depression management in the USA. There is little UK
evidence on its clinical effectiveness and cost-effectiveness.
Objective: To determine the clinical effectiveness and cost-effectiveness of collaborative care compared
with usual care in the management of patients with moderate to severe depression.
Design: Cluster randomised controlled trial.
Setting: UK primary care practices (n= 51) in three UK primary care districts.
Participants: A total of 581 adults aged ≥ 18 years in general practice with a current International
Classification of Diseases, Tenth Edition depressive episode, excluding acutely suicidal people, those with
psychosis, bipolar disorder or low mood associated with bereavement, those whose primary presentation
was substance abuse and those receiving psychological treatment.
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Interventions: Collaborative care: 14 weeks of 6–12 telephone contacts by care managers; mental health
specialist supervision, including depression education, medication management, behavioural activation,
relapse prevention and primary care liaison. Usual care was general practitioner standard practice.
Main outcome measures: Blinded researchers collected depression [Patient Health Questionnaire-9
(PHQ-9)], anxiety (General Anxiety Disorder-7) and quality of life (European Quality of Life-5 Dimensions
three-level version), Short Form questionnaire-36 items) outcomes at 4, 12 and 36 months, satisfaction
(Client Satisfaction Questionnaire-8) outcomes at 4 months and treatment and service use costs at
12 months.
Results: In total, 276 and 305 participants were randomised to collaborative care and usual care
respectively. Collaborative care participants had a mean depression score that was 1.33 PHQ-9 points lower
[n= 230; 95% confidence interval (CI) 0.35 to 2.31; p= 0.009] than that of participants in usual care at
4 months and 1.36 PHQ-9 points lower (n= 275; 95% CI 0.07 to 2.64; p= 0.04) at 12 months after
adjustment for baseline depression (effect size 0.28, 95% CI 0.01 to 0.52; odds ratio for recovery 1.88,
95% CI 1.28 to 2.75; number needed to treat 6.5). Quality of mental health but not physical health was
significantly better for collaborative care at 4 months but not at 12 months. There was no difference for
anxiety. Participants receiving collaborative care were significantly more satisfied with treatment.
Differences between groups had disappeared at 36 months. Collaborative care had a mean cost of £272.50
per participant with similar health and social care service use between collaborative care and usual care.
Collaborative care offered a mean incremental gain of 0.02 (95% CI –0.02 to 0.06) quality-adjusted
life-years (QALYs) over 12 months at a mean incremental cost of £270.72 (95% CI –£202.98 to £886.04)
and had an estimated mean cost per QALY of £14,248, which is below current UK willingness-to-pay
thresholds. Sensitivity analyses including informal care costs indicated that collaborative care is expected to
be less costly and more effective. The amount of participant behavioural activation was the only
effect mediator.
Conclusions: Collaborative care improves depression up to 12 months after initiation of the intervention,
is preferred by patients over usual care, offers health gains at a relatively low cost, is cost-effective
compared with usual care and is mediated by patient activation. Supervision was by expert clinicians
and of short duration and more intensive therapy may have improved outcomes. In addition, one
participant requiring inpatient treatment incurred very significant costs and substantially inflated our cost
per QALY estimate. Future work should test enhanced intervention content not collaborative care per se.
Trial registration: Current Controlled Trials ISRCTN32829227.
Funding: This project was funded by the Medical Research Council (MRC) (G0701013) and managed by
the National Institute for Health Research (NIHR) on behalf of the MRC–NIHR partnership.
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Plain English summary
Depression causes misery to many people and is a major health problem in the UK. Although effectivetreatments are available, many people do not have access to them and we are always looking for
treatments that are easier and quicker for patients to receive. New ways of organising treatment have
been developed in the USA but we do not know if they are better than usual care in the UK.
In this study we compared a way of organising treatment for depression called collaborative care with the
usual care given by general practitioners (GPs). Collaborative care involves a care manager talking to
patients regularly on the telephone to give advice about depression and increasing patient activity, helping
people make the best use of medical treatments from their GP and co-ordinating care between GPs
and specialists.
We found that the people seeing a care manager improved more than those receiving usual care.
These results were seen at 4 months and 12 months after collaborative care started. We also found that
collaborative care was affordable to the NHS. When we followed up people after 3 years we no longer
found a difference between the groups. What seemed to make collaborative care work best was when
patients were successful in carrying out more routine, pleasurable and necessary activities in their lives.
We recommend that any further research should concentrate on improving the treatments that care
managers can use to help people as we think that the collaborative care system itself is effective
and affordable.
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Scientific summary
Background
Depression results in substantial disability and is recognised as a major health problem; it is currently the
second largest cause of global disability. Around 350 million people are impacted by depression across
the world and each year up to 5.8% of men and 9.5% of women will suffer from an episode of
depression. Depression has a very significant impact on physical health, occupational functioning and the
social lives of sufferers. Often anxiety is also present, causing further disability.
A systematic review of 36 organisational intervention studies concluded that simple models such as
guidelines and practitioner education were ineffective in improving the management of depression.
However, evidence is stronger on the role of organisational interventions in improving the management
of a range of chronic conditions. The application of organisational strategies to the management of
depression includes ‘collaborative care’, a complex intervention developed in the USA. Previous reviews
of the management of depression have identified collaborative care as the most effective of
organisational approaches.
Collaborative care incorporates a multiprofessional approach to patient care; a structured management
plan; scheduled patient follow-ups; and enhanced interprofessional communication. In practice, this is
achieved by the introduction of a care manager into primary care, responsible for delivering care to
depressed patients under supervision from a specialist and for liaising between primary care clinicians and
mental health specialists. Systematic reviews demonstrate that collaborative care improves depression
outcomes, with some studies showing benefit for up to 5 years.
In 2008, at the commencement of the CollAborative DEpression Trial (CADET), collaborative care had
generally been developed and tested in the USA within managed health-care settings. The limited non-US
data and the relatively small effect size in trials of patients with depression alone led the UK National
Institute for Health and Care Excellence (NICE) to issue a research recommendation that ‘The efficacy
of organisational interventions, such as chronic disease management programmes or other programmes of
enhanced care for depression, should be tested in large-scale multicentre trials in the NHS’. This provided
us with the rationale to undertake a fully powered UK evaluation of collaborative care. Prior to this trial in
a Phase II test, we found preliminary evidence that collaborative care adapted to the UK was acceptable
to patients and clinicians and may be effective outside the USA, but that a cluster randomised controlled
trial was required to guard against potential contamination between trial arms.
Objectives
l To determine the clinical effectiveness and cost-effectiveness of collaborative care compared with usual
care in the management of patients with moderate to severe depression.
l To investigate the potential moderators of differential participant response, the possible mechanisms of
symptom change and the process of implementation of collaborative care.
Design
This study was a cluster randomised controlled trial.
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Setting
This study took place in 51 UK primary care practices in three UK primary care districts.
Participants
A total of 581 adults aged ≥ 18 years who met International Classification of Diseases, Tenth Edition
(ICD-10) criteria for a depressive episode on the revised Clinical Interview Schedule were included in the
trial. We excluded acutely suicidal patients and those with psychosis or type I or type II bipolar disorder,
patients whose low mood was associated with bereavement or whose primary presenting problem was
alcohol or drug abuse and those receiving psychological treatment for their depression from specialist
mental health services. We identified potentially eligible participants by searching general practice
computerised case records for patients with depression.
Randomisation
We randomly allocated primary care practices to either collaborative care or treatment as usual as they
were recruited into the trial, minimised within sites by Index of Multiple Deprivation (IMD) rank, number of
general practitioners (GPs) and practice size.
Allocation concealment
The allocation sequence was concealed from researchers who recruited practices and was administered
centrally by the trial statistician using Minim (www.sghms.ac.uk/depts/phs/guide/randser.htm). The
Peninsula Clinical Trials Unit (PenCTU) remotely managed participant identification and the trial databases.
Blinding
Research workers blind to practice allocation assessed participants for eligibility and collected outcome
measures using participant self-report questionnaires to minimise the effect of potential unblinding.
Because of the nature of the intervention, it was not possible to blind participants, care managers or GPs
to allocations.
Interventions
Collaborative care
Developed in our previous studies, collaborative care was delivered by a team of care managers, supervised
by mental health specialists. Supervision of care managers for their trial work was provided by psychiatrists
and psychological therapists from the trial team. During sessions, care managers:
l assessed participants’ views of depression and their attitudes to and concordance with psychosocial
and pharmacological treatments
l negotiated shared treatment decisions with participants
l assisted participants to manage antidepressant medication if prescribed
l delivered a brief low-intensity psychosocial intervention in the form of behavioural activation
l provided participants with relapse prevention advice.
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Usual care
Participants received care from their GP according to usual clinical practice, which for these participants
included treatment with antidepressants and referral for other treatments. We recorded every aspect of
usual care but did not specify a treatment programme, in line with the pragmatic nature of this trial.
Measures
Baseline information
We collected demographic data at baseline through a purposely designed form. We recorded data on sex,
age, ethnic origin, education level, employment, marital status, presence or absence of antidepressant
treatment, previous history of depression, severity of depression, any secondary diagnosis of an anxiety
disorder, any long-standing physical illness, health and social care resource use by participants over the
previous 6 months and informal care from friends/relatives, and patient costs over the previous 6 months.
Primary clinical outcome
Our primary clinical outcome was individual participant depression severity measured by the [Patient Health
Questionnaire-9 (PHQ-9)] at 4 months.
Secondary clinical outcomes
Our secondary outcomes were the PHQ-9 at 12 months, quality of life [Short Form questionnaire-36 items
(SF-36)], worry and anxiety [General Anxiety Disorder-7 (GAD-7)] at 4 and 12 months, health state values
(health-related quality-of-life) [European Quality of Life-5 Dimensions three-level version (EQ-5D-3L)] at
4 and 12 months and participant satisfaction (Client Satisfaction Questionnaire-8) at 4 months. We also
collected PHQ-9, GAD-7 and SF-36 data at 36 months.
Economic outcomes
Our primary economic end point was the cost per quality-adjusted life-year (QALY) at 12 months’ follow-up.
We derived these QALY estimates using EQ-5D-3L trial data from the baseline and 4- and 12-month
assessments, applying the area under the curve approach, a recognised approach for assessing repeated
measures. We collected resource use associated with delivery of the collaborative care intervention within
the trial, consisting of care manager contact time and supervision of care managers by specialists. We
collected other health and social care resource use by participants over the 12-month follow-up and data
on informal care from friends/relatives and patient costs using self-report, interviewer-administered
questionnaires (at 4 and 12 months, covering the previous 4-month and 8-month time periods, respectively).
Process analysis outcomes
At baseline we recorded six possible moderators: measures of patient attitudes towards antidepressant
medication, attitudes towards behavioural activation, depression severity (PHQ-9), history of depression
(number of previous episodes), physical health (comorbidity) and socioeconomic status using the
postcode for participants’ residence to obtain an IMD score at the lower super output area level.
We measured participants’ adherence to antidepressant medication and level of behavioural activation at
4 and 12 months through self-report of medication adherence and the Behavioural Activation for
Depression Scale – Short Form. We conducted face-to-face interviews with care managers and
supervisors involved in delivering and supervising collaborative care and undertook telephone interviews
with a sample of GPs from intervention practices. We used routinely collected data from session audio
tapes collected by care managers for supervision to analyse the process of implementation.
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Sample size
We powered the trial at 90% (alpha= 0.05) to detect an effect size of 0.4, which we regarded as a
clinically meaningful difference between interventions. This figure was within the 95% confidence interval
(CI) of the effect predicted from data collected during our pilot work (effect size 0.63, 95% CI 0.18 to
1.07). To detect this difference would have required 132 participants per group in a two-armed
participant-randomised trial. For our cluster trial, with 12 participants per primary care cluster and an
intracluster correlation (ICC) of 0.06 from our pilot trial, the design effect was 1.65 leading to a sample
size of 440. To follow up 440 participants, we aimed to randomise 550 participants (anticipating 20%
attrition). Because recruitment would not be uniform between practices, we aimed to recruit 48 practices
with up to 14 participants in a practice.
Statistical methods and analyses
Clinical outcomes
We undertook intention-to-treat analyses for all outcomes, reported in accordance with Consolidated
Standards of Reporting Trials (CONSORT) guidelines. All analyses were undertaken in Stata 10.1
(StataCorp LP, College Station, TX, USA), following a predefined analysis plan agreed with the Trial
Steering Committee. We analysed outcome data at 4, 12 and 36 months by ordinary least squares or
logistic regression, allowing for clustering by use of robust standard errors, adjusting at the cluster level for
minimisation variables and site and at the individual level for age and, when appropriate, the baseline
measurement of the variable. We analysed the effect of missing data as a sensitivity analysis, estimated by
chained regression equations multiple imputation using all available scale clinical scores, age, sex, practice
variables, site and treatment group.
Economic outcomes
We adopted the perspective of the UK NHS and Personal Social Services (third-party payer perspective),
with a broader participant and carer perspective considered in sensitivity analyses. We estimated the costs
associated with health and social care service use and the additional cost for delivery of the collaborative
care intervention and estimated QALYs. The primary economic analyses estimated mean cost and mean
QALYs by treatment allocation and used prespecified covariates for age (at the individual level) and
deprivation (IMD), site and practice size (at the cluster level). We used a multilevel regression model for the
primary analyses, to consider the hierarchical (clustered) nature of the data, presenting the ICC for the
main analyses.
Process data
To explore the role of moderators, we analysed the direct effects of our six baseline covariates on
depression severity (PHQ-9) at 4 and 12 months using multilevel multiple linear regression. Potential
mediating effects of collaborative care were investigated using structural equation modelling in Stata.
We used an iterative approach using constant comparison techniques to analyse interview transcripts.
Following the thematic analysis we conducted a further theory-driven analysis of the data guided by the
four main constructs of normalisation process theory. We analysed the implementation of the intervention
by transcription and analysis of audio files using a thematic analysis similar to that for the interview data.
Results
Collaborative care participants had a mean depression score that was 1.33 PHQ-9 points lower (95% CI 0.35
to 2.31; p= 0.009) than that of participants in usual care at 4 months and 1.36 PHQ-9 points lower (95% CI
0.07 to 2.64; p= 0.04) at 12 months after adjustment for baseline depression. Quality of mental health
but not physical health was significantly better for collaborative care at 4 months but not 12 months and there
was no difference for anxiety. Participants receiving collaborative care were significantly more satisfied with
treatment. There were no differences between groups at 36 months’ follow-up.
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Collaborative care had a mean cost of £272.50 per participant with similar health and social care service
use between collaborative care and usual care. Collaborative care offered a mean incremental gain of 0.02
(95% CI –0.02 to 0.06) QALYs over 12 months, at a mean incremental cost of £270.72 (95% CI –£202.98
to £886.04) and resulted in an estimated mean cost per QALY of £14,248. When costs associated with
informal care were considered in sensitivity analyses collaborative care is expected to be less costly and
more effective (–£1114, 95% CI –£3366 to £1117).
There was little evidence of overall moderation of depression severity at 4 months (χ2= 10.01; p= 0.35) or
12 months (χ2= 5.63; p= 0.78). The effect of collaborative care at 4 and 12 months was mediated fully
by behavioural activation at 4 months (coefficients: 4.00, 95% CI 1.46 to 6.55 and 3.86, 95% CI 1.30 to
6.42, respectively) with no mediation by medication adherence (coefficients: –0.03, 95% CI –0.14 to 0.08
and –0.01, 95% CI –0.12 to 0.17, respectively). We found a similar but weaker pattern of mediation by
12-month variables on outcomes at 12 months.
Supervisors and care managers demonstrated coherence in their understanding of collaborative care and
consequently reported good levels of cognitive participation and collective action regarding delivering
and supervising the intervention. GPs showed limited understanding of the collaborative care framework
and reported limited collaboration with care managers. All participants identified the potential or experienced
benefits of a collaborative approach to depression management and were able to discuss ways in which
collaboration can be facilitated.
We derived three themes on the process of treatment delivery: (1) engaging the patient, with care
managers making efforts to develop a therapeutic relationship with participants, (2) adopting a counselling
model, with care managers moving beyond simply being empathic to engage the participant and towards
something more recognisable as counselling and (3) variations in the delivery of behavioural activation
describing variations in the adherence of the care managers to the behavioural activation protocol.
Conclusions
Collaborative care improves depression up to 12 months after initiation of the intervention, is preferred by
patients over usual care, offers health gains at a relatively low cost, is cost-effective compared with usual
care and is mediated by patient activation. Future work should test enhanced intervention content not
collaborative care per se.
We found that collaborative care improved depression at our primary end point of 4 months compared
with usual care, an effect that persisted up to 12 months. Collaborative care is cost-effective when service
commissioners are willing to pay up to £20,000 per QALY gained and was preferred by patients over
usual care. The differences in clinical outcomes between participants treated by collaborative care and
participants treated by usual care were no longer apparent at 36 months’ follow-up. In our process
analyses we have demonstrated that only one variable, the amount of behavioural activation undertaken
by participants, predicted better outcomes, despite the fact that there was considerable variation in how
behavioural activation was both explained and operationalised by care managers in sessions. We also
found that care managers and supervisors regarded collaborative care as coherent but that the collective
action required to implement elements of collaborative care was made difficult by GPs’ lack of
engagement with the collaborative care framework.
There is now evidence to answer NICE’s uncertainty in that collaborative care is a clinically effective and
cost-effective system leading to better short- and medium-term (but not long-term) effects compared with
usual care that could be applied to the UK NHS. Future trials should test enhancements of the basic
collaborative care model by developing, examining and delivering better treatments within the effective
collaborative care organisational framework, or improve the delivery of existing treatments, rather than test
collaborative care per se, given that the effects of collaborative care are now firmly established.
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This trial is registered as ISRCTN32829227.
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Funding for this study was provided by the Medical Research Council (MRC) (G0701013) and managed by
the National Institute for Health Research (NIHR) on behalf of the MRC–NIHR partnership.
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Chapter 1 Introduction
This chapter utilises material from three1–3 of the four Open Access articles previously published by theresearch team in accordance with the terms of the Creative Commons Attribution licences (CC BY 2.0,
CC BY 3.0 and CC BY 4.0).
Depression
Depression results in substantial disability and is recognised as a major health problem; it is currently the
second largest cause of global disability.4 Around 350 million people are impacted by depression across
the world and each year up to 5.8% of men and 9.5% of women will suffer from an episode of
depression.5 Depression has a very significant impact on physical health, occupational functioning and the
social lives of sufferers.6 Often anxiety is also present, causing further disability.7
Depression is the acknowledged reason for two-thirds of all suicides.8 The nature of depression is that it
can frequently be chronic, with regular bouts of relapse and subsequent new episodes. After one
depressive episode, around 50% of people will experience additional episodes. The risk of subsequent
relapse is 70% after a second bout of depression and as much as 90% following three or more episodes.9
Among other diagnostic criteria, depressive symptomatology incorporates depressed mood, loss of interest
or pleasure in activities, insomnia or sleeping too much and fatigue or loss of energy.10
Although effective pharmacological and psychological treatments for depression are available, people are
often treated with a less than optimal programme. Internationally, there is often poor patient adherence
to pharmacological treatment11 and further problems caused by organisational barriers between generalists
and specialist mental health professionals.12,13 There is often very limited support for primary care doctors
when treating participants with both psychosocial interventions and pharmacological methods. Such
support may be critical given that, in systems such as that in the UK and elsewhere, the general
practitioner (GP) is the sole responsible medical clinician for 90–95% of patients.14
Collaborative care
In a previous systematic review of 36 studies testing organisational interventions,15 it was concluded that
guidelines, practitioner education and other simple interventions were not effective in studies attempting
to improve the management of depression. However, there is better evidence for the role of organisational
interventions in improving the management of a range of chronic conditions generally. Organisational
strategies have been used in the management of depression, including ‘collaborative care’. This is a
complex intervention developed in the USA that has been supported by previous reviews. Collaborative
care has been identified as the most effective of the range of organisational approaches studied.15–20
Collaborative care incorporates a multiprofessional approach to patient care; a structured management
plan; scheduled patient follow-ups; and enhanced interprofessional communication.21 In practice, this is
achieved by the introduction of a care manager into primary care, responsible for delivering care to
depressed patients under supervision from a professionally qualified mental health specialist and for liaising
between primary care clinicians and specialists. Care management has been described as a health worker
taking responsibility for proactively following up a patient, assessing patient adherence to psychological and
pharmacological treatments, monitoring patient progress, taking action when treatment is unsuccessful and
delivering psychological support.18 Care managers work closely with the primary care provider (who retains
overall clinical responsibility) and can receive regular supervision from a mental health specialist.15,22
The specific disciplines vary by country context but can include counsellors, paraprofessionals or nurses as care
managers, and psychiatrists, psychologists and mental health nurses acting in the specialist role.
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Systematic reviews23,24 demonstrate that collaborative care improves depression outcomes, with some
studies showing benefit for up to 5 years. Before developing the CollAborative DEpression Trial (CADET),
our 2006 systematic review24 of 28 collaborative care studies showed collaborative care to be effective
[standardised mean difference (SMD) –0.24, 95% confidence interval (CI) –0.17 to –0.32]. The I2 estimates
of inconsistency were 80% for antidepressant use and 54% for depressive outcomes. In metaregression
analyses three intervention content variables predicted improvement in depressive symptoms, recruitment
by systematic identification (p= 0.061), care managers having a specific mental health background
(p= 0.004) and provision of regular supervision for care managers (p= 0.033), which reduced the overall
heterogeneity (I2) from 54% to 48% for systematic identification, 43% for case manager background
and 49% for supervision.
More recently (after the initiation of the CADET trial) we have undertaken a Cochrane review.23 Our new
analyses show greater improvement in depression outcomes for adults with depression treated with the
collaborative care model compared with usual care in the short term (0–6 months) [SMD –0.34, 95% CI
–0.41 to –0.27; relative risk (RR) 1.32, 95% CI 1.22 to 1.43], medium term (7–12 months) (SMD –0.28,
95% CI –0.41 to –0.15; RR 1.31, 95% CI 1.17 to 1.48) and long term (13–24 months) (SMD –0.35,
95% CI –0.46 to –0.24; RR 1.29, 95% CI 1.18 to 1.41). However, these significant benefits were not
demonstrated into the very long term (≥ 25 months) (RR 1.12, 95% CI 0.98 to 1.27). In metaregression of
this significantly larger study data set (n= 79) collaborative care that included psychological interventions
predicted improvement in depression (beta-coefficient 20.11, 95% CI 20.01 to 20.20; p= 0.03).
These new data include the results of our CADET trial along with another nine UK studies and a greatly
expanded study data set. We include them here for completeness and refer to them further in
the discussion.
In 2008, at the commencement of the CADET trial, collaborative care had generally been developed and
tested in the USA within managed health-care settings. It is possible that the overall effectiveness of
collaborative care programmes might vary when it is implemented and evaluated in non-US settings.
In other areas of mental health care results from US-developed organisational interventions have not
generalised outside the original health-care context.25 For collaborative care, there was some supportive
evidence from other contexts, including the developing world,26,27 but prior to the CADET trial there has
been uncertainty around the standardised effect size in UK trials (SMD 0.24, 95% CI –0.060 to 0.547) and
elsewhere.24 These limited non-US data and the relatively small effect size in trials of patients with
depression alone led the UK National Institute for Health and Care Excellence (NICE)28 to issue a research
recommendation that ‘The efficacy of organisational interventions, such as chronic disease management
programmes or other programmes of enhanced care for depression, should be tested in large-scale
multicentre trials in the NHS’ (research recommendation 5.6.8.1, p. 103). This provided us with the
rationale to undertake a fully powered UK evaluation of collaborative care.
Development of the CollAborative DEpression Trial
In published studies there is considerable between-study heterogeneity in terms of the duration and
intensity of collaborative care and the training and background of care managers. Therefore, to investigate
the clinical effectiveness and cost-effectiveness of collaborative care in the UK, we conducted a series of
Medical Research Council (MRC)-funded preparatory studies. We wished to develop an intervention in
anticipation of a fully powered randomised controlled trial. We carefully developed our collaborative care
intervention to be applicable outside the USA, in health-care systems with a well-developed primary
care sector.29–31
In our Phase II testing of this intervention,30 we found preliminary evidence that collaborative care adapted
to the UK was acceptable to patients and clinicians and may be effective outside the USA, but that a
cluster randomised controlled trial was required to guard against potential contamination between trial
arms. We amended the clinical protocol studied in our pilot trial to take account of acceptability data in
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our qualitative interviews and designed a cluster randomised controlled trial of sufficient power to detect
clinically meaningful and achievable differences between collaborative care and usual care. We now report
the results of this pragmatic cluster randomised controlled trial1 to determine whether or not collaborative
care is more clinically effective and cost-effective than usual care in the management of patients with
moderate to severe depression. This report is divided into chapters detailing the methods and results of our
primary clinical effectiveness and cost-effectiveness questions followed by similar chapters for our process
evaluation. We have undertaken an additional long-term follow-up of clinical outcomes and report this in
a separate chapter. Finally, we conclude with a discussion chapter summarising our results and considering
their implications for the management of depression.
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Chapter 2 Trial methods
This chapter utilises material from three1–3 of the four Open Access articles previously published by theresearch team in accordance with the terms of the Creative Commons Attribution licences (CC BY 2.0,
CC BY 3.0 and CC BY 4.0).
Research question
Is collaborative care more clinically effective and cost-effective than usual care in the management of
participants with moderate to severe depression in UK primary care?
Study design
The CADET trial was a multicentre, two-group, cluster randomised controlled trial with allocation of
general practice clusters to two trial arms: collaborative care (experimental group) or usual care
(GP management). We chose a cluster design given that our Phase II trial30 described in the previous
chapter demonstrated that a participant-randomised trial of collaborative care could be vulnerable to
contamination and open to type II error, underestimating the true effect size of the intervention through
potential intervention ‘leakage’.
Patient and public involvement
We involved patient and public representatives at all stages of the project. A patient and public
involvement (PPI) advisor (CM) was a trial applicant, investigator and full member of the Trial Management
Group (TMG). He attended all meetings of the TMG and advised on patient-facing materials including
ethics materials and participant therapeutic manuals and on the conduct of the trial including project
management, questionnaire development, data collection and project dissemination. There were two PPI
representatives on the Trial Steering Committee (TSC), one from a depression consumer advocacy group
and another with lived experience of depression. Both provided important checks and balances as part
of the independent TSC oversight of the trial.
In addition, the trial was initially co-ordinated from the Mood Disorders Centre at the University of Exeter
and latterly from the University of Exeter’s Medical School. Both the Mood Disorders Centre and the
Medical School operate within a culture of PPI, guided by published theories of participation,
empowerment and engagement, through the Mood Disorders Centre’s 20-strong Lived Experience Group
and the National Institute for Health Research (NIHR) CLAHRC (Collaboration for Leadership in Applied
Health Research and Care) for the South West’s patient involvement group PenPIG (Peninsula Public
Involvement Group).
Setting and participants
We recruited participants between June 2009 and January 2011 from the electronic case records of
primary care general practices in three UK sites: Bristol, London and Greater Manchester.
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Inclusion criteria
Our eligibility criteria were as follows:
l Adults aged ≥ 18 years meeting International Classification of Diseases, Tenth Edition (ICD-10)
criteria for a depressive episode.32 Diagnosis was determined by research personnel interviewing
potential participants using the Clinical Interview Schedule – Revised (CIS-R),33 a computerised interview
schedule that establishes the nature and severity of neurotic symptoms and identifies a categorical
diagnosis of mild, moderate or severe depression.
l Newly identified as depressed, including those with or without previous episodes; in treatment for an
existing diagnosis of depression but not responding; suffering from peri- or postnatal depression;
or suffering with comorbid physical illness or comorbid psychological disorders such as anxiety.
l People were eligible to participate whether or not they were in receipt of antidepressant medication in
line with the pragmatic nature of this trial and to reflect usual primary care management of depression
in the UK.
Exclusion criteria
We excluded people for whom there was a sufficiently severe risk of suicide that they required immediate
specialist mental health crisis management; those with type I and type II bipolar disorder; those with
psychosis; those with depression that was associated with a recent bereavement; those with an alcohol or
drug abuse primary presenting problem; and those who, at the time of interview, were receiving specialist
mental health treatment for their depression, including psychotherapy.
Randomisation
We randomly allocated primary care practices to either collaborative care or treatment as usual as they
were recruited into the trial. We minimised randomisation within our three sites using the Index of Multiple
Deprivation (IMD) rank,34 the number of GPs and practice size.
Allocation concealment
We concealed the allocation sequence from the researchers as they recruited practices by ensuring that
researchers were unaware of prior allocations or the allocation sequence. Randomisation was undertaken
by the trial statistician using Minim (www.sghms.ac.uk/depts/phs/guide/randser.htm).35 We managed
participant identification and the trial databases through our partnership with the Peninsula Clinical Trials
Unit (PenCTU), who undertook these functions remotely from the trial team and trial statistician.
Blinding
In this type of trial, in which interventions are complex and clearly different from each other, it is not
possible to blind participants, care managers or GPs and so our procedures focused on helping to keep
research workers blind to participant allocation and protecting the study against assessment interpretation
bias through the use of self-report measures. Our research workers were blinded to practice allocation.
To help control for the effect of any potential unblinding after research workers assessed and confirmed
that people were eligible for the trial, they then collected participant outcomes as self-report measures.
After assessments had been completed, research workers recorded participants’ data on a remote,
web-based system. This database, administered by PenCTU, allocated each participant an identification
number and, if in a collaborative care cluster practice, automatically advised the relevant care manager to
contact the participant. The system also automatically communicated with each participant’s GP by letter.
TRIAL METHODS
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Recruitment
Potential participants were identified by clinical studies officers (CSOs) or practice staff from July 2009 to
January 2011. These workers searched the computerised records of participating practices over a 19-month
period, looking for records of people with at least one identification code for depression recorded against
their name by their GP in the previous 4 weeks. We searched for those codes most widely used by GPs
to classify participants as depressed.
The lists of people generated by the searches were screened by GPs to remove the names of anyone
whom GPs knew would not meet our inclusion criteria or who would be excluded at interview. Staff then
sought permission from potentially eligible people for researchers to contact them. Potentially eligible
people were sent an information sheet and reply slip in the post. Practice staff or CSOs followed up this
letter by telephone after 1 week.
Those who gave research interview consent were contacted by a researcher trained in the specific
interview procedures by study investigators and an interview was organised at the convenience of the
participant. Interviews took place either in their home or at their GP practice no earlier than 48 hours after
they had received the trial information letter. The first part of the research interview consisted of the
researcher outlining the trial in detail and answering questions. Once the potential participants were fully
briefed and willing to enter the trial, researchers asked them to fill in and sign the trial consent form,
following which the diagnostic component of the baseline interview was undertaken.
If the diagnostic component of the baseline interview – the CIS-R33 – confirmed that a potentially eligible
person met our depression diagnostic inclusion criteria, he or she was included as a participant in the trial,
the research interview proceeded and a full baseline data set was taken.
Intervention and comparator groups
Intervention: collaborative care
Our experimental intervention was collaborative care. As detailed earlier, the specific components of
the intervention had been developed, tested and amended in our earlier trial and process evaluation.30 Care
managers in three UK sites provided the intervention under supervision from specialists in mental health
care. A copy of the complete clinical protocol is provided in Appendix 1. A summary of the collaborative care
protocol is given in the following sections.
Care management
All participants received usual care from their GP. Collaborative care consisted of 6–12 contacts between
the care manager and the trial participant, with contacts spanning a period of no more than 14 weeks.
The initial appointment was of 30–40 minutes’ duration and was conducted in a face-to-face manner.
Subsequent appointments were undertaken on the telephone and were of 15–20 minutes’ duration.
Although most follow-on appointments were by telephone, care managers could arrange to meet the
participant face-to-face if either party thought that this was desirable. Routinely, however, the telephone
was the preferred contact medium for the majority of follow-on appointments.
Although the frequency of contacts was determined by a participant’s needs, in our protocol we suggested
that contacts should be undertaken weekly during the first month or so of care management. We
recommended that fortnightly appointments could be arranged after this. Once again, we designed our
protocol to be sufficiently flexible to permit more frequent sessions if either party regarded this as
important, given the progress of the participant or his or her clinical presentation. We recommended short
frequent sessions to care managers as opposed to lengthy appointments on a less frequent basis. We
asked care managers to be flexible with appointment schedules to permit sessions to be delivered outside
usual 0900–1800 working hours, but our expectation was that the majority of sessions would occur during
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these hours. We advised care managers to try many times to contact participants if they did not manage to
get through on the telephone at first. This is an important component of collaborative care protocols
worldwide, because many people with depression avoid contact with other people because of their mood
state, with social avoidance being a common symptom.
During appointments, care managers would:
l assess participants’ views about psychological and medication treatments
l negotiate a treatment programme that was acceptable to participants
l help participants with their management of any prescribed antidepressants
l support participants to use behavioural activation, a brief low-intensity psychosocial treatment
for depression
l provide advice on relapse prevention.
Symptom assessment
Care managers conducted a symptom assessment every time they had a session with a participant,
whether face to face or by telephone. They used the Hospital Anxiety and Depression Scale (HADS)36 to
evaluate and record common symptoms of depression and then engaged participants in a discussion
regarding these symptoms. We chose the HADS so as not to use the same measure [the Patient Health
Questionnaire-9 (PHQ-9)37] as our primary research outcome measure. Care managers also conducted a
risk assessment to assess the level of risk to self and others for each participant. These assessments were
undertaken at the beginning of each appointment.
Medication management
We instructed care managers to help participants engage appropriately with any medicines that they had
been prescribed for their depression. Each participant’s GP remained the responsible medical practitioner in
terms of medication prescription but the care manager helped participants understand the reason for their
prescription, reinforced information from their GP and problem solved any difficulties that participants had
in tolerating their medicines.
Behavioural activation
Behavioural activation is a psychological treatment with good evidence that it is as effective as
cognitive–behavioural therapy in depression.38 Behavioural activation is a brief psychological treatment that
helps people interrupt patterns of avoidance that maintain depression. Behavioural activation assists people
to increase their levels of activity to help them experience more examples of situations likely to lead to a
positive mood. Behavioural activation was suitable for care managers to use given its simplicity and brevity
and had been tested previously in our pilot work. We provided participants with support information
prepared by the trial team. In summary, participants were supported through a self-guided behavioural
activation treatment programme that helped them to increase the frequency and range of activities in their
day-to-day lives.
Communicating with general practitioners
We outlined three levels of care manager contact with GPs:
l Level 1. Care managers communicated a brief statement of the participant’s main problem and
treatment plan to the GP after the first treatment session, using a structure outlined in our protocol.
If participants were progressing satisfactorily and/or willing to engage in the treatment plan, routine
records of each contact were recorded.
l Level 2. If participants were not progressing satisfactorily, or they wanted to change their
pharmacological treatment regime, the case manager could alert their GP as required. In these
instances care managers could inform the GP about changes that may need to be made to the
treatment plan. Care managers could also let the GP know if a participant had been advised to make
an appointment with his or her GP.
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l Level 3. We instructed care managers to contact GPs in person directly or by telephone should there be
an urgent need to do so. Circumstances requiring level 3 contact included a participant experiencing
intolerable medication side effects, a substantial worsening in a participant’s mental health or a
participant being at acute risk to self or others.
Care managers
Care managers were existing NHS mental health workers working in a primary care environment. They had
been previously trained as paraprofessional mental health workers. They continued to treat patients in their
existing NHS role, undertaking care management of CADET participants alongside their NHS caseload. Care
managers were supervised each week by specialist mental health workers including clinical psychologists,
psychiatrists, academic GPs with a special interest in mental health or senior nurse psychotherapists. Every
CADET participant was discussed at least once a month. Discussions were organised using a bespoke
computerised patient case management information system [PC-MIS (see www.pc-mis.co.uk; accessed
17 November 2015)]. PC-MIS includes automated alerts so that supervisors and care managers are informed
of their supervision discussion schedules automatically, including algorithms driven by routine outcome
measures that identify participants not responding to treatment.
Specialist mental health worker members of the investigator team trained care managers using a 5-day
collaborative care instruction programme. The training consisted of protocol instruction, modelling and
treatment session role play. All components of the collaborative care protocol were included in the
programme. This included the initial contact, subsequent appointments, telephone working, GP liaison
and supervision. The training instructed care managers on both specific case management skills such as
participant education, medication support and behavioural activation and non-specific factors necessary to
develop therapeutic engagement.
Each care manager received a handbook to accompany the training programme (see Appendix 1). The
handbook included a collaborative care management session-by-session guide and participant information
materials on depression, medication and behavioural activation. The handbook contained all of the
worksheets and diaries that care managers were to use in supporting participants with their collaborative
care activity programme. It also included information on, and examples of, how care managers should
communicate with GPs and provided worksheets to help them prepare case materials for
supervision discussions.
Supervision
Specialist mental health professionals – psychiatrists and psychological therapists (RA, JC, LG, DK, KL and
SP) – supervised the care managers. Supervisors helped and supported care managers through discussion
with them about participant progress. Care managers discussed participant symptom levels, treatment
plans and their own care management activities. In this, they were prompted by alerts on PC-MIS. In
addition to routinely triggered discussions they were also able to bring any problems experienced in
managing specific cases to supervision. Supervisors assisted care managers with any communications that
they needed to have with GPs, for example communicating medication advice for individual participants.
Supervisors undertook sessions with care managers over the telephone, either on an individual basis or in
groups on a weekly basis. At each supervision session the following cases were reviewed:
l all new participants
l participants who had reached a scheduled supervision review point after being in the trial for 4, 8 or
12 weeks
l participants who were not improving as expected, for example when an adequate trial of
antidepressant medication was not having a therapeutic effect or when participants were not
benefiting from or engaging in the behavioural activation programme
l overdue participants; that is, when the care manager had not been able to make contact with a
participant as previously arranged
l any other participants requiring discussion and/or an overview of current caseloads.
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Supervision was principally informed by ratings collected from participants using the HADS, assessments of
participant risk to self and others, details of participant concordance with treatment plans and discussions
of care management strategies. Supervision focused care managers’ attention on their overall decision-making
for individual participants while also helping them practice care management principles for their whole caseload.
Control condition: usual care
General practitioners provided control participants with care that reflected their standard practice. For
control participants this included antidepressant therapy and/or referral to specialist mental health care.
Given that the CADET trial was a pragmatic trial, we did not specify any clinical protocols for usual
care. However, we did measure the components of usual care received by participants.
Outcomes
Primary clinical outcome
The primary clinical outcome was depression severity at 4 months’ follow-up using the PHQ-9.37
Secondary clinical outcomes
Secondary outcomes were the PHQ-9 at 12 months, quality of life [Short Form questionnaire-36 items
(SF-36)39], worry and anxiety [General Anxiety Disorder-7 (GAD-7)40] at 4 and 12 months, health state
values (health-related quality of life) [European Quality of Life-5 Dimensions three-level version
(EQ-5D-3L)41,42] at 4 and 12 months and participant satisfaction [Client Satisfaction Questionnaire-8
(CSQ-8)43] at 4 months.
Demographic data on sex, age, ethnic origin, education level, employment, marital status, presence
or absence of antidepressant treatment, previous history of depression, severity of depression, any
secondary diagnoses of an anxiety disorder and any participant self-reported long-standing physical illness
were also collected at baseline.
Economic outcomes
The health economic end point was the cost per quality-adjusted life-year (QALY) at 12 months. We used
the recommended area under the curve approach for assessing repeated measures.44,45 Resource use
pertaining to the collaborative care intervention as delivered by care managers and supervisors in the trial
was collected directly from our trial and case records. These data included care manager and specialist
supervision contact time. Participant-level health and social care resource use data, information on informal
care from friends/relatives and other participant costs (e.g. over-the-counter costs, one-off participant
costs) were collected at the 4-month and 12-month follow-up points using a self-report format with
assistance from interviewers. These same data were collected at baseline using the same self-report data
collection approach, asking participants to report their resource use during the 6-month period prior to the
baseline assessment. Given the difficulties in collecting data on medication use using the self-report format
we did not include medication use in the estimates of health and social care resource use. However, data
are reported on the proportion of participants on antidepressant medications at baseline and 12 months’
follow-up.
Although all baseline interview data were collected during a face-to-face interview, we were more flexible
with our follow-up assessments. We used face-to-face, telephone or postal methods of data collection
in accordance with participants’ wishes and to maximise data collection. For resource use data we used
face-to-face or telephone methods of data collection, all using an interviewer-assisted self-report format.
TRIAL METHODS
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Sample size
The CADET trial was powered at 90% (alpha= 0.05) to detect an effect size of 0.4. This effect size is
regarded as a clinically meaningful difference between interventions of this type.46 The proposed effect size
was also within the 95% CI of the effect that we had predicted following our analysis of our feasibility
and pilot study.30 This study had shown a potential effect size of 0.63 with a 95% CI from 0.18 to 1.07.
However, an effect size of 0.4 is greater than that in the meta-analysis results of trials published at the
time that we were commissioned to undertake the CADET trial (effect size 0.25, 95% CI 0.18 to 0.32).24
In a two-arm randomised controlled trial in which participants are the unit of randomisation, we would
have required 132 participants per group to detect a difference of 0.4 between groups. However, cluster
randomisation produces a design effect and inflates the required sample size. In our trial, we planned
for 12 participants in each primary care cluster and we used data from our pilot study30 to estimate the
intracluster correlation (ICC) as 0.06. The design effect was calculated as 1.65 and we estimated our
required sample size without any attrition to be 440. We estimated that the CADET trial might suffer from
around 20% participant attrition at our primary end point. In this scenario, to be able to follow up
440 participants, we planned to randomly allocate 550 participants across the trial arms. To deliver this
target we decided to recruit 48 practices with up to 14 participants per practice, given that our recruitment
rate would not be exactly even between practices.
Statistical methods and analyses
Clinical outcomes
All of our analyses for all of our outcomes used the intention-to-treat principle. We reported all outcomes
according to Consolidated Standards of Reporting Trials (CONSORT) guidelines.47 We analysed all data
in Stata 10.1 (StataCorp LP, College Station, TX, USA). We wrote, and agreed with the TSC, an a priori
analysis plan. We used ordinary least squares or logistic regression, allowing for clustering by use of robust
standard errors, to analyse outcomes at 4 and 12 months. We adjusted at the cluster level for minimisation
variables and site and at the individual level for age and, when appropriate, the baseline measurement of
the variable. We undertook sensitivity analyses to assess the effect of missing data. We estimated this by
chained regression equations multiple imputation48 using all available scale clinical scores, age, sex, practice
variables, site and treatment group.
Standardised effect sizes for our outcome variables were calculated by taking the mean difference
between the intervention group and the control group and dividing the difference by the pooled standard
deviation (SD). We also calculated the degree of clustering within our participant clusters by GP practice.
We have reported these as ICC coefficients.
We wanted to ensure that our results could be easily interpreted from a clinical perspective and compared
with existing published studies. Therefore, using the baseline SD for all participants, we calculated rates
of ‘recovery’ and ‘response’. These commonly used metrics can help service commissioners, managers,
clinicians and patients translate continuous outcome variables into a meaningful clinical figure. The rate
of recovery can be regarded as the proportion of participants with a PHQ-9 score of ≤ 9 at the end of the
trial whereas the response rate can be regarded as a ≥ 50% reduction in scores from baseline. Finally, to
further aid interpretation the numbers needed to treat were deduced from the inverse of the absolute risk
reduction adjusted for clustering by practice.
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Economic outcomes
In our economic evaluation we undertook our economic analyses from the UK NHS and Personal Social
Services perspective (third-party payer perspective). We also undertook a sensitivity analysis using the broader
participant and carer perspective. We estimated the costs associated with health and social care service use
and the additional cost of the delivery of the collaborative care intervention and estimated QALYs.
Data on resource use were combined with published unit costs to estimate the mean cost per participant.
We used nationally available data sources, in UK pounds sterling at 2011 costs (Table 1), adjusted for
inflation when necessary, to compute health-care resource values from unit costs. To estimate the
intervention cost for collaborative care, we based our calculations on costs for UK NHS Agenda for Change
(AfC) Band 5 staff. We chose a unit cost of £65 per hour for patient contact time,49 a rate equivalent to that
for a qualified mental health nurse. All staff cost components are included in this unit cost, for example
telephone and travel time, including an allowance of contact time to non-contact time of 1 : 0.89.49
Supervision costs were calculated by selecting the full costs for specialist mental health professionals at NHS
AfC Band 8a49 from a unit cost of £135 per hour for clinical supervisors. QALYs were estimated over the
12-month follow-up period using the EQ-5D trial data, applying UK tariffs obtained from a UK general
population survey to value the EQ-5D health states.53
We estimated mean costs and QALYs for our primary economic evaluation by treatment allocation.
We used covariates that were prespecified for age (at the individual level) and deprivation (IMD), site and
practice size (at the cluster level). A multilevel regression model (Stata, xtmixed) was used for the primary
analyses. This took into account the hierarchical (clustered) nature of the data, presenting the ICC for the
main analyses. We undertook data analyses using generalised linear modelling, with appropriate family
and link components to account for the non-normally distributed nature of cost data. Analyses were
undertaken in Stata 12.
We conducted a number of sensitivity analyses for areas of uncertainty in the cost-effectiveness analyses:
1. We considered the effect of missing data, estimated by multiple imputation (Stata MI command, with
25 replicated data sets), using all available data on the target variable together with covariates for
individual and cluster variables used in the base-case regression analyses.54
2. We undertook analyses using a broader analytical perspective, including estimated costs for informal
care and participant out-of pocket expenses.
3. We analysed data for a scenario using trial data from the SF-36 to estimate QALYs using the Short Form
questionnaire-6 dimensions (SF-6D),55 which presents tariffs obtained from a UK general population
survey to value health states as an alternative QALY outcome measure.
4. We considered uncertainty in the intervention costs.
5. We analysed a scenario in which one participant, with an extremely high level of self-reported resource use,
was excluded, as this potentially offers a more likely and policy-relevant estimate of cost-effectiveness.
We combined estimates of incremental costs and incremental benefits to present incremental
cost-effectiveness ratios (ICERs), allowing decision-makers to assess value for money using the cost per
QALY estimates [ICER= (CostCC –CostTAU)/(QALYCC –QALYTAU), where CC represents collaborative care and
TAU represents treatment as usual]. We used the NICE threshold of £20,000–30,000 per QALY,56,57 that is
the expected payer willingness to pay per unit of additional outcome, to assess the cost-effectiveness of
collaborative care, with ICERs below these values regarded as cost-effective. We used the non-parametric
bootstrap approach,58 with 10,000 replications, to estimate 95% CIs around estimated cost differences
and QALY differences to address uncertainty. To present the level of uncertainty in the cost-effectiveness
estimates we used the cost-effectiveness plane to present combinations of incremental cost and incremental
QALY data from bootstrap replicates and used the cost-effectiveness acceptability curve (CEAC) with the
‘net benefit statistic’ [net monetary benefit= (incremental QALYs ×willingness to pay per QALY) – incremental
cost)]59,60 to present the probability that the intervention is cost-effective (i.e. incremental net benefit statistic
is 0) against a range of potential cost-effectiveness thresholds.
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TABLE 1 Unit costs for different types of health and social care resource items
Resource item Unit cost (£)a Source Basis of estimate
GP (surgery/practice) 36.00 Curtis49 GP appointment/surgery; based on costing at
11.7 minutes
GP (home) 121.00 Curtis49
Practice nurse (surgery) 15.00 Curtis49 Assuming average contact time of 15.5 minutes and
using hourly rate for nurse contact time
Practice nurse (home) 30.00 Curtis49 Assuming average contact time of 25 minutes and
using hourly rate for nurse contact time
Walk-in centre (appointment) 41.00 Curtis49 Walk-in service (not admitted)
Counsellor 60.00 Curtis49 Per consultation
Mental health worker 76.00 Curtis49 Mental health nurse, £76 per 1-hour contact
(assumed 1 hour)
Social worker/care manager 212.00 Curtis49 Per 1-hour contact (assumed 1 hour)
Home help/care worker 18.00 Curtis49 Per weekday hour
Occupational therapist 82.00 Curtis49 Community-based occupational therapist per 1 hour
of client contact (assumed 1 hour)
Voluntary group (e.g. Mind) 21.73 Curtis50 Cost per user session, voluntary/non-profit
organisation (£21 per session in 2010)
Acute psychiatric ward (bed-day) 312.00 Curtis49 Cost per bed-day
Long-stay ward (bed-day) 222.52 Curtis50 Cost per bed-day (£215 in 2010)
General medical ward (bed-day) 321.00 Curtis49 Weighted average of all adult mental health
inpatient days
Accident and emergency
(contact)
106.00 Curtis49 Contact, not admitted
Day hospital (day) 126.00 Curtis49 Cost per day, weighted average of all
adult attendances
Psychiatrist (outpatient contact) 161.38 bDepartment
of Health51
2008–9 cost per consultation (£155;
code MHOPFUA2)
Psychologist (outpatient contact) 135.00 Curtis49 Cost per contact hour (assumed 1 hour)
Community psychiatric
nurse/care co-ordinator
(outpatient contact)
76.00 Curtis49 Mental health nurse, £76 per 1-hour contact
(assumed 1 hour)
Other outpatient contact 143.00 Curtis49 Outpatient consultant services, weighted average
Day care centre (community
services/social care)
34.00 Curtis49 Cost per user session
Drop-in club (community
services/social care)
34.00 Curtis49 Assume the same cost as day care centre, cost per
user session
Help from friends/relatives 18.00 Curtis49 Use cost per hour, based on unit cost for home
help/care worker
Lost work (day) (friends/relatives) 99.6 ONS52 Based on median gross weekly earnings in 2011 for
full-time employees of £498
Travel cost per mile (participant’s
own car)
0.44 Estimate of reclaim/expense rate (running cost per mile)
ONS, Office for National Statistics.
a At 2011 prices/costs.
b Costs uprated/adjusted to 2011 prices using the Hospital and Community Health Services index reported in Curtis.49
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Participant consent and ethical approval
We were granted ethical approval by the NHS Health Research Authority, National Research Ethics Service
(NRES) Committee South West (NRES/07/H1208/60). We ensured that informed consent was gathered
from participants before they undertook any engagement with the study, including data collection and
treatment allocation and receipt. In detail, the process was as follows.
First, potential participants had to indicate their potential interest in the trial. They then consented to a
researcher-led discussion. Everyone who reached this stage was sent the full participant information sheet by
a member of the CADET research team and an appointment was also made. At the initial appointment the
trial was explained in detail by the research interviewer, who also answered potential participant questions.
We informed all potential trial participants that being consented into the trial would not replace or
adversely affect usual care delivered by their GP. All interviewees were told that they could avail
themselves of other services or treatments and that they could withdraw from the trial without incurring
any penalty to their health or treatment choices. Having considered these facts and agreed to trial
participation, we asked potential trial participants to sign a formal consent form. All of our researchers
undertaking this consent process were trained and supervised by the CADET investigator team.
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Chapter 3 Results of the clinical and economic
analyses
This chapter utilises material from two2,3 of the four Open Access articles previously published by theresearch team in accordance with the terms of the Creative Commons Attribution licences (CC BY 3.0
and CC BY 4.0).
Participant flow and retention
Allocation of practices
In total, 53 practices were randomised, two of which dropped out after allocation (Figure 1). These
practices were removed from the minimisation schedule and their data did not influence later allocations.
During recruitment, we found that the cut-off adopted for the IMD had been set far too high, with all
practices so far recruited being below the cut-off. We changed this cut-off to one close to the median of
practices so far recruited, retaining allocations so far. One practice was found to have been mistakenly
recorded in the wrong geographical area; it was moved to the correct group, retaining its allocation.
Of the remaining 51 practices, two did not recruit any participants.
Tables 2 and 3 show the geographical distribution of practices and minimisation variables (IMD, number of
GPs and number of registered patients per practice), respectively, by intervention group. There was a wide
range for all three practice characteristics.
Participant recruitment
The mean number of participants recruited for the remaining 49 practice clusters was 11.9 (SD 3.9,
range 4 to 20). We recruited 581 participants in total and followed up 505 (87%) and 498 (86%) at 4 and
12 months, respectively. The CONSORT diagram in Figure 1 illustrates the flow of participants through
the trial.
Baseline characteristics of participants
The mean age of participants was 44.8 years (SD 13.3) and 72% were women. Fewer than half (44%) of
participants were in full- or part-time paid employment. More than half (56%) of the participants fulfilled
ICD-10 criteria for a moderately severe depressive episode, with a further 30% meeting criteria for severe
depression and 14% meeting criteria for mild depression and 73% of all participants having had
depression in the past (Table 4). Almost all (98%) participants had a secondary diagnosis of an anxiety
disorder, the most common being generalised anxiety disorder. Almost two-thirds of participants (64%)
reported a long-standing physical illness (e.g. diabetes, asthma, heart disease). At baseline, 83% of
participants had been prescribed antidepressant drugs by their primary care doctor.
The distribution of PHQ-9 scores at baseline was negatively skewed, with the majority of scores being in
the higher part of the range. The mean PHQ-9 score overall was 17.8 (SD 5.1), with the usual care group
having a slightly higher average score than the collaborative care group (18.1 vs. 17.4 respectively)
(Figure 2 and see Table 2). All subjects were selected for the trial using a different measure of depression
(CIS-R) from that used in the analysis to avoid problems of regression towards the mean. Low scores
represent random variation because of measurement error.
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GP surgeries: total in all sites
(n = 53)
Randomised: GP surgeries
(n = 53)
Patients
Identified by screening
(n = 7392)
Excluded by GP
(n = 2253)
Contacted by letter
(n = 5139)
Usual care group
Total number of surgeries
(n = 27)
List size of surgeries, mean 
(range) = 7152 (1850–14,528)
Excluded on interview
(n = 198)
• Not depressed, n = 174
• Bereaved, n = 2
• Declined, n = 1
• Receiving other
   treatment, n = 11
• Other, n = 10
Collaborative care group
Total number of surgeries
(n = 24)
List size of surgeries, mean 
(range) = 6615 (2200–15,000)
Patients
Opt in to baseline
(n = 633)
No interview conducted
(n = 130)
Interviewed
(n = 503)
Losses
Dropped out after allocation (n = 2)
Excluded on interview
(n = 168)
• Not depressed, n = 146
• Bereaved, n = 2
• Declined, n = 5
• Receiving other 
   treatment,a n = 5
• Other, n = 10
Patients
Opt in to baseline
(n = 569)
No interview conducted
(n = 125)
Interviewed
(n = 444)
Included patients
(n = 276)
• Received collaborative care, n = 234
• No contact with care manager, n = 42
• Could not be contacted, n = 21
• Withdrawn, n = 24
• Other, n = 1
4-month analysis
 
Patients analysed
(n = 230; 83.3%)
• Could not be contacted, n = 15
• Withdrawn, n = 25
• Other, n = 1
12-month analysis
 
Patients analysed
(n = 235; 85.2%)
Patients not analysed 
(n = 46)
Patients not analysed 
(n = 41)
Included patients
(n = 305)
• Could not be contacted, n = 9
• Withdrawn, n = 21
4-month analysis
 
Patients analysed
(n = 275; 90.2%)
• Could not be contacted, n = 14
• Withdrawn, n = 28
• Other, n = 0
12-month analysis
 
Patients analysed
(n = 263; 86.2%)
Patients not analysed
 (n = 30)
Patients not analysed 
(n = 42)
FIGURE 1 Trial CONSORT diagram. a, The number of patients in the collaborative care group who were excluded
on interview because they were receiving treatment from secondary care or ‘another mental health provider’
(n= 5) includes one participant who was initially allocated in error and who was subsequently excluded.
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TABLE 2 Geographical distribution of practices by intervention group
Site Collaborative care Usual care Total
Greater Manchester 7 9 16
Bristol 8 9 17
London 9 9 18
Total 24 27 51
TABLE 3 Distribution of the minimisation variables in the two intervention groups
Variable Group Number of practices Mean SD Minimum Maximum
IMD Collaborative care 24 9210 7416 317 27,365
Usual care 27 8449 6012 265 19,536
Total 51 8807 6651 265 27,365
Number of GPs
(whole-time equivalents)
Collaborative care 24 3.8 2.0 1.0 10.0
Usual care 27 4.0 1.9 1.0 7.8
Total 51 3.9 1.9 1.0 10.0
Number of patients Collaborative care 24 6615 3282 2200 15,000
Usual care 27 7152 3781 1850 14,528
Total 51 6899 3530 1850 15,000
TABLE 4 Baseline characteristics of participants
Characteristic Collaborative care (n= 276) Usual care (n= 305) Total (n= 581)
GP practices by centre, n
Bristol 8 9 17
London 9 9 18
Greater Manchester 7 9 16
Minimisation variables, mean (SD)
IMD 9210 (7416) 8449 (6012) 8807 (6651)
Number of GPs 3.8 (2.0) 4.0 (1.9) 3.9 (1.9)
Number of patients 6615 (3282) 7152 (3781) 6899 (3530)
Sex, n (%)
Female 202 (73.2) 216 (70.8) 418 (71.9)
Male 74 (26.8) 89 (29.2) 163 (28.1)
Age (years)
Mean (SD) 45.0 (13.2) 44.5 (13.4) 44.8 (13.3)
Range 18 to 82 17 to 79 17 to 82
continued
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TABLE 4 Baseline characteristics of participants (continued )
Characteristic Collaborative care (n= 276) Usual care (n= 305) Total (n= 581)
Ethnic origin, n (%)
White British 233 (84.4) 261 (85.6) 494 (85.0)
Other 43 (15.6) 44 (14.4) 87 (15.0)
Education, n (%)
None 54 (19.6) 74 (24.3) 128 (22.0)
GCSE/O-level 65 (23.6) 81 (26.6) 146 (25.1)
Post GCSE/O-level 84 (30.4) 79 (25.9) 163 (28.1)
Degree or higher 49 (17.8) 53 (17.4) 102 (17.6)
Other or don’t know 24 (8.7) 18 (5.9) 42 (7.2)
Employment, n (%)a
Employed/self-employed 130 (47.4) 122 (40.0) 252 (43.5)
Not working 144 (52.6) 183 (60.0) 327 (56.5)
Married/cohabiting, n (%) 127 (46.0) 114 (37.4) 241 (41.5)
Prescribed antidepressants, n (%) 231 (83.7) 249 (81.6) 480 (82.6)
CIS-R score, mean (SD) 28.8 (9.3) 30.3 (8.9) 29.6 (9.1)
ICD-10 diagnosis, n (%)b
Mild 42 (15.2) 41 (13.4) 83 (14.3)
Moderate 156 (56.5) 167 (54.8) 323 (55.7)
Severe 78 (28.3) 96 (31.5) 174 (30.0)
Previous history of depression, n (%) 202 (73.2) 220 (72.1) 422 (72.6)
Secondary diagnosis, n (%)
Any anxiety disorder 269 (97.5) 301 (98.7) 570 (98.1)
Long-standing physical illness 171 (62.0) 199 (65.2) 370 (63.7)
Baseline outcomes, mean (SD)
PHQ-9 score 17.4 (5.2) 18.1 (5.0) 17.8 (5.1)
GAD-7 score 12.9 (5.3) 13.6 (4.7) 13.3 (5.0)
SF-36 MCS score 23.2 (10.4) 22.3 (10.3) 22.7 (10.3)
SF-36 PCS score 44.8 (12.4) 44.5 (12.3) 44.6 (12.3)
EQ-5D score 0.50 (0.29) 0.46 (0.31) 0.48 (0.30)
SF-6D score 0.54 (0.08) 0.54 (0.09) 0.54 (0.08)
GCSE, General Certificate of Secondary Education; MCS, mental component summary; PCS, physical component summary.
a Employment data were missing for two participants.
b One participant did not meet ICD-10 criteria for mild, moderate or severe depression on the CIS-R score.
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Delivery and receipt of the intervention
A total of 10 care managers provided collaborative care for 276 participants. The mean number of
participants managed per care manager was 27.6 (SD 16.42, range 4 to 46).
Patients received a mean of 5.6 (SD 4.01, range 0 to 15) sessions with their care manager. Forty-two
(15.2%) participants did not attend any sessions with their care manager, 213 (77.2%) had two or more
contacts and 171 (62.0%) had four or more contacts. The mean total time in collaborative care was
3.03 hours (SD 2.18 hours) over a period of 12 weeks (SD 7.75 weeks). For those participants who
attended at least one session, the mean duration of the sessions was 34.5 minutes (SD 8.2 minutes). Most
participants in both collaborative care and usual care remained on antidepressant medication (74.8% vs.
73.8% at 4 months; 69.7% vs. 69.2% at 12 months).
The mean number of collaborative care sessions per participant in which medication was discussed was 3.2
(SD 3.43, range 0–13). The mean number of sessions incorporating behavioural activation was 5.4 (SD 3.4,
range 0–13). The mean number of face-to-face contacts per participant was 1.17 (SD 0.92, range 0–6).
The mean number of telephone contacts was 5.3 (SD 3.5, range 0–14).
We collected 220 supervision records reporting a mean supervision time of 35 minutes per week, with
six participants discussed on average per session. Participants were discussed in an average of three
supervisory sessions over the course of their intervention, at 6 minutes per participant per session. Care
managers, therefore, received the intended level of supervision and number of sessions, with the number
of participants discussed being dependent on the caseload of individual care managers.
Primary outcome: Patient Health Questionnaire-9 at 4 months
The primary and secondary outcomes at 4 and 12 months are presented in Table 5 and data on recovery,
response and numbers needed to treat are presented in Table 6. With regard to the primary outcome
(PHQ-9 at 4 months) we found a significant effect of collaborative care. The estimated mean depression
score was 1.33 PHQ-9 points lower (95% CI –2.31 to –0.35; p= 0.009) for participants receiving
collaborative care than for participants receiving usual care after adjustment for baseline depression. More
participants receiving collaborative care than those receiving usual care met criteria for recovery [odds ratio
(OR) 1.67, 95% CI 1.22 to 2.29; number needed to treat 8.4] and response (OR 1.77, 95% CI 1.22 to
2.58; number needed to treat 7.8).
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FIGURE 2 Distribution of PHQ-9 scores at baseline.
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TABLE 5 Intention-to-treat analysis of the primary and secondary outcomes at 4 and 12 months’ follow-up
Outcome
Collaborative care Usual care
Adjusted
difference 95% CI p-value
Effect
sizen Mean SD n Mean SD
Primary outcome
PHQ-9 score at
baseline
276 17.4 5.2 305 18.1 5.0
PHQ-9 score at
4 monthsa
230 11.1 7.3 275 12.7 6.8 –1.33 –2.31 to
–0.35
0.009 0.26
Secondary outcomes
PHQ-9 score at
12 months
235 10.0 7.1 263 11.7 6.8 –1.36 –2.64 to
–0.07
0.04 0.28
GAD-7 score at
baseline
276 12.9 5.3 305 13.6 4.7
GAD-7 score at
4 months
228 9.1 6.8 273 9.8 5.8 –0.39 –1.30 to
0.53
0.4 0.08
GAD-7 score at
12 months
227 7.7 6.2 253 9.1 6.2 –1.09 –2.21 to
0.03
0.06 0.22
SF-36 MCS score at
baseline
276 23.2 10.4 305 22.3 10.3
SF-36 MCS score at
4 months
227 34.6 15.4 268 30.7 13.7 3.4 1.1 to
5.7
0.005 0.33
SF-36 MCS score at
12 months
223 36.4 15.0 249 33.4 14.5 2.5 –0.6 to
5.5
0.1 0.24
SF-36 PCS score at
baseline
276 44.8 12.4 305 44.5 12.3
SF-36 PCS score at
4 months
227 45.8 13.2 268 45.6 13.8 –0.05 –1.67 to
1.56
0.9 –0.004
SF-36 PCS score at
12 months
223 46.1 13.2 249 44.9 13.3 –0.93 –0.93 to
3.01
0.3 0.08
CSQ-8 score at
4 months
232 25.3 5.8 269 22.1 6.2 3.13 1.87 to
4.39
< 0.001 0.52
MCS, mental component summary; PCS, physical component summary.
a One participant committed suicide. The PHQ-9 score for this participant cannot be regarded as missing at random.
We therefore set the 4-month and 12-month PHQ-9 scores to the maximum of 27 and the effect of this was examined.
This participant was classified as ‘withdrawn’.
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Secondary outcomes
Depression at 12 months
At 12 months’ follow-up, PHQ-9 data were available for 498 participants, 86% of those recruited (see
Table 5). There was a significant effect of collaborative care on depression at 12 months. The mean PHQ-9
score was 1.36 points lower (95% CI –2.64 to –0.07; p= 0.04) in participants receiving collaborative care
than in those receiving usual care (standardised effect size 0.28, 95% CI 0.01 to 0.52). More participants
in collaborative care than in usual care met criteria for recovery (OR 1.88, 95% CI 1.28 to 2.75; number
needed to treat 6.5) and response (OR 1.73, 95% CI 1.22 to 2.44; number needed to treat 7.3)
(see Table 6).
Anxiety
We found no significant effect of collaborative care on anxiety at 4 months, as measured by the GAD-7
(see Table 5). The adjusted difference between the groups in the anxiety score at 4 months was 0.39
(95% CI –1.30 to 0.53; p= 0.4). At 12 months there was also no significant effect of collaborative care
on anxiety. The adjusted difference between the groups in the anxiety score at 12 months was 1.09
(95% CI –2.21 to 0.03; p= 0.06).
Quality of life
Mental health
We found a highly significant effect of collaborative care on the mental component summary (MCS) score
of the SF-36 at 4 months, with the mean score higher by 3.4 T-score points (95% CI 1.1 to 5.7 T-score
points; p= 0.005) in the collaborative care group. This corresponds to an effect size of 0.33 SD (95% CI
0.11 to 0.56 SD). At 12 months this effect was no longer significant (mean difference 2.5 T-score points,
95% CI −0.6 to 5.5 T-score points; p= 0.1).
TABLE 6 Recovery, response and numbers needed to treat
Collaborative care Usual care
ORa 95% CIb p-valueb
Number
needed
to treatcn
Recovered/responded,
n (%) n
Recovered/responded,
n (%)
Recoveryd
4 months 230e 108 (47.0) 275 96 (34.9) 1.67 1.22 to
2.29
0.001 8.4
12 months 235 131 (55.7) 263 106 (40.3) 1.88 1.28 to
2.75
0.001 6.5
Responsef
4 months 230e 99 (43.0) 275 83 (30.2) 1.77 1.22 to
2.58
0.003 7.8
12 months 235 115 (48.9) 263 93 (35.4) 1.73 1.22 to
2.44
0.002 7.3
a Adjusted for age, site and minimisation variables.
b Adjusted for clustering by practice.
c Inverse of absolute risk reduction adjusted for clustering by practice.
d Recovery defined as a follow-up score of ≤ 9 on the PHQ-9.
e One participant committed suicide. The PHQ-9 data for this participant cannot be regarded as missing at random.
This participant’s 4- and 12-month PHQ-9 data were set to the maximum of 27 and are included in this analysis.
f Response defined as a ≥ 50% reduction in PHQ-9 score at follow-up compared with baseline.
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Physical health
We found no significant effect of collaborative care on the quality of physical health at 4 months, as
measured by the SF-36. The difference between the groups in the physical component summary (PCS)
score of the SF-36 was 0.05 T-score points (95% CI –1.67 to 1.56; p= 0.9). The same was true at
12 months, with a difference in PCS T-score points between the groups of 1.04 (95% CI −0.93 to
3.01; p= 0.3).
Table 7 shows the adjusted effect of collaborative care on each SF-36 subscale at 4 months. Four of the
subscales indicated significant benefits of collaborative care: mental health, role limitations (emotional)
and vitality of the mental components and general health of the physical components. Although not
significant, the other element of the mental dimension, social functioning, showed a small estimated
benefit, too.
Client satisfaction at 4 months
We found a highly significant effect of collaborative care on client satisfaction (see Table 5). The adjusted
difference between the groups in satisfaction score at 4 months was 3.13 (95% CI 1.87 to 4.39;
p< 0.001). The estimated effect size for the CSQ-8 was 0.52 (95% CI 0.31 to 0.73). This has been
calculated slightly differently from the effect sizes for the PHQ-9, GAD-7 and SF-36 because there is no
baseline SD. The crude SD within intervention groups for all participants at 4 months was used.
Missing data
In Table 8 we present the results after multiple imputation for the effect of collaborative care at 4 and
12 months on the main scales used, which also shows the results of the analyses using the available data,
which were reported in the preceding sections. The imputed estimates are very similar to the available
data estimates and so we can conclude that for all of these analyses the effects of collaborative care are
little affected by missing data. The lower GAD-7 anxiety score at 12 months in the collaborative care
group, which is not significant in the available data analysis, is just statistically significant in this simulation.
However, the difference in the p-value (0.06 or 0.05) is very small.
TABLE 7 Adjusted regression effects of collaborative care on SF-36 subscales at 4 months
Subscale Coefficient Robust standard error t p-value 95% CI
Physical functioning 0.038 0.078 0.49 0.6 −0.119 to 0.194
Role limitations, physical 0.065 0.096 0.68 0.5 −0.128 to 0.258
Bodily pain −0.021 0.095 −0.22 0.8 −0.211 to 0.170
General health perceptions 0.271 0.071 3.81 < 0.001 0.128 to 0.415
Social functioning 0.157 0.114 1.37 0.2 −0.074 to 0.387
Mental health 0.289 0.103 2.79 0.007 0.081 to 0.497
Role limitations, emotional 0.264 0.100 2.63 0.01 0.062 to 0.465
Vitality 0.337 0.097 3.48 0.001 0.142 to 0.531
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Missing data were related to intervention group. Table 9 shows missing PHQ-9 data at 4 months and
12 months by intervention group. At 4 months, missing data were significantly more likely in the
collaborative care group. At 12 months the difference between the groups was much smaller and not
significant. As far as we can tell, this difference in missingness at 4 months does not produce a difference
in the outcome variables between the two groups and does not explain the observed lower PHQ-9 score in
the collaborative care group. This difference persists at 12 months, when the difference in missingness is
much smaller.
TABLE 8 Adjusted regression effects of collaborative care after multiple imputation
Scale Data Coefficient Robust standard error t p-value 95% CI
PHQ-9 score at
4 months
Imputed −1.31 0.53 −2.49 0.02 −2.37 to −0.26
Available data −1.33 0.49 −2.72 0.009 −2.31 to −0.35
PHQ-9 score at
12 months
Imputed −1.29 0.62 −2.08 0.04 −2.54 to −0.04
Available data −1.36 0.64 −2.13 0.04 −2.64 to −0.07
GAD-7 score at
4 months
Imputed −0.37 0.45 −0.82 0.4 −1.27 to 0.53
Available data −0.39 0.45 −0.85 0.4 −1.30 to 0.53
GAD-7 score at
12 months
Imputed −1.07 0.52 −2.04 0.05 −2.12 to −0.01
Available data −1.09 0.56 −1.95 0.06 −2.21 to 0.03
SF-36 PCS score
at 4 months
Imputed 0.03 0.78 0.04 1.0 −1.53 to 1.59
Available data −0.05 0.80 −0.07 0.9 −1.67 to 1.56
SF-36 PCS score
at 12 months
Imputed 0.98 0.91 1.08 0.3 −0.84 to 2.80
Available data 1.04 0.98 1.06 0.3 −0.93 to 3.01
SF-36 MCS
score at
4 months
Imputed 3.6 1.2 3.13 0.003 1.3 to 6.0
Available data 3.4 1.2 2.97 0.005 1.1 to 5.7
SF-36 MCS
score at
12 months
Imputed 2.6 1.4 1.86 0.07 −0.2 to 5.4
Available data 2.5 1.5 1.60 0.1 −0.1 to 5.5
CSQ-8 score at
4 months
Imputed 3.20 0.61 5.23 < 0.001 1.97 to 4.44
Available data 3.13 0.63 4.98 < 0.001 1.87 to 4.39
TABLE 9 Missing PHQ-9 data by intervention group
Time point of
missing PHQ-9 data
Intervention group, n (%)
OR for missing data in
collaborative care group
p-value (robust
standard error)Collaborative care Usual care
4 months 46 (16.7) 30 (9.8) 1.83 0.03
12 months 41 (14.9) 42 (13.8) 1.09 0.7
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Results of the economic analyses
Our estimated mean cost per participant for the delivery of the collaborative care intervention was
£272.50. This cost estimate includes care manager costs at £232 and clinical supervision costs of £40.50.
Our probabilistic analyses used to explore uncertainty around the main cost component, drawing from
the distribution of contact time for care managers, showed that in 95% of simulations (cost estimates)
the estimated cost of collaborative care was between £101 and £592 per participant (median £249
per participant).
NHS and social care resource use and costs
We found no statistically significant differences between treatment groups in use of resources prior to the
baseline assessment. Table 10 presents resource use over the 12-month follow-up period and Table 11
presents the costs associated with the resource use over the 12-month follow-up period. Table 12 presents
cost data by category with comparison by treatment group. We found a broadly similar pattern of resource
use across groups, with estimated mean costs of NHS and social care (third-party payer perspective),
TABLE 10 Mean health and social care resource use (quantities) over the 12-month follow-up period
Resource item
Usual care (n= 305) Collaborative care (n= 276)
n Mean (SD) [range] n Mean (SD) [range]
Primary/community care (contacts)
GP (surgery/practice) 244 8.21 (6.69) [0–56] 217 7.77 (6.78) [0–45]
GP (home) 247 0.12 (0.80) [0–11] 218 0.05 (0.27) [0–3]
Nurse (surgery/practice) 247 1.77 (3.08) [0–24] 215 1.68 (3.10) [0–32]
Nurse (home) 247 0.06 (0.46) [0–4] 218 0.05 (0.45) [0–6]
Walk-in centre 247 0.32 (0.87) [0–8] 217 0.31 (0.86) [0–5]
Counsellor 246 3.58 (11.26) [0–116] 212 2.67 (7.21) [0–48]
Mental health worker 247 0.58 (3.51) [0–50] 215 0.79 (3.72) [0–36]
Social worker 247 0.34 (1.79) [0–14] 218 0.58 (3.94) [0–33]
Home help/care worker 247 4.35 (47.27) [0–722] 218 1.24 (15.07) [0–220]
Occupational therapist 247 0.22 (0.98) [0–9] 218 0.13 (0.61) [0–5]
Voluntary group 247 0.94 (5.80) [0–64] 218 0.22 (1.39) [0–16]
Secondary care
Hospital admissions, n 247 34 218 28
Acute psychiatric ward (days) 247 – 218 0.78 (11.51) [0–170]a
Psychiatric rehabilitation ward (days) 247 – 218 –
Long-stay ward (days) 247 0.06 (0.94) [0–15] 218 –
Psychiatric ICU ward (days) 247 – 218 –
General medical ward (days) 247 0.48 (2.02) [0–21] 217 0.42 (1.67) [0–12]
Other hospital ward (days) 247 0.28 (1.58) [0–17] 218 0.39 (2.12) [0–24]
Accident and emergency (attendance) 247 0.40 (0.93) [0–7] 218 0.34 (0.76) [0–5]
Day hospital (attendance) 247 0.60 (2.22) [0–24] 218 0.36 (1.19) [0–12]
Outpatient appointment 247 2.62 (5.60) [0–58] 217 2.63 (5.63) [0–65]
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TABLE 10 Mean health and social care resource use (quantities) over the 12-month follow-up period (continued )
Resource item
Usual care (n= 305) Collaborative care (n= 276)
n Mean (SD) [range] n Mean (SD) [range]
Social care (contact/session)
Used day care services (%)b 247 3/2 218 4/3
Day care centre 247 0.28 (4.54) [0–70] 218 0.07 (1.08) [0–16]
Drop-in club 247 0.56 (5.26) [0–70] 218 0.12 (1.40) [0–20]
Day care other 247 0.39 (2.85) [0–28] 217 0.65 (5.67) [0–74]
Informal care from friends/relatives
Had help/care from friends/relatives (%)b 45/48 38/35
Hours per week help from friends/relativesc 230 6.11 (15.44) [0–112] 209 3.95 (10.11) [0–104]
Report time off work for friends/relatives (%)b 7/9 7/10
Days off work lost by friends/relatives 246 4.05 (29.14) [0–360] 217 1.65 (11.28) [0–144]
Participant other costs
OTC cost (£) 246 28.40 (57.90) [0–429]d 215 40.31 (68.61) [0–507]d
Travel costs (£) 246 10.98 (30.30) [0–320] 216 14.33 (37.57) [0–202]
Own car travel (miles) 246 26.12 (77.68) [0–600] 214 31.53 (138.95) [0–1862]
Other ‘one-off’ costs (£) 246 35.77 (144.35) [0–1569] 218 51.58 (213.53) [0–1998]
ICU, intensive care unit; OTC, over the counter.
a Includes one participant with 170 psychiatric ward/admission days.
b These data refer to the proportions at 4 months’ follow-up and 12 months’ follow-up (months 5–12).
c Weekly number of hours (weighted average of data reported at 4 months’ and 12 months’ follow-up) (× 52 weeks to
give annual estimate of hours).
d Analysis of variance results show only the OTC cost (£) to be significantly different (at p< 0.05).
TABLE 11 Estimated mean costs of health, social care and other resource use over the 12-month follow-up period
Resource item
Usual care (n= 305) Collaborative care (n= 276)
n Mean (SD) (£) n Mean (SD) (£)
Primary/community care
GP (surgery/practice) 244 295.52 (241) 217 279.76 (243)
GP (home) 247 14.21 (97) 218 5.55 (32)
Nurse (surgery/practice) 247 26.54 (46) 215 25.19 (46)
Nurse (home) 247 1.94 (14) 218 1.38 (13)
Walk-in centre (attendance) 247 13.28 (35) 217 12.66 (35)
Counsellor 246 214.63 (676) 212 160.47 (433)
Mental health worker 247 44 (267) 215 59.74 (283)
Social worker 247 72.10 (379) 218 122.53 (835)
Home help/care worker 247 78.27 (851) 218 22.38 (271)
Occupational therapist 247 18.26 (80) 218 10.53 (50)
Voluntary group 247 20.50 (126) 218 4.88 (30)
continued
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TABLE 11 Estimated mean costs of health, social care and other resource use over the 12-month
follow-up period (continued )
Resource item
Usual care (n= 305) Collaborative care (n= 276)
n Mean (SD) (£) n Mean (SD) (£)
Secondary care
Acute psychiatric ward 247 0 218 243.30 (3,592)
Psychiatric rehabilitation ward 247 0 218 0
Long-stay ward 247 13.51 (212) 218 0
Psychiatric ICU ward 247 0 218 0
General medical ward 247 154.65 (649) 217 134.61 (535)
Other hospital ward/stay 247 90.97 (507) 218 123.69 (682)
Accident and emergency 247 43.06 (99) 218 36.47 (81)
Day hospital 247 74.99 (280) 218 45.08 (150)
Outpatient appointment, psychiatrist 247 26.79 (148) 217 43.88 (170)
Outpatient appointment, psychologist 247 25.14 (313) 217 25.51 (296)
Outpatient appointment, community
psychiatric nurse
247 8.92 (67) 217 12.61 (166)
Outpatient appointment, other 246 306.93 (588) 215 285.34 (498)
Social care
Day care centre 247 9.64 (151) 218 2.50 (37)
Drop-in club 247 19.13 (179) 218 4.06 (48)
Day care other 247 13.35 (97) 217 22.09 (193)
Informal care from friends/relatives
Help from friends/relatives 230 5714.73 (14,455) 209 3698.50 (9462)
Days off work lost by friends/relatives 246 403.26 (2902) 217 164.78 (1123)
Participant other costs
OTC costs (£) 246 28.40 (58) 215 40.31 (69)
Travel costs (£) 246 10.98 (30) 216 14.33 (38)
Own car travel 246 11.75 (35) 214 14.19 (63)
‘One-off’ costs (£) 246 35.77 (144) 218 51.58 (213)
ICU, intensive care unit; OTC, over the counter.
Kruskal–Wallis (non-parametric) test: no statistically significant differences between groups, other than for OTC costs and
costs for days of work lost by friends/relatives, which were statistically significant at p≤ 0.05.
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TABLE 12 Estimated costs and cost differences (adjusted, unadjusted) over the 12-month follow-up period
by group
Resource item
Usual care
(n= 305)
Collaborative
care (n= 276)
Difference, no
adjustment (£)
Difference, adjusted for
baseline and
participant/cluster covariates,a
mean (95% CI)b (£)n
Mean (SD)
(£) n
Mean (SD)
(£)
Primary and
community
services/care
243 801.49
(1476.98)
208 715.86
(1220.06)
–85.63 –116.48 (–341.06 to 110.91)
Secondary care:
hospital stay
247 259.14
(835.40)
217 402.65
(2282.88)
143.51 160.92 (–70.81 to 481.70)
Secondary care:
outpatient care
246 368.03
(781.43)
215 368.09
(692.60)
0.06 –30.68 (–148.85 to 111.70)
Secondary care:
day hospital
247 74.99
(280.31)
218 45.08
(149.65)
–29.91 –14.52 (–50–13 to 17.94)
Accident and
emergency
247 42.06
(98.66)
218 36.47
(80.51)
–5.59 –5.87 (–22.39 to 9.99)
Day services and
care
247 42.12
(334.85)
217 28.67
(203.43)
–13.45 1.83 (–38.51 to 41.01)
Total NHS and
Personal Social
Services (excluding
collaborative care)
242 1570.70
(2441.55)
205 1614.32
(3714.49)
43.62 1.78 (–454.82 to 640.81)
Collaborative care – 272.50 272.50 –
Total NHS and
Personal Social
Services
242 1570.70
(2441.55)
205 1886.82
(3714.49)
316.12 270.72 (–202.98 to 886.04)c
Patient personal
costs (OTC costs/
medications and
travel costs plus
patient ‘one-off’
costs)
244 86.64
(175.50)
211 120.79
(260.37)
34.15 24.95 (–12.41 to 65.61)
Informal care costs 230 5714.73
(14,455.18)
209 3698.50
(9642.61)
–2016.23 –1114.13 (–3366.09 to 1117.32)
Total costs (NHS
and patient/
related costs)
223 7010.59
(13,492.42)
195 5764.48
(10,796.40)
–1246.11 –312.83 (–2339.92 to 2035.27)c
OTC, over the counter.
a Regression analyses using multilevel model (‘xtmixed’, Stata) with baseline value as covariate and age and cluster-
level covariates.
b 95% CIs estimated using non-parametric bootstrap method.
c ICC= 0.0000 (95% CI 0.0000 to 0.0000).
For cost estimates for individual items/categories, analysis of variance showed no statistically significant differences between
groups (note: informal care cost difference at p= 0.088).
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excluding the collaborative care intervention, of £1571 and £1614 for usual care and collaborative care
participants respectively. After adjustment for baseline costs and individual and cluster covariates the cost
difference was not statistically significant, with wide CIs. When including the cost of the collaborative
care intervention, the mean total NHS and social care costs were £1571 and £1887 for usual care and
collaborative care participants, respectively, but, similarly, after adjustment the cost difference of £271 was
not statistically significant. Excluding the intervention cost, the one area of substantial cost difference
between groups was for hospital stay, with a mean cost difference of £161 (regression-adjusted estimate).
This estimated difference in hospital costs was driven by one participant in the collaborative care group
who reported an acute psychiatric hospital stay of 100 days. When we excluded this participant from the
analyses, the cost difference for hospital stay was adjusted to £34.27 (95% CI –£119 to £189) and
the related differences in NHS and social care costs, without collaborative care costs and with collaborative
care costs, were adjusted to –£209 (lower cost for collaborative care) and £63 (additional cost for
collaborative care), respectively.
Broader participant-level and social costs
In Tables 10 and 11 we report resource use and cost estimates associated with informal care from friends
and/or relatives and other participant out-of-pocket expenses. Our findings show that informal care costs,
when estimated using a shadow price for informal care (an estimate of £18 per hour; see Table 1),
represented the largest resource and cost burden associated with participants’ depression. Participants in
the usual care group reported a high use of informal care, which resulted in a higher mean (SD) cost
estimate over 12 months of £5715 (£14,455); this compared with £3699 (£9462) in the collaborative care
group. However, there is wide variation in the self-report data as shown by the large SDs. When adjusting
for baseline costs and other covariates the difference in estimated cost for informal care was –£1114
(95% CI –£3366 to £1117), with lower costs for the collaborative care group and, therefore lower total
costs for the collaborative care group (see Table 12).
Quality-adjusted life-years
In Table 13 we report data on health state values for the EQ-5D and SF-6D and the estimated QALY values
over the 12-month follow-up period. When adjusted for baseline and for individual and cluster covariates
we found a difference of 0.02 QALYs (95% CI –0.02 to 0.06 QALYs) over 12 months for the EQ-5D and
0.017 QALYs (95% CI 0.000 to 0.032 QALYs) for the SF-6D. Both measures show a QALY gain for
collaborative care, although the EQ-5D difference is not statistically significant.
Cost-effectiveness analyses
In Table 14 we present estimates of cost per QALY, based on participants with data on costs and
outcomes at follow-up. The base-case cost per QALY for collaborative care was £14,248, adopting a NHS
and social care perspective, with uncertainty around this estimate illustrated in Figure 3 (cost-effectiveness
plane) and Figure 4 (CEACs). The probability that collaborative care is cost-effective compared with
treatment as usual is 0.58 at a willingness to pay of £20,000 per QALY and 0.65 at a willingness to pay
of £30,000 per QALY.
Sensitivity analyses
The results of the sensitivity analyses are also presented in Table 14, in which we estimated incremental
costs and QALYs and cost per QALY using alternative assumptions. In the base-case analysis 23% of the
cost data are missing at the 12-month follow-up (21% control, 25% collaborative care) and 20% of
the QALY (EQ-5D) data are missing at the 12-month follow-up (19% control, 21% collaborative care).
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TABLE 13 Health state values and QALY comparisons (adjusted, unadjusted) over the 12-month follow-up period
by group
Resource item
Usual care
(n= 305)
Collaborative
care (n= 276)
Difference,
no adjustment
Difference, adjusted for
baseline and participant/
cluster covariates,a mean
(95% CI)n
Mean (SD)
[range] n
Mean (SD)
[range]
EQ-5D: baseline 305 0.464 (0.313)
[–0.29 to 1.00]
276 0.504 (0.288)
[–0.349 to 1.00]
0.040
EQ-5D: 4 months 273 0.557 (0.331)
[–0.239 to 1.00]
228 0.599 (0.341)
[–0.484 to 1.00]
0.042
EQ-5D: 12 months 254 0.593 (0.338)
[–0.349 to 1.00]
227 0.650 (0.317)
[–0.484 to 1.00]
0.057
EQ-5D: QALYs
(12 months)
248 0.554 (0.286)
[–0.27 to 0.97]
218 0.605 (0.261)
[–0.29 to 0.97]
0.051b 0.019 (–0.019 to 0.06)c
SF-6D: baseline 303 0.538 (0.86)
[0.30 to 0.77]
274 0.540 (0.83)
[0.30 to 0.82]
0.002
SF-6D: 4 months 269 0.597 (0.126)
[0.30 to 1.00]
227 0.614 (0.140)
[0.32 to 1.00]
0.017
SF-6D 12 months 250 0.605 (0.131)
[0.30 to 1.00]
223 0.634 (0.144)
[0.30 to 1.00]
0.029b
SF-6D: QALYs
(12 months)
241 0.591 (0.109)
[0.30 to 0.90]
211 0.609 (0.114)
[0.35 to 0.91]
0.018 0.0168 (0.000 to 0.032)
a Regression analyses using multilevel model (‘xtmixed’ [STATA), with baseline values as covariate and age and
cluster-level covariates.
b Analysis of variance p≤ 0.05.
c ICC= 0.0000 (95% CI 0.0000 to 0.0000).
TABLE 14 Cost-effectiveness analyses
Scenario/analysis
Difference, adjusted for baseline
and participant/cluster
covariates,a mean (95% CI)
ICER, cost (£)
per QALY
Probability collaborative care
cost-effective at WTPb per QALY gained of
£20,000 per QALY £30,000 per QALY
Base case
Total NHS and
Personal Social
Services costs (£)
270.72 (–202.98 to 886.04)
EQ-5D: QALYs
(12 months)
0.019 (–0.019 to 0.06) 14,248 0.58 0.65
Sensitivity analyses
1. Base-case cost-effectiveness analysis with multiple imputation of missing data
Total NHS and
Personal Social
Services costs (£)
292.08 (–216.88 to 801.04)
EQ-5D: QALYs
(12 months)
0.017 (–0.020 to 0.054) 17.490 NA NA
2. Cost-effectiveness analysis using SF-6D QALY data
SF-6D: QALYs
(12 months)
0.0168 (0.000 to 0.032) 16,114 0.57 0.72
continued
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TABLE 14 Cost-effectiveness analyses (continued )
Scenario/analysis
Difference, adjusted for baseline
and participant/cluster
covariates,a mean (95% CI)
ICER, cost (£)
per QALY
Probability collaborative care
cost-effective at WTPb per QALY gained of
£20,000 per QALY £30,000 per QALY
3. Cost-effectiveness analysis when excluding one high-cost participant
Total NHS and
Personal Social
Services costs (£)
63.34 (–295.98 to 422.67)
EQ-5D: QALYs
(12 months)
0.019 (–0.018 to 0.06) 3334 0.76 0.79
4. Cost-effectiveness analysis using higher cost estimate for collaborative care (mean cost of £338.80)
Total NHS and
Personal Social
Services costs (£)
337.02 (–136.67 to 952.34) 17,738 0.54 0.62
5. Cost-effectiveness analysis using a broader perspective, including patient costs and informal care costs
Total costs
(NHS and
patient/
related costs)
–£312.83 (–2339.93 to 2035.27) Collaborative
care is
dominantc
NA NA
NA, not applicable; WTP, willingness to pay.
a Adjusted for baseline measures and prespecified covariates for age (individual level) and the cluster-level covariates for
deprivation (IMD), site and practice size (cluster level).
b Based on the assessment of incremental net benefit and WTP thresholds commonly applied in the UK NHS.56
c Dominance: lower expected costs with greater expected QALY gain.
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FIGURE 3 Cost-effectiveness plane (payer perspective).
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Imputation of missing data resulted in an estimated incremental cost of £292 and an incremental EQ-5D
QALY gain of 0.017, with a cost per QALY of £17,490. When we adopted a broader analytical perspective,
including all participants with data on costs and outcomes at follow-up, we estimated a mean cost saving
of £313 with collaborative care, alongside an estimated incremental gain in QALYs of 0.02. This therefore
represents a position of dominance for the collaborative care intervention compared with usual care.
Using the SF-6D QALY estimate the cost per QALY increased to £16,114, with 0.57 and 0.72 probability
of collaborative care being cost-effective at a willingness to pay of £20,000 and £30,000 per QALY,
respectively. When we used an alternative cost for the collaborative care intervention, assuming a cost
of £338.80 per participant (compared with the base case of £272.50) to allow for additional clinical
supervision time for the care manager, and therefore per participant, and for supervision from a psychiatrist
(unit cost per hour £267),49 the cost per QALY estimate increased to £17,738. When we excluded from the
analysis the participant with extremely high resource use the cost per QALY was reduced to £3334, with
a 0.76 and 0.79 probability of collaborative care being cost-effective at a willingness to pay of £20,000 and
£30,000 per QALY, respectively.
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Chapter 4 Results of the process evaluation
A longside the main clinical and economic evaluation we undertook a process evaluation to investigatethe implementation of the intervention, moderators of outcome and possible mechanisms of effect.
This chapter utilises material from one61 of the four Open Access articles previously published by the
research team in accordance with the terms of the Creative Commons Attribution (CC BY 2.0)61 licence.
Qualitative data from this work are reproduced verbatim to preserve the integrity of the data analysis.
Objectives
The objectives of the process evaluation were to investigate:
l the potential moderators of differential participant response62,63 and the possible mechanisms of
symptom change in collaborative care
l the process of implementation of collaborative care.
Methods
To investigate moderators and mechanisms of effect we recorded a number of baseline covariates together
with intermediate process variables that were targets of the intervention, regressing these against
depression severity (PHQ-9) at 4 and 12 months using multilevel multiple linear regression.
Measures
Moderators
We recorded six possible moderators at baseline: patients’ attitudes towards antidepressant medication,
patients’ attitudes towards behavioural activation, depression severity (PHQ-9), history of depression (number
of previous episodes), physical health (comorbidity) and socioeconomic status. To measure attitudes towards
treatment we asked ‘How acceptable is it to you to use antidepressant medication?’ and ‘How acceptable
is it to you to review and change your routines and increase your daily activities as a way of helping with
depression?’ Response options were from 1 (definitely acceptable) to 4 (definitely not acceptable). To
investigate the moderating effect of patients’ socioeconomic status we used their postcode to obtain an IMD34
score at the lower super output area level.
Mechanisms of change
We measured participants’ adherence to antidepressant medication and level of behavioural activation
at 4 and 12 months through self-report of medication adherence and the Behavioural Activation for
Depression Scale – Short Form.64
Process of implementation
We conducted face-to-face interviews with six care managers and five supervisors involved in delivering and
supervising collaborative care and undertook telephone interviews with a sample of GPs from intervention
practices. Telephone interviews were offered to GPs in such a way as to cause minimum disruption to their
working day. We sampled GPs purposively based on location, GP surgery, years of experience and practice
demographics. We ceased recruitment when category saturation of data was achieved (n= 15). We used
a flexible topic guide for all interviews with open-ended questions to encourage discussion. All interviews
were audio-recorded with consent, anonymised and transcribed verbatim.
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Further, we used routinely collected data from session audio tapes collected by care managers for
supervision to analyse the process of implementation. We purposively sampled 30 files for transcription
and analysis from 656 collected, to cover as wide a range as possible of care managers, patient sex and
different treatment sessions, from assessment to the final session.
Analysis
Consistent with the mechanisms of change framework described by Kraemer and colleagues for
randomised controlled trials, all of our analyses were exploratory, hypotheses generating activities.62
Analyses were undertaken in Stata 12.1 following a predefined analysis plan.
To explore the role of moderators we analysed the direct effects of our six baseline covariates on depression
severity (PHQ-9) at 4 and 12 months using multilevel multiple linear regression, with a preliminary step to
assess ‘overall moderation’ (regression including all moderator variables), thereby controlling for type I error
inflation as a result of performing a large number of statistical tests.65 We used the xtmixed command in
Stata, modelling surgery as a random effect, to account for nested structure of the data (patients nested
within surgeries). Trial site location was modelled as a fixed effect rather than the top random-effects level
to reduce model complexity and avoid non-convergence issues. Each of the six baseline covariates and
their interactions with the intervention (through which we investigated moderation) were included in the
overall model; all variables were appropriately centred.66 We planned to proceed with individual moderator
analyses only in the presence of ‘overall moderation’.
Potential mediating effects of collaborative care were investigated using structural equation modelling
(SEM) in Stata. We analysed available data on the effect of medication adherence and behavioural
activation at 4 months on PHQ-9 scores at 4 and 12 months and we explored the effect of medication
adherence and behavioural activation at 12 months on the 12-month PHQ-9 scores. To explore and
control for possible confounding,63,67 for mediators that were found to have a statistically significant effect
on outcome, we analysed the effect of pre-randomisation variables on mediation by including all of the
baseline covariates (hypothesised moderators) in the respective structural equation model. To investigate
the effect of possible post-randomisation confounding variables on mediation, we analysed the direct
effects of the collaborative care participants’ care manager and number of treatment sessions on the
intervention group’s 4- and 12-month PHQ-9 scores using multilevel multiple linear regressions, with GP
surgery modelled as a random effect and trial site as a fixed effect. We planned to proceed with mediation
analyses (SEM) allowing for post-randomisation confounding variables only if there was evidence of a
direct effect of care manager or number of treatment sessions on depression severity.
In all mediation and confounding analyses we analysed the effect of missing process data in sensitivity
analysis, in which we used 1000 sample bootstraps. For the post-randomisation confounding investigation
we performed an additional sensitivity analysis in which we controlled for all of the baseline covariates in
the regression model and bootstrapped 1000 times.
Qualitative interview analysis
The transcripts from each interview formed the data. We used an iterative approach using constant
comparison techniques68 and topic guides that we reviewed and adapted after each interview following
discussions between authors as the study progressed, allowing for emerging themes to be incorporated into
the topic guides. CCG, NC, EA and PS conducted an initial thematic analysis and coding,69 independently
at first, and themes were agreed through discussion between researchers of different professional
backgrounds (general practice, nursing, psychology). Following the thematic analysis we conducted a
further theory-driven analysis of the data guided by the four main constructs of normalisation process
theory24 (coherence, cognitive participation, collective action and reflexive monitoring), detailed in Box 1,
building on a previous process evaluation in which we had used the normalisation process model71 to
identify the work required to implement collaborative care for depression.72 Our analyses aimed to identify
barriers to and facilitators of the successful implementation of collaborative care into UK primary care.
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This analysis was conducted individually by CCG, NC, EA and LG and the final analysis was agreed through
discussion, with data being tabulated to illustrate the four constructs of normalisation process theory.
Disconfirmatory evidence was sought in the data throughout the analysis.
Audio-tape analysis
We analysed the implementation of the intervention by initial transcription of 30 audio files and then
analysis of the files by reading the transcriptions, referring in detail to the trial manual. We undertook a
thematic analysis69 similar to that for the interview data, with initial open coding of themes carried out first
by SB and then by LG, utilising MAXQDA version 10 qualitative software [VERBI Software GmBH, Berlin,
Germany; www.maxqda.com/ (accessed 10 December 2015)] to manage the data and develop codes and
categories within the data set. Memos were used in the development of emerging themes, specifically
comparing the interviews with the CADET manual and model of intervention. LG and SB met regularly to
discuss, clarify and characterise the themes.
BOX 1 The four key elements of normalisation process theory
Coherence: a set of ideas about the meaning, uses and utility of a practice (defined as an ensemble of beliefs,
behaviours and acts that manipulate or organise objects and others), which hold the practice together and
make it possible to share and enact it.
l This is the sense-making work that people do individually and collectively when they are faced with the
problem of operationalising some set of practices.
Cognitive participation: the symbolic and real enrolments and engagements of human actors that position
them for the interactional and material work of collective action.
l This is the relational work that people do to build and sustain a community of practice around a new
technology or complex intervention.
Collective action: the chains of interactions that are the site of mental and material work to organise and enact
practice, which might include reshaping behaviours or actions, employing objects or artefacts or reorganising
relationships and contexts.
l This is the operational work that people do to enact a set of practices, whether these represent a new
technology or complex health-care intervention.
Reflexive monitoring: the continuous evaluation, both formally and informally, of implementation processes by
participants, which may involve judgements about the utility and effectiveness of a new practice with reference
to socially patterned and institutionally shared beliefs.
l This is the appraisal work that people do to assess and understand the ways that a new set of practices
affect them and others around them.
Source: from May and Finch70 and www.normalizationprocess.org (accessed 18 November 2015).
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Results
Moderation
The level of participants’ depressive symptoms, number of previous depressive episodes, attitudes to
antidepressant medication, attitudes to behavioural activation, number of limiting physical health problems
and socioeconomic status at baseline are summarised in Table 15. There was little evidence of overall
moderation of depression severity at 4 months (χ2= 10.01; p= 0.35) or 12 months (χ2= 5.63; p= 0.78).
Multiple imputation data produced similar results (overall moderator effect at 4 months F9,37799.1= 0.76;
p= 0.66; at 12 months F9,30924.1= 0.42; p= 0.93).
Mediation
Participants’ levels of behavioural activation, medication adherence and PHQ-9 scores at 4 and 12 months
are provided in Table 16.
TABLE 15 Mean baseline scores and regression coefficients for potential moderators of collaborative care
Moderator (n)a
Mean (SD) score or %,
CC vs. UC
4-month coefficient
(95% CI)b
12-month coefficient
(95% CI)c
PHQ-9 (505) 17.54 (5.18) vs. 17.96 (5.02) 0.49 (0.37 to 0.60) 0.37 (0.25 to 0.49)
Number of previous depressive episodes (475)
0 28.4 vs. 29.3 Reference category Reference category
1 10.7 vs. 9.7 –2.15 (–4.25 to –0.05) –1.76 (–3.95 to 0.42)
2–4 30.1 vs. 33.6 –1.31 (–2.77 to 0.16) –0.005 (–1.52 to 1.53)
5+ 16.2 vs. 15.4 –0.004 (–1.85 to 1.84) 1.46 (–0.47 to 3.40)
Chronically 14.8 vs. 12.0 1.66 (–0.22 to 3.53) 2.23 (0.27 to 4.19)
Positive attitude towards
ADM (504)
76.42 vs. 79.27 –1.66 (–3.08 to –0.24) –1.48 (–2.97 to 0.001)
Positive attitude towards
BA (504)
94.32 vs. 93.09 –0.48 (–2.92 to 1.95) 1.82 (–0.72 to 4.36)
Limiting physical
problems (454)
1.40 (1.46) vs. 1.59 (1.64) 1.16 (0.78 to 1.54) 0.77 (0.37 to 1.17)
Socioeconomic status (483) 29.22 (16.13) vs. 33.47 (15.53) 0.04 (–0.002 to 0.07) 0.04 (–0.003 to 0.07)
ADM, antidepressant medication; BA, behavioural activation; CC, collaborative care; UC, usual care.
a n refers to the number of patients who provided data on each moderator variable at baseline.
b 407/505 (81%) participants for whom 4-month PHQ-9 scores were available were included in the analysis.
c 405/498 (81%) participants for whom 12-month PHQ-9 scores were available were included in the analysis.
TABLE 16 Level of behavioural activation, medication adherence and depression severity at 4 and 12 months
Variable
4-month score 12-month score
Collaborative care Usual care Collaborative care Usual care
Behavioural activation, mean (SD) 19.60 (11.11) 16.04 (10.63) 20.80 (11.73) 17.27 (10.35)
Medication adherence (% incomplete) 39.51 35.83 35.97 37.74
Depression severity (PHQ-9), mean (SD) 11.10 (7.28) 12.68 (6.85) 10.03 (7.10) 11.74 (6.79)
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Effect of 4-month mediators on depression at 4 months
We found strong evidence of an effect of behavioural activation (coefficient 4.00, 95% CI 1.46 to 6.55)
but not medication adherence (coefficient –0.03, 95% CI –0.14 to 0.08) on the intervention. The effect of
behavioural activation led to strong evidence of an indirect effect of collaborative care on depression
severity (coefficient –1.53, 95% CI –2.49 to –0.57). This is larger than the effect of collaborative care if the
model did not include behavioural activation and medication adherence (coefficient –1.22, 95% CI –2.86
to 0.41). The effect of collaborative care at 4 months was therefore mediated in full by behavioural
activation at 4 months.
When we undertook a structural equation model including behavioural activation at 4 months but not
medication adherence we also found strong evidence for the effect of behavioural activation on the
intervention (coefficient 3.56, 95% CI 1.78 to 5.34) and an indirect effect of collaborative care on
depression severity (coefficient –1.33, 95% CI 1.99 to –0.67). There was little evidence of a direct effect of
collaborative care (coefficient –0.08, 95% CI –1.10 to 0.94), suggesting that its effect on depression
severity at 4 months was mediated in full by behavioural activation at 4 months. However, including the
pre-randomisation variables in the model produced little evidence of an indirect effect of collaborative care,
although the size of the effect was similar (coefficient –1.33, 95% CI –3.53 to 0.86). The direct effect of
the intervention remained small and non-significant (coefficient –0.15, 95% –1.03 to 0.73). These results
of the structural equation models were verified after a 1000-replication bootstrap.
Effect of 4-month mediators on depression at 12 months
When we analysed the effect of medication adherence and behavioural activation at 4 months on PHQ-9
scores at 12 months we found strong evidence of an effect of behavioural activation (coefficient 3.86,
95% CI 1.30 to 6.42) but not medication adherence (coefficient –0.01, 95% CI –0.12 to 0.17) on the
intervention. There was strong evidence of an indirect effect of collaborative care on depression
(coefficient –1.20, 95% CI –2.00 to –0.39), larger than the equivalent effect if the model did not include
behavioural activation and medication adherence (coefficient –0.97, 95% CI –2.89 to 0.96). The effect of
collaborative care at 12 months was therefore mediated in full by behavioural activation at 4 months.
Moreover, when we undertook SEM including behavioural activation at 4 months but not medication
adherence we found strong evidence for the effect of behavioural activation on the intervention
(coefficient 3.57, 95% CI 1.78 to 5.37) and an indirect effect of collaborative care on depression severity
at 12 months (coefficient –1.03, 95% CI –1.54 to –0.52). Although there was little evidence of a direct
effect of collaborative care and the magnitude was relatively small (coefficient –0.42, 95% CI –1.63 to
0.80), we observed partial (not full) mediation; the effect of the intervention on depression severity at
12 months did not completely pass through levels of behavioural activation at 4 months. Including the
pre-randomisation variables in the model produced little evidence of an indirect effect of collaborative care
(coefficient –0.86, 95% CI –2.53 to 0.80). The direct effect of the intervention was larger but non-significant
(coefficient –0.77, 95% CI –1.91 to 0.36). The results of the structural equation models were verified after
a 1000-replication bootstrap.
Effect of 12-month mediators on depression at 12 months
When we undertook a structural equation model including medication adherence and behavioural
activation at 12 months we found weak evidence of a moderately sized effect of behavioural activation
(coefficient 2.52, 95% CI –0.80 to 5.85) but not medication adherence (coefficient 0.02, 95% CI –0.12 to
0.15) on the intervention. There was weak evidence of an indirect effect of collaborative care on depression
severity (coefficient –0.96, 95% CI –2.19 to 0.28), which was similar to the size and strength of the direct
effect (coefficient –0.95, 95% CI –2.29 to 0.40). We therefore conclude that the effect of the intervention
on depression severity at 12 months partly passed through levels of behavioural activation at 12 months.
Using similar procedures to those at 4 months, including behavioural activation at 12 months but not
medication adherence we found that the effect of the intervention on depression severity at 1 year was
partly mediated by level of behavioural activation at 12 months. There was strong evidence for the effect of
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behavioural activation on the intervention (coefficient 3.53, 95% CI 1.09 to 5.97) and an indirect effect of
collaborative care on depression severity (coefficient –1.40, 95% CI –2.34 to –0.45). However, although the
direct effect of the intervention is relatively small and non-significant (coefficient –0.31, 95% CI –1.38 to
0.76), the effect of the intervention on depression severity is not fully mediated by behavioural activation at
12 months. Including the pre-randomisation variables produced strong evidence of a larger indirect effect
of collaborative care (coefficient –2.87, 95% CI –4.94 to –0.80) and little evidence of a direct effect
(coefficient –0.62, 95% CI –1.74 to 0.50). Results were verified after a 1000-replication bootstrap.
Effect of post-randomisation confounding variables on mediation
When we undertook multilevel multiple linear regression to explore the effect of participants’ care
manager and number of treatment sessions on the intervention group’s 4-month PHQ-9 scores we found
little evidence of an effect of care manager (χ2= 2.21; p= 0.99) or number of sessions (coefficient –0.11,
95% CI –0.38 to 0.15). We also found little evidence of an effect of care manager (χ2= 7.57; p= 0.58)
or number of treatment sessions (coefficient –0.07, 95% CI –0.32 to 0.17) on depression severity at
12 months. We observed no difference between the result of the multilevel multiple linear regression
including observed data and the sensitivity analyses. The mediating effects of behavioural activation on
treatment outcome were not confounded by care manager or number of treatment sessions.
Results of the qualitative interview analyses
We present our results using the a priori normalisation process theory concepts of coherence, cognitive
participation, collective action and reflexive monitoring with respect to the implementation of collaborative
care as described in the methods section. We present data to support the analysis, which is labelled by
identifier (CM= care manager, S= supervisor, GP= general practitioner) and number.
The demographics of care managers and supervisors have not been included to ensure the anonymity
of participants. GP demographics can be seen in Table 17. The initial thematic analysis is summarised in
Table 18, with some illustrative data provided.
Understanding the collaborative care framework (coherence)
Behavioural activation, which formed the psychological intervention component of collaborative care in this
study, was described by care managers as a user-friendly intervention and easy to understand, not just for
themselves as practitioners but also for the patients, as they didn’t find it ‘too overcomplicated’ (CM105).
The care managers did find that the intervention encouraged them to develop joint plans with patients to
a greater extent than in their usual practice:
By collaborative care what do I mean? Erm, I mean more that sense of working with the patient . . .
and I think it’s more about reaching a shared understanding and working towards shared goals with
enough input from other professionals that are involved in that person’s care.
CM101
Supervisors and care mangers understandably demonstrated a good understanding of the collaborative
care framework in addition to the intervention itself. For supervisors, this level of understanding was
because of their role as co-investigators in the trial. Care mangers reported that the CADET training had
provided them with sufficient information and opportunities to clarify and improve their understanding of
collaborative care, the intervention they were to deliver to patients and the expectation of working with
GPs. Care mangers described how their understanding of collaborative care and their role had been
changed by the training prior to working on the trial:
I’d assumed [collaborative care] would be self-help-based stuff because we were primary care, and
collaborating with other professionals. Since doing the training it’s mainly GPs that I’ve learned, but I
kind of had the idea that it would be collaborating with other mental health workers, but not
specifically GPs.
CM103
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TABLE 17 Demographics of GPs interviewed
GP Sex
Years of
experience
as a GP
Practice
population
Practice
size IMD rank
CADET
recruitment
figures
Actively
involved in
commissioning
GP001 Female 25 African Caribbean,
Asian, Eastern European
and Turkish population,
long stay, suburban
14,000 4339 16 No
GP002 Male 17 50% Caucasian, 50%
Asian population, urban,
deprived, socioeconomic
mix, many family residents
2800 2938 12 Yes
GP003 Male 39 Urban, mixed social
class – less deprived
(groups 1 and 2)
8000 26,048 13 No
GP004 Male 31 Urban, mixed social
class – less deprived
(groups 1 and 2)
8000 26,048 13 No
GP005 Female 25–26 Almost totally white
population, not
deprived, urban edges/
semi-rural. Core of
family-based patients
2350 14,588 11 No, but is
mental health
lead for primary
care trust
GP006 Male 28 5–10% Asian
population, one-third
transient, two-thirds
settled (lots of families),
high-deprivation area,
over-represented in
mental health compared
with other practices
3500 1128 9 No
GP007 Female 21 White British population,
high-deprivation area,
high unemployment,
many patients with
smoking-related illnesses
6000 317 13 Yes in future
GP008 Male 15 African Caribbean,
Asian, Eastern European
and Turkish population,
long stay, suburban
14,000 4339 16 No
GP009 Male 14 Younger population,
high turnover. Eastern
European, African
Caribbean, South Asian,
minority Far East Asian
population, higher than
‘normal’ number of
patients with mental
health issues
7500 1809 8 Yes but
resigning
because of
political nature
GP010 Male 30 Diverse, multiethnic. Top
10% most deprived areas
in the country. A lot of
mental health issues
8000 3428 12 Not for last
18 months
continued
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TABLE 17 Demographics of GPs interviewed (continued )
GP Sex
Years of
experience
as a GP
Practice
population
Practice
size IMD rank
CADET
recruitment
figures
Actively
involved in
commissioning
GP011 Male 18 Two branches, slightly
different demographics
in each. One has new
Eastern European
immigrants; other has
significant Asian and
African Caribbean
population. Suburban
teaching/training
practice
8300 9601/128,182
(two branches)
12 Not any more
GP012 Male 7 Same surgery as above.
This GP says this is an
inner-city practice. Lots
of people with English
as a second language.
Mobile patient
population (high
turnover)
8300 9601/128,182
(two branches)
12 Not asked
GP013 Male 17 Mainly white males
aged 25–35 years,
a few Asian, Chinese
and black people
7600 8179 16 No
GP014 Female 10 Mainly white males
aged 25–35 years,
a few Asian, Chinese
and black people
7600 8179 16 No
GP015 Male 22 Majority white British,
very few black and
minority ethnic groups
7750 317 13 No
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TABLE 18 Qualitative data thematic analysis illustrations
Main theme Subthemes Illustrative data
Recognising the
need for change
GPs’ understanding
of current services
Theoretically we have access to counselling services. There is a group
commissioned by the PCT [primary care trust] called [names team] which I
think has changed over the years from being a purely sort of counselling
service to one with a range of psychological services
GP011
Limited access
to services
[P]sychological services as opposed to psychiatric acute services are dire
locally, absolutely dire . . . we have such limited access, there’s just such a
burden of . . . mild to moderate psychiatric illness and that isn’t well catered
for at all
GP001
Reflections on
the past
The structure, I think, the way we used to work in the old days we used to
work collaboratively anyway, which was really good, erm, but we haven’t got
that structure now, so it’s about number crunching really, you know, in terms
of referrals coming through to you, and being based at . . . a main health
centre where they have to come to you
CM102
Operationalising
collaborative
care
Understanding
collaborative care
I was rereading the protocol for this session [interview] and thinking, should I
have been doing more with GPs? Talking with them more about medication?
So I thought, maybe I’ve done something kind of wrong and not quite
completely as collaborative as I could have been, I think I probably could’ve
done more
CM106
Delivering the
intervention
I didn’t really understand collaborative care; I’ll be quite honest . . . I didn’t
know what collaborative care was, although I could have had a guess.
Collaborative care would have meant care that involved both myself and
someone else, if you see what I mean
GP004
It’s a better experience for the therapist, I’ve kind of had a really positive
experience of CADET, which I think if I’d purely had experience of IAPT
[Improving Access to Psychological Therapies] I wouldn’t be feeling quite so
positive about BA [behavioural activation] or telephone support or telephone
supervision or whatever, so 100% I think it’s great
CM105
Facilitating
communication
Something that is quite helpful . . . if a client’s got an issue, especially
something that is about medication, I will say you know, ‘why don’t you
speak to your GP about that?’ and I will say ‘I will be writing to your GP just
to let him know that this is what we’ve discussed’, so the client would go, I
would write a letter on the other side as well, and it’s quite nice because the
client would then come back and go ‘Oh yeah, the GP got your letter’ and
when I speak to the GP they say ‘Oh yeah the client did come back to me
after what you said’ so I think, it really does work
CM104
[T]here’s that sort of linking where the GP was linked in, and I think that he
was really pleased that erm, he was actually able to have a conversation with
me about the medication, because he was actually feeling stuck and I think
[names CM] was feeling a bit stuck
S102
continued
DOI: 10.3310/hta20140 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 14
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Richards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
41
TABLE 18 Qualitative data thematic analysis illustrations (continued )
Main theme Subthemes Illustrative data
[A] lot of the time I’ve also noticed that through the GP if you do mention
that through supervision what I have been told is X, Y and Z, then they could
be, you know, they could be more likely to listen as well, to accept your
opinion, so yeah, I think that works quite well as well, if you do tell them
‘after discussing this in supervision, this is what we thought’
CM104
I’ve had very little, if any, involvement with the study except notification from
you that a particular patient has been included on the study
GP004
Enhanced
supervision
I think sometimes I’ll write to them asking them something or asking their
opinion of something, then the GP will kind of contact me, get back to me,
and I think on one or two occasions I have had a GP ringing just to ask if I’d
seen a client or when am I next seeing a client, so yeah, I think that’s the only
thing, it’d not something that happens that often, one or two occasions
CM104
Communication
vs. collaboration
It’s such a big problem; I’m not blaming anybody because GPs don’t have the
time . . . You could try to make it happen, it would be nice just to see that,
increasing that contact . . . it sounds like a very desirable thing that would be
helpful for everybody . . . I think collaborative is too strong a word for
collaborative care, it’s not truly collaborative in my opinion, but that’s
my opinion
S105
Catering for
complexity
Recognition of
complexity
I don’t think there is such a thing as pure depression, it comes in a package
with lots of other things so when I say comorbid things, very often comorbid
psychiatric problems, but also physical problems and never to forget, lots of
social problems around, so you’ve got those three things there that are all
competing, so there is a person with depression but at the same time there is
obsessive–compulsive disorder, or query, you know
S104
The need to avoid
mind–body dualism
I think that would be really helpful actually, for us to have more
understanding of physical health problems and how they affect people . . . we
need to recognise physical health problems and long-term conditions and
how they affect people . . . I think knowledge about those is really important,
we just need to know more
CM106
I would have thought logically yes, it’s likely to be those sorts of people, the
more complex your problem the more likely you are to benefit from it, erm,
yeah, I would say comorbidity, absolutely
GP015
Usefulness of a
collaborative care
approach for people
with complex
problems
I think that the whole thing about collaborative care isn’t about the
interventions, it’s actually about the system, and so that case management
role is great . . . you know, I guess if you’re saying, well there’s the system
which is about active follow-up, is absolutely right and that covers all of
these people
S101
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Only a minority of GPs demonstrated a good understanding of collaborative care, either because of their
self-declared interest in mental health or because of previous experience of working within a collaborative
care framework:
So we’ve got more likelihood of being aware of what’s happening in terms of the management and
then that can affect any input that we might have, say in terms of medication if we’re treating
patients with antidepressants, we can get a feel for whether things were moving in the right direction
and get the therapists’ input as well as our own assessment. So it can potentially improve our
understanding of how the patient is progressing and responding and aid our management.
GP010
However, the majority of GP respondents did not fully understand the collaborative care framework and
could not differentiate between the management of patients with depression in collaborative care and
routine care. As a result, some GPs used the qualitative interview as an opportunity for further clarification,
perhaps suggesting a lack of such opportunities during their initial discussions about involvement in
the trial:
GP014: Are you able to define collaborative care for me so I know what you’re talking about, or not?
Researcher: Erm, I mean what we’re trying to do it get an understanding of your understanding of it,
so if you’re not aware.
GP014: I mean they’re all buzz words, so collaborative care, what it actually means?
Some GPs described the main benefit of participating in the trial as the potential for increased support in
their management of patients with depression in the context of limited access to psychological therapy
services to which to refer patients:
The CADET trial offered to me a resource which I thought would be beneficial. Another opportunity
for somebody else to look at these patients, talk to them and share the workload in a way, with me.
GP011
This GP is not reflecting specifically on the collaborative care framework; rather, she seems to be reflecting
on the benefits of participation in any trial in which patients can access an additional ‘service’.
Most GPs identified the potential benefits of adopting a more collaborative approach to patient care,
particularly for patients with more complex problems:
[I]t’s likely to be those sorts of people, the more complex your problem the more likely you are to
benefit from it, erm, yeah, I would say comorbidity, absolutely . . . the more complicated the things
are, the more likely it is that the collaborative approach is going to help.
GP015
It was not clear, even with probing in the interviews, what GPs actually meant by a ‘collaborative
approach’ and GPs were not clear whether or not a collaborative care intervention would fit with their
existing ways of working.
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Establishing relationships (cognitive participation)
A number of new relationships needed to be established within the collaborative care intervention.
Supervisors and care managers reported well-structured, weekly, scheduled supervisory sessions that were
arranged as part of the trial. Supervisors and care managers reported the value of an initial face-to face
meeting to establish the relationship, followed by weekly telephone supervision. Supervision was also
supported by the PC-MIS, a web-based patient management system, demonstrating evidence of the work
carried out for both establishing and sustaining collaboration between these two parties:
The supervision has been excellent I must say. It’s really nice to have it weekly, and it’s great to have
PC-MIS because it means we’re both looking at the same screen, so it’s been really good.
CM103
Supervision as part of the CADET trial was also considered by care managers as ongoing learning,
affirming to their practice and confidence boosting:
[T]hey might point stuff out to me or they might anticipate problems before they arrived which in my
lesser experience maybe wouldn’t have foreseen so therefore they gave me some advice about how I
might manage certain situations or what I might say to prepare a patient for something, erm, so yeah,
it was fantastic, really, really good.
CM105
Supervisors also considered that supervision in the trial was superior to that received in usual care and
highlighted the importance of such supervision to the success of collaborative care, with one describing it
as an ‘integral part of . . . the whole collaborative care process’ (S102).
However, supervisors identified potential problems around identifying the right people to provide
supervision outside of the research study, including finding people who are both willing and able to
provide the same level of supervision as was delivered in the CADET study.
I think the biggest issue is the amount of supervisor time, and I think that, I think that we’re fairly
generous in CADET in that the same supervisor is involved in following people up, and that means
that you do get, that means that people do get really good supervision, but it’s quite, there’s quite a
lot of time involved in that . . . It’s not that there’d be less time, there’d be less people that, erm, that
are used to doing that kind of supervision.
S102
In contrast, there was limited evidence of new relationships being established between the care managers
and GPs in participating practices. Any liaison between care managers and GPs consisted of written
information from the care manager to the practice, with direct contact unusual and reported to have
occurred only when risk was deemed high, with few reports of care managers having direct access to the
practice information technology system:
[E]very 4 weeks we send a review letter, obviously you send the initial assessment letter to say ‘we’ve
assessed this person, their main problem is, their scores are’ and then follow-up letters every 4 weeks.
CM105
Researcher: Have you been able to access to the patient records, has there been a sharing
of information?
CM103: Erm, there’s a couple where I’ve needed to, and I can’t remember what practice it was but I
went there and she said I had to send them a letter, so I had to come back here to fax them and then
they faxed me a letter back, it was a bit, kind of ridiculous.
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One care manager did report having access to the patient records at some GP practices, but encountered
different information technology systems in different practices, which was initially problematic, and she
reported that developing good relationships with the practice administrative staff was essential to enable
utilisation of these:
[T]he other barrier I had was using the different computer systems in different surgeries, so that was
dead complicated, but I got past that, and I found the staff were great because they’d just come and
sign you on and things like that, because I couldn’t remember the password.
CM102
As care managers were already working within existing services and were seconded to the trial, a minority
of care managers described pre-existing relationships with GPs that they found beneficial to engaging GPs
in the collaborative care framework. Care managers also described a number of strategies that they had
attempted to use to enhance opportunities for collaboration with GPs, including identifying the GPs’
preferred method of communication at the beginning of the trial in anticipation of the need to
communicate with them when working within a collaborative care framework:
Initially with the study, what I did was, I went out and visited the GPs . . . and just said ‘what’s the best
way for communicating?’ . . . so it’s looking at what’s best for that GP, you know if you do get a
relationship with them.
CM102
Data suggest that the work carried out around setting up supervision and establishing care manager–supervisor
relationships was important and appreciated by both parties. However, direct contact between care managers
and GPs seemed to be the exception rather than the rule, and occurred at a time of crisis for an individual
patient. Additional work was needed by care managers, as well as building on prior knowledge of practices, to
establish working relationships with GPs that would enable engagement as a routine.
Working within a collaborative care framework (collective action)
Care managers identified few difficulties in delivering the psychosocial intervention to patients; rather,
they focused on the difficulties encountered in liaising or collaborating with GPs. Despite care managers
reporting sending regular summary letters to GPs, the majority of GPs reported limited or no
communication with care managers. It is unclear, therefore, whether GPs did not receive these letters or
whether they did not have time to read them:
I’ve had very little, if any, involvement with the study except notification from you that a particular
patient has been included on the study.
GP004
I don’t think I had any contact personally with the case manager. I think I saw a letter or two, but no
sort of telephone or e-mail or anything of that sort.
GP007
Either way, the limited communication reported by some GPs may account for their lack of awareness of
the involvement of the care managers in the trial and the work that was being carried out with
their patients.
Researcher: You said that there would be someone with more specialist interest might be involved,
erm, did you know who else was going to be involved?
GP014: Recruiting patients?
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Researcher: Erm, so the person you would be collaborating with?
GP014: No.
Researcher: No. OK. Erm, and so, are you aware now about the case managers that were involved in
the study? That was involved in seeing the patient therapeutically?
GP014: No.
The lack of GP involvement is supported by some care managers’ reports that, although GPs were helpful
once they had managed to contact them, GPs rarely initiated contact, which left care managers feeling
that communication was one-sided:
[S]ince I’ve been working here, and that’s been 2 years now, I think I’ve only ever had GPs initiate
contact with me twice. Yep. It’s really, really rare, which is a shame really.
CM105
Despite the difficulties identified in contacting GPs, care managers reported improved relationships with
participating GPs, along with identifying the benefits of this:
Yeah, I think, I mean there are some GPs who are really difficult to get hold of or, you do write to
them and you don’t get a response and you have to try to chase them up, but a lot of the time what I
have found is that they are quite helpful, you know, certain GPs are very easy to talk to on the phone,
or make appointments with, so that’s been quite helpful, and erm, yeah, kind of discussing the patient
as well, it’s, you know, I can suggest something, they can give me their side of what they’re doing,
again, come to some sort of conclusion.
CM104
Some care managers suggested that co-location within GP practices could bring more opportunities for
collaboration with GPs because of the increased possibility of informal communication and they compared
this with their previous ways of working:
[I]n the old days if we worked at a surgery, based there, it’s that relationship building that you have a
chance to do, erm, and so at the moment we don’t do that as part of normal care, it’s harder to do,
I think it’s impossible to do really, so what we get is, we’re based at one health centre and we get
people from all different surgeries being referred through to that one health centre so we don’t get a
chance to build those relationships.
CM102
Supervisors recognised the difficulty experienced in achieving true collaboration between care managers
and GPs:
I mean you’ve got to have people together to collaborate, you know, I just wonder to what extent this
really is collaboration, because it’s only collaboration in name, in a way and the interested parties
don’t really get down and talk to each other very much . . . It’s such a big problem . . . I’m not blaming
anybody because GPs don’t have the time. . . . You could try to make it happen, it would be nice just
to see that, increasing that contact . . . it sounds like a very desirable thing that would be helpful for
everybody . . . I think collaborative is too strong a word for collaborative care, it’s not truly collaborative
in my opinion, but that’s my opinion.
S105
The supervisors recognised that the collaborative care framework did not seem to fit within existing
working practices of GPs.
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Probably because of the set-up and frequency of supervision, supervisors and care managers reported
good professional relationships with each other. Supervisors and care managers reported being impressed
with each other’s skills, suggesting confidence in each other’s abilities. More specifically, supervisors
reported satisfaction with the care managers’ skills for delivering behavioural activation within a
collaborative care framework, even to those patients identified as complex:
I’ve been pretty impressed by the ability of the case managers to assess and manage some people
who have not always been that straightforward, by any means, and these are people who are
supposed to have, you know, these are people who have I suppose moderate degrees of depression,
but they’ve got complicated life problems as well, some of them have been in crisis, and they’ve
managed them. I think it’s gone pretty well.
S102
Likewise, care managers were enthusiastic about what they considered to be enhanced supervision,
because of its increased frequency and the supervisors’ wealth of experience and knowledge:
[T]hey might point stuff out to me or they might anticipate problems before they arrived which in my
lesser experience maybe wouldn’t have foreseen so therefore they gave me some advice about how I
might manage certain situations or what I might say to prepare a patient for something, erm, so yeah,
it was fantastic, really, really good.
CM105
There was little evidence in the GP data that the work conducted by the care managers and supervisors
had any impact on GPs’ routine consultations or their work with patients:
[A]s far as the CADET study is concerned, we’ve not . . . it’s happened alongside us really, it hasn’t had
. . . it certainly hasn’t been detrimental to anything that we’ve been doing, but that’s not really what I
mean. What I mean is that we identified patients but then didn’t need to change what we were doing
very much.
GP007
Care managers reported that they had taken or planned to take many elements from collaborative care
(such as increased collaboration with GPs and medication management, as well as the behavioural
activation psychosocial intervention) back into their routine work, which demonstrates that this approach is
acceptable to care managers and has the potential to become normalised within their routine practice:
What I will probably take back is a lot more information on medication . . . when I was working prior
to that [CADET], the focus wasn’t so much on the medication, yeah, and I don’t think that I had much
idea of medication, and I think now, there was a time when I wasn’t too keen on medication myself,
I wasn’t too sure if medication really worked, whereas now I’ve seen that it is quite helpful so I would
probably emphasise the medication with my patients, yeah, and I probably will take the whole BA
[behavioural activation] in terms of being active and how that helps with the depression, so yeah,
as a whole, the whole thing, but if there’s one thing I’m going to focus on more it’ll be the
medication, yeah.
CM104
Our data suggest that organisational changes within practices would be required to establish relationships
between care managers and GPs and facilitate successful collaboration, such as integrated information
technology systems and enhanced opportunities for GP/care manager communication and possibly
co-location of professionals. Collaborative care would need to be seen as fitting in with the routine work
of the practice for GPs to make changes to accommodate the work involved.
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Evaluating collaborative care (reflexive monitoring)
The weekly supervision presented regular opportunities for care managers and supervisors to reflect on
patients and monitor their progress jointly. Collaborative care and the psychosocial intervention were
described as effective and acceptable by care managers and supervisors, although it seems that care
managers reflected on the perceived effectiveness of the psychosocial intervention (which formed the
majority of their work with individual patients) rather than the collaborative care framework as a whole.
The care managers described how they monitored patients through the collection of routine data
(HADS), their own perceptions of patients’ progress and discussions within supervision:
[A] couple of people who, especially one, he’s had long-standing social anxiety so a bit more of a
complicated problem, but also depression, and we just worked away on the depression and we saw
an improvement, so just by doing that behavioural activation, so sometimes even though someone’s
got more complex problems, for some people behavioural activation just saw quite an improvement,
you know.
CM102
I think it’s effective . . . I think that has been the most satisfying part, that I know it can work, I’ve seen
BA [behavioural activation] work.
CM105
Although care managers and supervisors identified some problems around delivering the trial psychological
intervention (behavioural activation) in line with the protocol for those with comorbid mental health and
complex social problems, the principles of intervention were still perceived to be acceptable in reducing
symptoms of depression:
I think I would’ve liked to work on anxiety a bit more, but at the same time . . . we’ve watched those
depression scores come down.
CM101
Some GPs did report receiving positive feedback from patients about their experiences with the care
managers and of the intervention, which led the GPs to believe that there was some value in the
intervention. This ‘second-hand’ knowledge was the only evidence on which GPs could reflect on the
intervention, or on the collaborative care framework:
A significant amount of them have reported personally that they have felt better after participating in
the trial, in the study and then whatever the numbers there is some benefit in it.
GP002
I think certainly with a number of patients they did seem to gain considerable benefit and their
depression was improved and their general social functioning seemed to be improved . . . I didn’t get
any negative feedback about the process.
GP006
In contrast to the care managers’ reports, GPs reported that they did not actively seek feedback from
patients regarding their experience of collaborative care, and feedback was received only when
volunteered by the patients:
Generally from the patients we have had very positive feedback, and often our patients are generally
kind of if there is something they don’t like they will come and tell us.
GP009
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Similarly, some GPs suggested that the results of the trial rather than their views would determine their
opinion on the future possibility of working in a new way:
[O]ne of my managers doesn’t see how, if CADET really works, so, and at the same time I’m not sure
because I’m waiting, I look for the actual, you know sometimes I think it hasn’t worked, sometimes
I think it has worked . . . I suppose that’s where the results will show, whether that’s worked.
CM101
[W]e’re talking small numbers and I think we need to see some outcome data rather than just my
anecdotal subjective views of possibilities.
GP010
The supervisors raised concerns about who would take on the responsibility of supervision of the care
managers if collaborative care was implemented into routine practice, because of both the expertise and
the time required to deliver supervision to the same standard and frequency as was delivered in the trial.
Care managers also identified time as the biggest resource necessary to implement collaborative care,
which included the time needed to maintain the prompt commencement of the intervention following
referral, the time required for the administration involved in communicating with GPs and the time
invested in supervision:
I think the collaborative care part of it, because, writing a letter after assessment and then keeping a
GP updated with letters, often what happens at [names team], the GPs are sent a letter on discharge
with a summary of what happened, so that’s kind of like no collaboration at all, for a lot of people
there’s absolutely no collaboration, and that’s just down to time really and just the number of patients
that everybody has.
CM106
However, GPs felt that the main obstacle to implementing collaborative care would be the financial cost of
commissioning collaborative care services, which they perceived would be more expensive than
current care:
Researcher: What are your views on whether collaborative care should be commissioned as a service
for management of people with depression in primary care?
GP005: I would say it is an excellent way forward. However, it couldn’t really have come at a worse
time could it?
Researcher: Could you explain that?
GP005: Well in terms of all the financial restrictions and all the changes that are going to be
happening at the moment.
Thus, care managers and supervisors valued the care manager role encompassing expert supervision as
well as the specific psychological intervention, including the behavioural activation and medication
management components. Care managers placed less emphasis on the liaison between care manager and
GP. GPs did not report actively reflecting on and monitoring the collaborative aspect of collaborative care,
between care managers and GPs, but care managers described examples of liaison and how it might be
facilitated. Care managers were positive about implementing collaborative care into routine practice,
although possibly the emphasis was on the psychosocial intervention rather than the broader collaborative
care framework; however, lack of time, concerns over supervisory arrangements in routine practice and
the perceived cost of implementation were identified by all participants as barriers to this.
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Results of the analysis of therapy recordings
Our analysis of the 30 session tapes sampled led to three emergent themes describing the process of
treatment delivery: (1) engaging the patient, (2) adopting a counselling model and (3) variations in the
delivery of behavioural activation. We describe these in the following sections.
Engaging the patient
The theme ‘engaging the patient’ describes the efforts and strategies employed by care managers to
develop a therapeutic relationship with participants. The theme covers not only these strategies and skills
but also communication examples in which care managers failed to connect with participants before trying
to engage in the more functional aspects of the CADET clinical protocol.
In terms of achieving engagement, care managers would use scripts, not necessarily those provided in the
CADET treatment manual, but rather from a routine framed by the organisation in which they worked.
Care managers were not directly employed by the trial team but were working with CADET participants
alongside their other responsibilities in the provider organisation for whom they worked. As such, their
‘script’ could represent standard introductory information that they were required to give as part of their
usual clinical practice. In most cases, this made specific reference to the limits of confidentiality:
OK so I’ve got a bit of a script to read out first but the rest of it is just completely free-flowing
conversation. It’s just to make sure I give you the information I need to begin with so I don’t miss
anything out.
Care manager, assessment T4
It was clear, however, that one of the difficult tasks for the care managers was to merge the script
described above with the need to address the immediate needs of the participant and to engage them in
the CADET clinical protocol. Non-specific therapeutic skills such as simply providing encouragement and
positive feedback seemed to help with achieving and maintaining engagement. A key skill that we
observed here was the verbal expression of empathy:
Participant: Oh, I don’t really have much confidence in myself let’s put it that way, I just plod on, I just
keep going through it.
Care manager: You’ve obviously had a struggle for quite some time but somehow you have managed
to keep going.
Assessment T3
Care managers did not always demonstrate engagement with participants and a number of examples of
styles of communication that seemed to result in a failure of engagement could be identified in the
sessions. There were examples of the care manager almost having a parallel dialogue in which the cues
provided by the participant were not picked up on, because of the need to progress with the CADET
interview task. One task, collecting factual assessment information, sometimes resulted in prolonged
interrogative sequences in which the opportunity to pick up on key emotional cues was lost. Likewise,
premature reassurance without understanding, acknowledging and empathising with the nature of the
problems was not a successful intervention in achieving engagement:
Participant: I feel useless, like I’m a bad mother.
Care manager: And what makes you say that?
Participant: I don’t know.
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Care manager: Because it seems like, although it is really hectic, it seems like there is a routine there
and there is control and just having a routine is a base for children, because they come home and –
Participant: They’re always playing up and that so I just think I don’t have that much control over them
that way, sometimes I just sit there and cry for nothing, I just feel like this is all there is to life, what
happened to me basically, because I used to be such a bubbly, outgoing person.
Assessment T2
Adopting a counselling model
The theme ‘adopting a counselling model’ describes two particular types of interaction that moved beyond
simply being empathic to engage the participant and towards something more recognisable as counselling.
The first (delivered in response to life events/emotional cues from the participant) involved offering not
simple empathic comments but explanatory hypotheses as a response to the participant talking about life
difficulties, an approach more associated with psychodynamic therapies. The second counselling focus
was when care managers talked about relationships rather than exploring the impact of depression
on behaviours, triggers and consequences, and working towards goals. In several of the recordings,
open-ended discussions of relationship issues rather than a focus on strategies to manage and address
low mood were observed:
Participant: I all too easily see the negative side in me, what I, what’s wrong with me and what I
haven’t done or what I did or shouldn’t have done or –
Care manager: Sounds like you’re very hard on yourself.
Participant: I am yeah.
Care manager: Well that’s going to have an impact on your confidence isn’t it? You know if, again if
you’re seeing the redeeming features in everybody then perhaps any situation that comes up you
might be more likely to take that on as if something bad happens then that’s something that you’ve
done rather than –
Participant: Yes, yes, like it couldn’t be their fault because they’re not like that it must be me.
Care manager: Yeah, ok, so you recognise that yet you still find that this has impacted on you in
certain ways. Well you’re not alone with that, certainly and it sounds again like I mean how long were
you with your wife for?
Assessment T4
This discussion topic could then become a primary feature of the shared problem statement, making it
difficult to move on to functional aspects of the CADET protocol such as symptom monitoring, medication
management, behavioural activation and GP liaison.
Variations in the delivery of behavioural activation
The theme ‘variations in the delivery of behavioural activation’ describes how care managers explained and
delivered behavioural activation, a core element of the CADET clinical protocol. Behavioural activation was
clearly described in the manual provided to the care managers and they received 5 days of training in
how to deliver it. Nonetheless, we observed differing approaches from care managers in terms of initial
explanations, identification of behavioural exercises and goal setting with participants. We also identified
care managers focusing on the content of participants’ cognitions, a cognitive treatment strategy not part
of the CADET clinical protocol.
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In terms of explaining behavioural activation, some of the care managers managed a reasonably accurate
explanation of it. In some sessions the explanation was brief and reduced simply to the idea of ‘getting
going and doing things again’, with quite cursory reference to it during later sessions. In a similar way to
the behaviours that we observed in the theme ‘engaging the patient’, this sometimes sounded rather like a
one-way preprescribed ‘script’, with little opportunity for the participant to ask questions:
Care manager: The idea is that depression leads to changes in how we behave, our routines change,
we withdraw from things that we enjoy and we tend to avoid doing necessary and important things,
so the idea is that by setting goals we act our way out of depression rather than waiting until we think
that we’re ready to think our way out of depression. So behavioural activation is a structured and
active method of helping yourself and it focuses on re-establishing daily routines, increasing the
pleasurable activities that we do and addressing necessary issues so we’ll help you to regain the
functions that may have been lost or reduced since you felt low. Does that make sense or –
Participant: Yeah, of course, get my brain back and functioning again, I’d appreciate that!
Assessment T5
There were examples of conversations in which care managers focused on the therapeutic effect of
increasing physical activity or exercise, whereas the behavioural activation protocol instructed care
managers to help participants increase a much broader range of personally relevant activities with the
objective of re-establishing routines that had been reduced or disturbed during their depression. Likewise,
we did observe variation in the way that care managers helped participants to set personal goals, another
key element of the behavioural activation protocol. Some care managers left goals rather vague whereas
others helped participants narrow down to specifics:
Care manager: OK, what are your expectations and your ideas of what you’d like to achieve in the
time that we’ve got together?
Participant: Just to be what people call normal, I suppose.
Care manager: What does normal mean? What are you not doing now that you’d like to do by the
time we’re finished working together?
Assessment T9
We saw how care managers could help participants to translate overall goals into specific activities.
Planning of activities could be detailed to help participants know what activity they were going to do and
how and when they were going to try and carry out the activity. The next two extracts show this variation
clearly; in the first extract the first care manager tries to establish clear procedural detail whereas, in the
second extract, the details remain somewhat vague and after cursory attention being paid to the detail of
how a goal was to be achieved the interview moves on to the care manager’s own agenda:
Care manager: Yeah, so what do you think you want to do over the next week to look at that, do you
think there’s anything you could change to put that in your diary or?
Participant: Yeah, I think the first thing I should do is clean myself up really. I mean I’m not dirty or
anything like that, don’t get me wrong, but my hygiene has gone out of the window looking at this,
it really has.
Care manager: So if you just look at the personal hygiene in a morning and work on that bit first that
sounds reasonable doesn’t it, so what are your aims there, is it a wash or a shower or a wash one day
and a shower the next?
Follow-up T7 (3)
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Yeah, I think maybe make that as a goal for this week or the next time we speak, maybe to contact
the Citizens Advice Bureau and see what you could do there, that’s quite an important thing to do
at the moment. Well that’s good, excellent. I am going to go on to the HADS scale, the HADS
questionnaire, do you have the paper in front of you?
Care manager, follow-up T2 (1)
In terms of care managers’ fidelity to the CADET clinical protocol, we did observe some use of clinical
strategies that we had not included in the manualised protocol. As noted previously in this section, our
care managers had established NHS clinical roles and were used to using a range of approaches as part of
their work. One common element of their established working practices – addressing cognitions directly
and using cognitive therapy concepts – could be seen to creep into their work with CADET participants
even though this was not in the CADET clinical protocol:
[W]hen we’re feeling low we have those automatic negative thoughts and if you’re a person who
tends to actually personalise things which is a thought bias then sometimes we can beat ourselves
up about it. I’m certainly not thinking this is your fault, I’m thinking oh a sinus infection, that’s
terribly painful.
Care manager, follow-up T4 (2)
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Chapter 5 Results of long-term follow-up at
36 months
Introduction
Our original funding and protocol1 included only a maximum 12-month follow-up period. However, we
were able to use some grant underspend to facilitate a no-cost extension from the MRC/NIHR to examine
the long-term effects of collaborative care.
Our procedures were adapted from those described in the preceding chapters. Given our limited resources,
36-month follow-up interviews could be conducted only over the telephone or by post from a central site
in Exeter.
Sample
Participants were those who were recruited and allocated at baseline to the intervention or control groups
of the CADET study.
Ethical considerations
We applied for and received ethics approval for this trial extension from the NHS Health Research
Authority, NRES Committee South West (NRES/07/H1208/60). Because of the unplanned nature of the
36-month follow-up, participants had not been warned that we would be contacting them at this point.
Therefore, we sent them a letter explaining the trial extension with an opt-out slip attached that they
could return to the research team if they did not wish to be contacted. If a participant could not be
contacted by the research team, the GP and/or clinical commissioning group were contacted as
appropriate and all reasonable attempts to re-establish contact were made.
Measures
Our outcomes at the 36-month follow-up point were depression (PHQ-9), quality of life (SF-36) and worry
and anxiety (GAD-7).
Analysis
We assessed the baseline characteristics of participants followed up and compared them with the baseline
characteristics of those lost to follow-up, using logistic regression predicting follow-up, adjusting for
clustering, age, site, practice size and IMD. When differences between those followed up and those lost to
follow-up were shown to be significant, we undertook further logistic regressions of treatment group on
significant baseline variables, adjusted for age and minimisation variables.
We analysed outcome data by ordinary least squares or logistic regression, allowing for clustering by use of
robust standard errors, adjusting at the cluster level for minimisation variables and site and at the individual
level for age and, when appropriate, the baseline measurement of the variable.
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We analysed the effect of missing data as a sensitivity analysis, estimated by chained regression equations
multiple imputation48 using all available scale clinical scores, age, sex, practice variables, site and
treatment group.
Results
At 36 months we obtained follow-up data, defined as primary outcome (PHQ-9) data, from 354 of the
581 participants who were observed at baseline (61% of those recruited).
Comparison between those followed up and those lost to follow-up
We compared the following variables between those followed up at 36 months and those lost to
follow-up: intervention group, age, sex, baseline PHQ-9 score, baseline GAD-7 score and baseline SF-36
PCS score and MCS score. We defined a participant as being present at 36 months if he or she returned a
PHQ-9 questionnaire. We successfully followed up 63.8% of the collaborative care group and 58.4% of
the usual care group. Table 19 shows the comparison between those followed up at 36 months and those
not followed up at 36 months. Table 20 shows the same analysis broken down by treatment group.
There is little evidence of a difference at baseline between those followed up and those not followed up
apart from a significant tendency for participants with a higher level of education to be followed up at
36 months. Table 21 shows education level by treatment allocation for those participants with data
at 36 months. Our logistic regression of group on education, adjusted for age and minimisation variables,
gives χ2 (4 degrees of freedom)= 7.8 (p= 0.1) indicating that there is no evidence that education differs
between treatment groups in those followed up for 36 months.
Outcomes
Summary statistics for available data are presented in Table 22. The results for the effect of collaborative
care at 36 months using the available data are reported in Tables 23 and 24.
Depression
There was no significant effect of collaborative care on depression (n= 354). The mean PHQ-9 score was
0.04 scale points lower (95% CI −1.59 to 1.66; p= 1.0) in participants receiving collaborative care than in
those receiving usual care (standardised effect size 0.01, 95% CI −0.31 to 0.33) (see Table 23). More
participants in collaborative care than those in usual care met criteria for recovery (OR 1.29, 95% CI 0.77
to 2.15; number needed to treat 18.8) and response (OR 1.33, 95% CI 0.80 to 2.21; number needed to
treat 15.6) but neither difference was significant (p= 0.3 for both) (see Table 24).
Anxiety
With data available for 281 (48.4%) participants we found no significant effect of collaborative care on
anxiety as measured by the GAD-7 (mean difference between collaborative care and usual care 0.53,
95% CI −0.78 to 1.85; p= 0.4) (see Table 23).
Quality of life
Mental health
With data available for 277 (48%) participants we found a non-significant difference (mean difference
0.42, 95% CI −3.40 to 4.24; p= 0.8) in the SF-36 MCS score between collaborative care and usual care.
Physical health
We found no significant effect of collaborative care on quality of physical health at 36 months (n= 277)
as measured by the SF-36 PCS score (mean difference between collaborative care and usual care 0.69,
95% CI −1.79 to 3.17; p= 0.6).
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TABLE 19 Comparison of baseline data between those with PHQ-9 data at 36 months and those without PHQ-9
data at 36 months
Variable at baseline PHQ-9 data at 36 months No PHQ-9 data at 36 months p-valuea
n 354 227
Collaborative care group, n (%) 176 (49.7) 100 (44.1) 0.2
Male sex, n (%) 102 (28.8) 61 (26.9) 0.7
Age (years), mean (SD) 44.5 (12.4) 45.1 (14.6) 0.6
Ethnic origin white British, n (%) 305 (86.2) 189 (83.3) 0.2
Education, n (%)
None 67 (18.9) 61 (26.9) 0.004
GCSE/O-level 87 (24.6) 59 (26.0)
Post GCSE/O-level 94 (26.6) 69 (30.4)
Degree or higher 78 (22.0) 24 (10.6)
Other or don’t know 28 (7.9) 14 (6.2)
Employed or self-employed, n (%) 105 (29.7) 61 (26.9) 0.2
Married or cohabiting, n (%) 149 (42.1) 92 (40.5) 0.7
Prescribed antidepressants, n (%) 292 (82.5) 188 (82.8) 0.9
CIS-R score, mean (SD) 28.8 (9.3) 30.3 (8.9) 0.06
ICD-10 diagnosis, n (%)b
Mild 50 (14.2) 33 (14.5) 0.5
Moderate 203 (57.5) 120 (52.9)
Severe 100 (28.3) 74 (32.6)
History of depression, n (%) 258 (72.9) 164 (72.2) 0.9
Anxiety disorder, n (%) 344 (97.2) 226 (99.6) 0.06
Long-standing physical illness, n (%) 230 (65.0) 140 (61.7) 0.3
PHQ-9 score, mean (SD) 17.5 (5.1) 18.2 (5.1) 0.1
GAD-7 score, mean (SD) 13.0 (5.1) 13.7 (5.0) 0.2
SF-36 PCS score, mean (SD) 44.5 (12.1) 44.8 (12.7) 0.6
SF-36 MCS score, mean (SD) 23.4 (10.0) 21.7 (10.7) 0.08
GCSE, General Certificate of Secondary Education.
a Logistic regression predicting follow-up, adjusting for clustering, age, site, practice size and IMD.
b One participant did not meet ICD-10 criteria for mild, moderate or severe depression on the CIS-R score.
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TABLE 20 Comparison of baseline data between those with PHQ-9 data at 36 months and those without PHQ-9
data at 36 months by treatment group
Variable at baseline
Collaborative care Usual care
PHQ-9 data at
36 months
No PHQ-9 data at
36 months
PHQ-9 data at
36 months
No PHQ-9 data at
36 months
n 176 100 178 127
Male sex, n (%) 48 (27.3) 26 (26.0) 54 (30.3) 35 (27.6)
Age (years), mean (SD) 44.7 (12.1) 45.6 (15.0) 44.3 (12.8) 44.8 (14.2)
Ethnic origin white British, n (%) 149 (84.7) 84 (84.0) 156 (87.6) 105 (82.7)
Education, n (%)
None 28 (15.9) 26 (26.0) 39 (21.9) 35 (27.6)
GCSE/O-level 37 (21.0) 28 (28.0) 50 (28.1) 31 (24.4)
Post GCSE/O-level 57 (32.4) 27 (27.0) 37 (20.8) 42 (33.1)
Degree or higher 38 (21.6) 11 (11.0) 40 (22.5) 13 (10.2)
Other or don’t know 16 (9.1) 8 (8.0) 12 (6.7) 6 (4.7)
Employed or self-employed, n (%) 55 (31.3) 27 (27) 50 (28.1) 34 (26.8)
Married or cohabiting, n (%) 87 (49.4) 40 (40.0) 62 (34.8) 52 (40.9)
Prescribed antidepressants, n (%) 144 (81.8) 87 (87.0) 148 (83.1) 101 (79.5)
CIS-R score, mean (SD) 28.4 (9.7) 29.4 (8.6) 29.6 (9.0) 31.3 (8.6)
ICD-10 diagnosis, n (%)a
Mild 27 (15.3) 15 (15.0) 23 (13.0) 18 (14.2)
Moderate 97 (55.1) 59 (59.0) 106 (59.9) 61 (48.0)
Severe 52 (29.6) 26 (26.0) 48 (27.1) 48 (37.8)
History of depression, n (%) 131 (74.4) 71 (71.0) 127 (71.3) 93 (73.2)
Anxiety disorder, n (%) 169 (96.0) 100 (100.0) 175 (98.3) 126 (99.2)
Long-standing physical illness, n (%) 112 (63.6) 59 (59.0) 118 (66.3) 81 (63.8)
PHQ-9 score, mean (SD) 17.2 (5.3) 17.7 (5.1) 17.8 (4.9) 18.5 (5.1)
GAD-7 score, mean (SD) 12.5 (5.4) 13.6 (5.2) 13.5 (4.7) 13.8 (4.9)
SF-36 PCS score, mean (SD) 44.7 (11.6) 44.8 (13.6) 44.2 (12.6) 44.8 (12.0)
SF-36 MCS score, mean (SD) 23.5 (9.2) 22.7 (12.1) 23.3 (10.7) 20.9 (9.5)
GCSE, General Certificate of Secondary Education.
a One participant did not meet ICD-10 criteria for mild, moderate or severe depression on the CIS-R score.
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TABLE 21 Educational attainment by treatment group for those followed up
Education Collaborative care, n (%) Usual care, n (%)
None 28 (15.9) 39 (21.9)
GCSE/O level 37 (21.0) 50 (28.1)
Post GCSE/O level 57 (32.4) 37 (20.8)
Degree or higher 38 (21.6) 40 (22.5)
Other or don’t know 16 (9.1) 12 (6.7)
TABLE 22 Measures at baseline and 36 months, participants retained at 36 months
Measure
Collaborative care Usual care
n Mean SD Minimum Maximum n Mean SD Minimum Maximum
PHQ-9 score
baseline
176 17.2 5.3 5 27 178 17.8 4.9 4 27
PHQ-9 score
36 months
176 10.2 7.2 0 27 178 10.4 7.1 0 27
GAD-7 score
baseline
139 12.3 5.5 1 21 141 13.2 4.6 3 21
GAD-7 score
36 months
140 8.2 6.5 0 20 141 8.1 6.3 0 20
SF-36 MCS score
baseline
137 23.7 9.4 1.3 44.8 137 23.9 10.6 –3.9 50.4
SF-36 MCS score
36 months
139 37.1 15.2 –1.8 63.6 138 37.0 14.6 5.4 63.4
SF-36 PCS score
baseline
137 44.7 12.2 17.7 70.7 137 43.9 12.3 18.2 68.2
SF-36 PCS score
36 months
139 45.4 12.1 15.9 66.2 138 44.3 12.9 13.5 66.0
TABLE 23 Primary and secondary outcomes at 36 months’ follow-up
Measure
Collaborative care Usual care
Adjusted
difference 95% CI p-value Effect sizen Mean SD n Mean SD
PHQ-9 score
36 months
176 10.2 7.2 178 10.4 7.1 –0.04 –1.59 to 1.66 1.0 0.01
GAD-7 score
36 months
140 8.2 6.5 141 8.1 6.3 0.53 –0.78 to 1.85 0.4 0.10
SF-36 MCS score
36 months
139 37.1 15.2 138 37.0 14.6 0.42 –3.40 to 4.24 0.8 0.04
SF-36 PCS score
36 months
139 45.4 12.1 138 44.3 12.9 0.69 –1.79 to 3.17 0.6 0.06
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Missing data
We undertook additional analyses using imputation. The imputed estimates in Table 25 are very similar to
the available data estimates (see Table 23) so we can conclude that for all of these analyses the effects of
collaborative care are little affected by missing data. Missing data were also not related to intervention
group (Table 26). At 36 months, we conclude, therefore, that, despite the inevitable large losses to follow-up
over 3 years, there is no evidence of bias in the treatment effect estimates from available data.
TABLE 24 Recovery, response and numbers needed to treat at 36 months’ follow-up
Collaborative care Usual care
ORa 95% CIb p-valueb
Number
needed
to treatcn
Recovered/responded,
n (%) n
Recovered/responded,
n (%)
Recoveryd
36 months 176 87 (49.4) 178 78 (43.8) 1.29 0.77 to 2.15 0.3 18.8
Responsee
36 months 177 81 (46.0) 178 70 (39.3) 1.33 0.80 to 2.21 0.3 15.6
a Adjusted for age, site and minimisation variables.
b Adjusted for clustering by practice.
c Inverse of absolute risk reduction adjusted for clustering by practice.
d Recovery defined as a follow-up score of ≤ 9 on the PHQ-9.
e Response defined as a ≥ 50% reduction in PHQ-9 score at follow-up compared with baseline.
TABLE 25 Adjusted regression effects of collaborative care after multiple imputation
Scale Data Coefficient Robust standard error t p-value 95% CI
PHQ-9 score,
36 months
Imputed −0.18 0.73 −0.25 0.8 −1.65 to 1.30
Available data 0.04 0.81 0.05 1.0 −1.59 to 1.66
GAD-7 score,
36 months
Imputed 0.53 0.67 0.79 0.4 −0.84 to 1.90
Available data 0.53 0.65 0.82 0.4 −0.78 to 1.85
SF-36 MCS score,
36 months
Imputed −0.12 1.71 −0.07 0.9 −3.62 to 3.38
Available data 0.42 1.90 0.22 0.8 −3.40 to 4.24
SF-36 PCS score,
36 months
Imputed 0.94 1.14 0.83 0.4 −1.41 to 3.29
Available data 0.69 1.23 0.56 0.6 −1.79 to 3.17
TABLE 26 Missing PHQ-9 data by intervention group
Intervention group, n (%)
OR for missing data in
collaborative care group
p-value (robust
standard error)Collaborative care Usual care
Missing PHQ-9 data
at 36 months
99 (35.9) 127 (41.6) 1.26 0.20
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Summary
Our results at 36 months’ follow-up showed that, after 3 years, participants in this trial were greatly
improved with regard to depression, anxiety and quality of mental health. There were no longer any
treatment differences, suggesting that the usual care participants had caught up with the earlier greater
improvements in the collaborative care group. There was little change in physical quality of life; however,
we would not have expected this as both collaborative care and usual care in this population were directed
towards participants’ mental health. This provides evidence for the validity of the trial.
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Chapter 6 Discussion
This chapter utilises material from three2,3,61 of the four open-access articles previously published by theresearch team in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) licence
explicitly permitting the unrestricted distribution, remixing, adaption and reuse of these works.
We found that collaborative care improved depression at our primary end point of 4 months compared
with usual care, effects that persisted up to 12 months. Collaborative care is cost-effective when service
commissioners are willing to pay up to £20,000 per QALY gained and was preferred by patients over
usual care. The differences in clinical outcomes between participants treated by collaborative care and
participants treated by usual care were no longer apparent at 36 months’ follow-up. In our process
analyses we demonstrated that only one variable, the amount of behavioural activation undertaken by
participants, predicted better outcomes, despite the fact that there was considerable variation in how
behavioural activation was both explained and operationalised by care managers in sessions. We also
found that case managers and supervisors regarded collaborative care as coherent but that the collective
action required to implement elements of collaborative care was made difficult by GPs’ lack of
engagement with the collaborative care framework.
Clinical outcomes
Collaborative care improved depression compared with usual care at both 4 and 12 months’ follow-up.
Our observed effect size was less than that used to power the study, although the 95% CI around it (0.26,
95% CI 0.07 to 0.46) encompassed our original target (0.4). Our result also lies within the 95% CI of the
SMD found in the most recent meta-analysis of collaborative care,73 which includes our results (overall
SMD 0.28, 95% CI 0.23 to 0.33), and is no different from US (SMD 0.28, 95% CI 0.21 to 0.35), non-US
excluding the UK (SMD 0.36, 95% CI 0.13 to 0.59), and other UK (SMD 0.32, 95% CI 0.07 to 0.57)
trials.23 Collaborative care is as effective in the UK health-care system, an example of an integrated health
system with a well-developed primary care sector, as in the USA. Our study adds to the emerging
international literature from countries such as Chile26 and India27 indicating that collaborative care is a
model that reliably generalises outside the USA.
We also found that participants rated their satisfaction with treatment more highly in the collaborative care
group than in the usual care group, the largest difference between groups of any of our measures. These
results are in line with data showing that most participants were adherent to collaborative care, with the
majority receiving more than two contacts with care managers and the average contact rate being
between five and six sessions. Collaborative care is therefore not only effective but patients receiving it
are more satisfied with their care than those receiving usual care and are adherent to the intervention.
In the long-term, at 36 months, there was no significant difference between the groups. This confirms the
picture described in the recent Cochrane review23 in which the clinical benefits of collaborative care were
not found beyond 2 years after the intervention. Despite the lack of significant difference it is worth noting
that in the collaborative care group > 5% more participants had responded or recovered at 36 months.
Economic outcomes
Although previous reviews74,75 have identified evidence from cost–utility (cost per QALY) studies to support
the economic value of collaborative care for depression in the US health-care system, the CADET trial is the
first study to estimate the cost-effectiveness of collaborative care in a UK primary care setting. We have
shown that collaborative care is cost-effective compared with usual care in treating people with depression
in a UK primary care setting when providers are willing to pay up to £20,000 per QALY gained.
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Furthermore, when taking a broader analytical perspective and including costs associated with informal
care, the results show that collaborative care is expected to be cost saving, with expected health gains, and
therefore dominates the usual care comparator.
Our cost-effectiveness analyses report an expected modest mean QALY gain for collaborative care at a
relatively low cost. Although the mean QALY gain is modest, it is comparable, and favourable, to that
recently reported in the evaluation of a UK Improving Access to Psychological Therapies (IAPT) service,76
which estimated a mean EQ-5D QALY gain of 0.014 (SF-6D gain of 0.008). Our estimated costs for health
and social care in the CADET trial are similar to those reported in the IAPT service evaluation for IAPT
service or comparator mental health-care services.76 Furthermore, despite differences in the populations,
the QALY gain from the collaborative care intervention is in a similar range to that reported in an
evaluation of therapist-delivered cognitive–behavioural therapy for depression,77 in which the mean
incremental QALY benefit was reported as 0.027 (95% CI –0.012 to 0.066).
Our base-case difference in health and social care (NHS and Personal Social Services) costs over 12 months
(£272.50) and the subsequent cost per QALY estimate of £14,248 are heavily influenced by one
participant who reported extremely high levels of service use for specialist care, including a 100-day stay in
an acute psychiatric hospital. This participant, in the collaborative care group, had an estimated service use
cost of £48,522 compared with a mean cost of £1637 for all other trial participants with cost data over
12 months (n= 446) averaged across both groups; 94% of participants had cost estimates of < £5000, all
but four participants had cost estimates of < £10,000 and three participants had costs estimated between
£10,000 and £24,000. When we excluded this one participant from the analyses, the difference in NHS
and personal social services costs between collaborative care and usual care when including the cost of
collaborative care was £63, with an estimated cost per QALY of £3334.
Our probabilistic analyses indicate that collaborative care has a 58% and 65% probability of being
cost-effective at commonly assumed UK NICE willingness-to-pay thresholds of £20,000 and 30,000 per
QALY respectively. When we considered the uncertainty around the cost-effectiveness estimate that
excludes one participant with high service use and costs (£3334 per QALY), the probability of collaborative
care being cost-effective at these cost per QALY thresholds was > 75%. The most conservative expectation
(based on the intention-to-treat principle) would be that the introduction of collaborative care will involve
an additional cost of £272.50 per participant for the UK NHS and this potential cost, alongside estimated
EQ-5D QALY gains, will result in an expected cost per QALY of £14,342, which is similar to the base-case
analysis presented here and represents a cost-effective use of NHS resources. We would suggest that
the likely cost-effectiveness of collaborative care in practice might be closer to the estimate in the
sensitivity analysis with the very high-cost participant excluded.
Process analyses
The principal finding from our moderation and mediation analyses was that the effects of collaborative
care on depression at 4 months’ follow-up can be entirely attributed to the amount of behavioural
activation undertaken by participants and the effects at 12 months are strongly mediated by behavioural
activation. Despite the fact that collaborative care is a complex intervention that also includes medication
management, we found evidence only for the mediating effect of behavioural activation. We found no
evidence that depression severity, number of previous depressive episodes, attitudes towards treatment
components, physical health problems or socioeconomic status influenced treatment outcome, and nor did
we find that the care manager, number of contacts between care manager and participant and adherence
to medication influenced outcome, albeit our study was not powered to detect these effects per se.
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The second component of our process analysis, interviews with care managers, supervisors and GPs,
showed that collaboration around the management of patients with depression in primary care was valued
by professionals. However, GPs’ understanding of collaborative care, compounded by long-standing
organisational barriers, hindered their engagement in the intervention. It is unclear whether or not more
GP engagement would have led to better outcomes. Enhanced supervision as reported in this study may
be collaboration enough to result in improved patient care.
Our final process evaluation element, in which we analysed care manager/participant contact audio-tape
recordings, revealed variation in the way that care managers engaged participants, how they behaved
clinically and how they undertook behavioural activation. Verbal expression of empathy, encouragement
and positive feedback seemed to be key in achieving both initial engagement and its maintenance.
Some care managers strayed from merely demonstrating empathy into a style of treatment more closely
identifiable as counselling. There was variation in how the elements of behavioural activation were
demonstrated by care managers, with considerable difference in how behavioural activation was both
explained and operationalised. Despite the protocol focus on behaviour alone, some care managers also
chose to address cognitions.
Strengths and limitations of the study
The CADET study is one of the largest studies of collaborative care with an integrated economic evaluation.
Less than 50% of published collaborative care trials have followed up participants for ≥ 12 months and our
levels of attrition at 4 and 12 months are comparable with those in 70% of collaborative care trials and
better than those in other trials of brief interventions in this area.78 There was no evidence that missing
follow-up data biased the findings, even at 36 months when, not surprisingly, attrition was higher than at
other follow-up time points.
Although our cluster design protected against contamination of the usual care arm by changes in
behaviour being tested in the collaborative care arm, cluster trials are prone to selection bias. We
minimised this bias by recruiting participants through electronic case note searches rather than clinician
referral. Given the nature of the intervention and comparator we could not blind GPs, patients or care
managers to treatment allocation but we used self-report outcome measures to minimise the impact of
detection bias. The supervisors who we interviewed were also CADET co-investigators and therefore their
views are likely to be framed by their academic investment in the study. As CADET trial researchers
conducted the qualitative interviews some researcher bias may be evident, as this is likely to have affected
the participants’ responses, particularly those of the supervisors and care managers.79 We attempted to
use interviewers from another study site to reduce this bias. Although purposive sampling of GPs was
attempted, GPs were difficult to recruit to this qualitative study, with a majority of those who refused
citing lack of time or limited involvement in the trial as reasons for this. However, category saturation was
achieved within the data, although the difficulties experienced in recruiting GPs may mean that the data
may not represent the views and experiences of GPs in all participating practices.
Our within-trial analysis demonstrates cost-effectiveness at the willingness-to-pay threshold of £20,000 per
QALY, without the need to extrapolate potential benefits over the longer term. Our analyses used data
collected within the trial to estimate resource use and costs associated with delivery of the intervention,
but relied on self-report data from interviewer-administered questionnaires to estimate health and social
care service use and broader resource impacts. Routinely collected service use data may have provided
a more rigorous estimate of service use, particularly for primary care contacts.80 However, there would be
difficulties and costs related to the collection of service use data from 42 general practices and to
necessary routine data collection for aspects of care not recorded in GP records and therefore we chose
to use participant self-report data. We also relied on self-reported records of care manager contacts and so
have no means to assess record accuracy.
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Difficulties in collecting detailed data on medication use by self-report methods can lead to errors in
self-reporting. These errors include the potential for variation in medication names, variation in reported
dose and complexity in relation to the use of medications for a wide range of comorbid conditions. These
issues led us to exclude medication costs from the economic analysis plan1 and this may be a limitation in
the results presented here, as medication adherence has been shown to be one of the potential benefits of
collaborative care.23 However, most participants in both the collaborative care group and the usual care
group remained on antidepressant medication (74.8% vs. 73.8% at 4 months; 69.7% vs. 69.2% at
12 months). Finally, the collection of resource use data using self-report methods over 4-month and 8-month
durations may have introduced recall bias and this has not been explored as part of the current analyses.
Although care managers were already employed by organisations providing primary care mental health
services in the UK NHS, supervisors were senior members of the investigator group and so it is unclear how
much their, albeit minimal, supervision can be generalised beyond the trial. Our intervention was brief
and it is possible that a more intensive intervention might have improved outcomes further, particularly
for the more complex cases. We could have chosen a different psychological intervention such as
cognitive–behavioural therapy81 but a review38 and a randomised controlled trial82 showed that behavioural
activation is as effective as cognitive–behavioural therapy, potentially more so for severe cases,83 and
can be delivered effectively by junior, less intensively trained health-care personnel.82
The perspective on the analyses does not extend to the broad welfare and economic impacts of
depression, including impact on productivity costs, as such costs are not included in the reference case
analyses suggested by NICE56 for UK analyses. However, data collection did cover aspects of care and
support and patient costs, which has extended the primary perspective (of NHS and Personal Social
Services costs) to a broader patient- and societal-orientated perspective. We accept that the use of a
relatively small number of categories for these broader considerations may be a limitation in the analyses.
However, as in other studies (e.g. Romeo et al.84), we found that resources and estimated costs associated
with informal care were a dominant aspect when taking a wider perspective and this gives us clear
guidance on the magnitude of these wider perspective costs.
Implications of the clinical and economic findings for the NHS
During the time that we undertook the CADET study the number of international trials of collaborative
care more than doubled, albeit with many of them still conducted in the USA. Although the
generalisability of a US collaborative care model to the UK had been suggested by previous small-scale
studies, the CADET trial has provided definitive confirmation of generalisability and that collaborative care
is preferred over usual care by depressed patients and is cost-effective in the UK. We have therefore
answered a specific research need highlighted in the NICE guidelines for depression,28 providing critical
evidence for service delivery improvement. The NICE guidelines can now be reviewed to reassess the place
of collaborative care in the stepped care pathway in light of our findings that collaborative care is clinically
effective and cost-effective for a range of depressed patients, not necessarily those who fail at
other treatments.
Although our results sit within the expected effect range of collaborative care reported in the latest
meta-analysis of international collaborative care trials,23 the clinical implications of our results are more
difficult to interpret given that the average difference in treatment response was less than that we had
anticipated (actual effect size 0.26 vs. 0.4 anticipated). Between-group differences can obscure response
rates in individual patients. We have therefore presented the data on meaningful clinical difference using
numbers needed to treat and two criteria commonly applied in the depression literature and regarded
as clinically meaningful: that of recovery (falling below a recognised point on the PHQ-9 symptom scale)
and response (a ≥ 50% reduction in symptoms of depression). Using these metrics it is particularly
noteworthy that at 12 months 56% of patients receiving collaborative care were ‘recovered’, 15% more
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than in usual care. Health services would therefore need to treat 6.5 patients using collaborative care
to produce one additional patient with a sustained recovery compared with usual care.
Studies that have achieved higher effects have been undertaken in countries with less developed primary
care services26,27 or have used more highly qualified workers such as nurses or social workers.85 These
workers are in acute short supply in the UK and hence this would not have been a translatable model for
our health system.
Our results represent a slightly higher recovery rate than that reported by the UK IAPT programme.
Recovery rates of around 45% have been achieved in the IAPT programme following an investment of
£700M over 6 years.86 We suggest that integration of our CADET protocol into IAPT services might
enhance outcomes for depressed patients receiving treatment and provide guidance to international
mental health services that this model can be applicable outside the USA.
The finding that collaborative care is the dominant intervention compared with usual care when we
included informal care costs in our analyses is an important issue. Family members and others involved in
informal care contribute to the care of depression in a substantial manner. As Richard Layard87 and others
have often asserted, the implications of these care costs on productivity are a significant burden
on the economic activity of a nation. The introduction of collaborative care has the potential to relieve
some of the significant burden that falls on informal carers and reduce this economic load.
Given that collaborative care is more effective over a sustained period of time than usual care and
represents value for money to the NHS at commonly used thresholds for cost per QALY, we suggest that
commissioners of health care in the UK might review the organisation of their routine depression
management services and consider using a collaborative care model. Evidence here indicates that services
could benefit from being commissioned to support the management of patients with depression in UK
primary care using a collaborative care model, as it would be both clinically effective and cost-effective to do so.
Implications of the results for treatment development and
future research
Although collaborative care is an organisational intervention that improves outcomes, much remains to be
done to improve the effectiveness of treatments for depression. Even intensive psychological treatments
for depression have been shown to achieve only modest gains (effect size of 0.42 in 51 studies88). Our
careful selection of intervention ingredients, directed by our identification of components present in the
better-performing trials from our previous metaregression,89 did not succeed in achieving the larger effects
we had hoped for. In the trial, 44% of participants receiving collaborative care had PHQ-9 scores that
remained above the PHQ-9 depression threshold at 12 months’ follow-up.
The strong finding that behavioural activation was the only mediator of effect is important. Behavioural
activation is hypothesised to operate by providing people with more opportunities for positively reinforcing
experiences and reducing the amount of negatively reinforced avoidance behaviours, thereby improving
affect. This hypothesis would appear to be supported by our results. We would encourage future
researchers to measure the mediational contribution of behavioural activation to patient outcomes in other
trials, to determine the universality or otherwise of our findings. If replicated, this would have considerable
implications for the inclusion of activating strategies in other effective depression management strategies.
Further, in the context of the findings from our audio-tape analysis that there was variation in the delivery
of behavioural activation in care managers’ contacts with participants, we may have achieved better
outcomes, more in keeping with our predictions, had care managers been able to deliver a more rigorous
and consistent behavioural activation programme. We may have achieved better outcomes, more in
keeping with our predictions, had care managers been able to deliver a more rigorous and consistent
behavioural activation programme. Our supervision model did not require supervisors to listen to audio
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tapes and give care managers specific clinical feedback on these tapes. It might be that we could optimise
the delivery of behavioural activation to ensure that it is more consistent by amending our supervision
model to require supervisors to sample audio tapes and feed back their analyses. It seems clear that clinical
and supervisory practice should focus much more on enhancing the quality and consistency of behavioural
activation within the collaborative care model. However, our supervisory system was delivered by
professionals with considerable expertise in case management and behavioural activation. The ability of
routine services to replicate this standard of supervision would need to be tested and then monitored in
any implementation programme.
The limited liaison reported between GPs and care managers could suggest that more work is needed to
facilitate collaboration around individual patients. Some structural aspects were identified that may
facilitate liaison, including shared place of working, shared information technology systems, facilitating
opportunities for informal meetings and building in formal collaboration into the collaborative care
framework. However, although considered by many to be desirable, it is unclear if such an increase in
collaboration between care managers and GPs would improve clinical outcomes. Despite being a core
component of the collaborative care model, the extent to which additional collaboration between care
managers, supervisors and GPs beyond established communication lines is actually necessary for effective
patient management of depression is as yet undetermined. For example, a recent trial of collaborative care
for people with long-term physical health conditions and depression90 introduced joint sessions with
primary care staff (practice nurses) and mental health-care managers to reflect the comorbid problems
that patients had, but the effects were no different from those in the CADET study.
Although the vast majority (98%) of our participants had a secondary diagnosis of anxiety we found no
differential effect of collaborative care compared with usual care on anxiety at any follow-up point.
Patients in both groups had less anxiety at 12 months in particular but the difference between the two
groups at this point fell just short of being significant. It seems that a fruitful area of potential treatment
development would be the addition of specific anxiety-directed treatment components to the basic
collaborative care package. In addition, the high prevalence of long-term physical health conditions in our
study population is worthy of note and suggests that specific attention given to this aspect of collaborative
care might reap rewards. Indeed, several studies in the USA91,92 and more recently the UK90 have done this.
Unfortunately, the addition of this focus in the UK did not deliver significantly enhanced outcomes
compared with the CADET study.90
Future trials should therefore test enhancements of the basic collaborative care model by developing,
testing and delivering better treatments within the effective collaborative care organisational framework
or improve the delivery of existing treatments through more rigorous supervision, rather than test
collaborative care per se, given that the effects of collaborative care are now firmly established.
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The Universities of York, Manchester and Leeds 
The Treatment of Depression in General Practice 
A Randomised Controlled Trial 
 
Introduction 
 
This protocol contains guidelines for delivering the case management 
element to patients with depression treated as part of the Enhanced Care 
for Depression clinical trial.  
 
Section A describes the research trial and details the overall principles of 
case management.  
 
Section B outlines a session by session overview.  
 
Section C describes the case management interventions (including education 
about depression, medication management and behavioural activation) and 
provides patient information leaflets.  
 
Section D provides resource materials for use by case managers. 
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The Universities of York, Manchester and Leeds 
The Treatment of Depression in General Practice 
A Randomised Controlled Trial 
 
 
 
Section A 
 
 
 
Principles and Practice of 
Case Management 
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The Universities of York, Manchester and Leeds 
The Treatment of Depression in General Practice 
A Randomised Controlled Trial 
 
Explaining the Trial 
 
This trial is funded by a project grant from the Medical Research Council. It 
is a randomised controlled trial where patients are allocated to either the 
‘experimental condition‛, in this instance case management, or ‘usual care‛ 
which in this study is care which would be offered in normal circumstances 
to patients with depression by the GP. 
 
Eligible patients are patients from 18 years onwards with a diagnosis of at 
least moderate depression who are not suicidal and who would normally be 
treated by GPs in primary care. Patients with very severe depression who 
would be referred to local psychiatric services are excluded from the trial. 
In essence, the trial is trying to find out what impact case management can 
have on the usual care of patients with depression in primary care. 
 
Although case management has a strong evidence base internationally, its 
application has not been studied in the UK. The trial is a ‘trial platform‛. This 
means that we want to understand the fine details of case management. For 
example, we do not know who would be the best person to act as a case 
manager in a UK primary care setting. In order to answer this and other 
questions, we are conducting the trial in four PCT sites across the North of 
England and deliberately varying the background of people who are acting as 
case managers. We are very interested in the outcomes of patients with 
depression who are assisted by a case manager but we are equally interested 
in the experiences of case managers themselves and in how the process of 
case management unfolds. 
 
Hopefully, by the time the trial is complete in March 2006, we will have 
tested this protocol and will understand more about the process and 
outcomes of case management for depression in primary care. We will use 
this information to make recommendations for both clinical practice and 
further research if this is indicated. Your help in this process is very much 
appreciated and we thank you for becoming involved.  
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The Universities of York, Manchester and Leeds 
The Treatment of Depression in General Practice 
A Randomised Controlled Trial 
 
Questions and Answers 
 
What is Case Management? 
 
Case management involves one health worker in primary care making 
proactive contact with patients. It includes regular, scheduled contacts 
(usually by telephone but may include some face to face contact). Case 
managers take responsibility for: 
 
1 assessing patients‛ views of depression, their attitudes to and 
concordance with psychosocial and pharmacological treatments  
 
2 negotiating shared treatment decisions with patients 
 
3 assisting patients with managing antidepressant medication 
 
4 delivering brief guided self-help psychosocial interventions 
 
5 feeding back of information about treatment and progress to the GP and 
mental health specialist to assist in treatment decision making  
 
How is Case Management Different from Other Forms of Community 
Mental Health Care? 
 
In a few areas, case management will be very similar to current practice. 
However, case management contacts are generally shorter than traditional 
community mental health care and start as soon as a patient is diagnosed 
with depression by a GP. The telephone is the most likely mode of contact in 
case management. Contacts with patients are structured around medication 
concordance and self-help psychosocial interventions. Psychosocial 
interventions are less intensive, less dependant on professional delivery and 
focussed more around self-help interventions. Contact frequency is explicitly 
organised around the phenomenology of depression and the response and 
side effect profiles of antidepressant medication and psychosocial 
interventions. 
DOI: 10.3310/hta20140 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 14
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Richards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
81
The Universities of York, Manchester and Leeds 
The Treatment of Depression in General Practice 
A Randomised Controlled Trial 
 
Who is Case Management Indicated for?
 
Case management is suitable for all patients with moderate depression who 
a) have been prescribed antidepressant medication or b) have chosen not to 
take medication. 
 
How are Case Managers Supported? 
 
Case managers are part of a system of ‘collaborative care‛. They do not work 
alone, but receive support from a specialist mental health professional and 
share information with the GP. Case managers operate to provide an 
extension of the GP‛s work and are in regular contact with the GP. Case 
managers are also supported by a specialist mental health professional who 
provides weekly supervision of cases together with advice and support. 
How long will Case Management Last? 
 
For the purposes of the trial, the duration of Case Management will be for 
12 weeks and include a maximum of 10 contacts per patient. 
 
What is the desired frequency of Contact Sessions? 
 
The minimum frequency should be weeks 1, 2, 4, 8, 12. Additional session 
frequency should be negotiated with individual patients. Negotiation of 
contact frequency should take into account patient preference, response to 
treatment, PHQ9 scores, the requirements of the psychosocial support 
programme and the amount of GP-patient contact. However, in general, 
weekly sessions are good practice during the first month of contacts, 
reducing to fortnightly in the second and third months. Where treatment is 
progressing satisfactorily, contacts may be less frequent than for patients 
who are struggling to overcome their depression.   
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How often should Case Managers try to Contact Patients?
 
Most case management contacts will be by telephone. Case managers should 
try to contact patients until they are successful in reaching the patient. The 
most successful strategy is to arrange a time when patients will be expecting 
a telephone call from the case manager. However, if patients cannot be 
reached, case managers should persist in trying to get through to the 
patient. In some cases, this may require very many attempted calls or calls 
to be made in the evenings or at weekends where this is possible. Clinical 
experience tells us that patients are overwhelmingly positive when case 
managers are persistent. We know of no cases where this has been regarded 
negatively by patients. 
 
What happens at the End of the Trial? 
After the period of case management comes to an end, case managers should 
discuss options with the patient‛s GP and their local mental health services. 
For some patients whose condition has substantially improved, no more 
assistance will be required aside from regular GP review. In other cases it 
may be appropriate for the GP to organise a referral to specialist mental 
health services, where these are available locally. In some cases, following 
discussion with service managers locally, case managers may wish to maintain 
further ongoing support to patients. Trial supervisors will be available to 
advise case managers on next steps; however, all decisions should be taken in 
consultation with GPs and local service managers.  
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Summary: Who Does What in the Trial.
 
The GP 
 
The GP is responsible for identifying patients with depression and referring 
them into the trial. They retain all medical responsibility for the treatment 
of trial patients. 
 
The Case Manager 
 
The case manager is responsible for supporting patients in their treatment 
choices for depression. They help the patient manage pharmacological 
treatments where these have been initiated and are also responsible for 
delivering a programme of self-help psychosocial support to patients. Case 
managers are responsible for communicating with the GP and supervisors on 
the progress of patients in the trial. 
 
The Supervisors 
 
Supervisors are responsible for providing support to case managers on the 
process of case management and on specific pharmacological and 
psychosocial interventions. They will initiate regular, scheduled reviews of 
patients and help case managers problem solve any difficulties. They will 
assist case managers in their communications with GPs. 
 
The Researchers 
 
Researchers are responsible for assessing GP referrals for suitability for 
the trial. They will interview suitable patients at the beginning and end of 
the trial to collect clinical outcome measures. The research trial unit is 
responsible for the random allocation of patients to each arm of the trial 
and for informing case managers of patient contact details once 
randomisation has taken place.
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Arranging Contacts with Patients 
 
The First Contact 
 
It is extremely important that patients are contacted by a case manager as 
soon as they consent to be involved in the trial, within 24-48 hours of 
allocation to a case manager. Case management should start as soon as 
possible after a patient is diagnosed. This is particularly important for 
patients who have chosen to take antidepressants so that they can be helped 
through the early stages where side-effects of treatment are common. The 
case manager should interview all patients within a few days of diagnosis, 
preferably within the first week following their diagnosis by a GP. 
 
Ideally, the first contact should be face to face unless this is difficult to 
arrange from the patient‛s perspective, in which case telephone contact is 
acceptable. Initial contact appointments should be arranged by telephone, 
not a letter. 
 
Subsequent Contacts 
 
Most case management contacts should be conducted on the telephone. Time 
and day for each contact should be negotiated with the patient. Face to face 
contacts can be arranged if the patient and case manager think that this is 
desirable but the first option should always be using the telephone. 
 
Contact Frequency 
 
Contacts should be titrated against the patient‛s needs. However, weekly 
contacts are recommended for the first five weeks of case management, 
followed by fortnightly contacts thereafter. More frequent sessions can be 
arranged if the patient and case manager think that this is desirable. In 
most cases the maximum number of sessions will be ten. Short but frequent 
sessions are more important than lengthy individual sessions. 
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Contact Duration
 
The initial session should take no more than 30-40 minutes. Subsequent 
sessions should be timed at 15-20 minutes. Sessions can be shorter. Case 
managers should strive to keep sessions brief and focussed. 
 
Contact Timing 
 
Unless case managers normally work in the evenings as part of their contract 
of employment, contacts should be scheduled for between 9.00am and 
6.00pm. However, we know that many patients prefer to be contacted out of 
hours and case managers should try to accommodate patient preferences if 
at all possible. 
 
Patient-Initiated Contacts
 
Although the timetable for all scheduled contacts should be negotiated with 
the patient, some patients may want to be able to contact the case manager 
between sessions. If a patient specifically requests this, case managers 
should inform patients of times when they may be available for such patient-
initiated contacts. 
 
The Contact Log 
 
All contacts with patients should be recorded on the contact log contained in 
section D. It is essential that the research team are able to measure the 
frequency, duration and mode of contact between case managers and 
patients. This will also be useful in supervision and should be kept up to date 
at all times. It is a separate record from standard clinical records which 
case managers would have to fill in under the policies and procedures of 
their organisations. Please keep a log for each patient in the special study 
folder, adding extra pages per patient as these are required. 
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Assessing and Managing Risk
 
Patients who are actively suicidal are not eligible for inclusion in the trial. 
However, some patients may experience a deterioration in their mental state 
during the trial. Each contact, therefore, should always include a risk 
assessment. No case manager should be managing patients at significant risk 
of suicide, self-harm or harm to others. Where patients express such ideas 
and where clear plans are evident, case managers should inform the GP 
immediately and make use of the local psychiatric service‛s arrangements for 
handling patients who present a risk to themselves or others. 
 
Communicating with GPs. 
 
Regular communication with GPs is an essential aspect of case management. 
There are three levels of communication:
 
Level 1: A statement of the patient‛s main problem and treatment plan should 
be entered into record systems held at the practice level after the first 
patient contact using the guidelines in Section D.  Thereafter, a brief record 
of each contact should be entered into the general practice notes where the 
patient is progressing satisfactorily and/or willing to engage in the 
treatment plan.  
 
Level 2: Where the case manager wishes to alert the GP to changes that may 
need to be made to the treatment plan, for example in response to lack of 
progress or changes in patient preference, a specific note should be sent to 
the patient‛s GP. Where the case manager has suggested to the patient that 
s/he should arrange an appointment with the GP in the next few days, the 
case manager should always inform the GP before the patient makes an 
appointment. 
 
Level 3: Case managers should communicate in person by telephone to the GP 
when an urgent message needs to be passed on, for example where a patient 
is experiencing intolerable antidepressant side effects or where there is a 
significant worsening in a patient‛s mental health. 
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Using Supervision
 
Supervision to case managers for their trial work will be provided weekly by 
psychiatrists and psychological therapists working in the trial team. Case 
managers are expected to report their activity, results of patient monitoring 
outcome measures, plans for managing their caseload and any problems they 
are experiencing with specific cases. Supervisors will guide and advise case 
managers in their management of pharmacological and psychosocial 
interventions. They will also help the case manager communicate good 
practice guidelines (particularly on medication) for individual patients to GPs. 
 
At each supervision session there will be a priority ordering of cases to be 
discussed: 
 
1. All new patients
2. Patients who have reached a scheduled supervision review point after 
being in the trial for 4, 8 and 12 weeks 
3. Patients who are not improving as expected, for example where an 
adequate trial of antidepressant medication is not having a therapeutic 
effect or where patients are not benefiting from or engaging in the 
psychosocial self-help support programme 
4.  ‘Overdue‛ patients, i.e. where the case manager has not been able to 
make contact with patients as previously arranged 
5. All other patients 
 
Supervisors will expect to base their supervision on reports of regular PHQ9 
scores, risk assessments, concordance information and treatment plans. 
Most supervision content will concern the process of decision making in 
overall case management, although some specific clinical supervision will be 
provided. 
 
Section D contains several copies of a sheet to help you prepare for 
supervision and provides a structure for each type of supervision discussion, 
together with the information which will be required by supervisors in their 
discussions with case managers. Photocopy more as you need them. 
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Interventions 
 
There are two types of intervention in case management for depression: 
pharmacological and psychosocial. These reflect the treatment options 
commonly used in primary care for patients with depression. The case 
manager‛s role is to help patients make the best use of the treatment(s) 
they have decided to opt for.  In this trial all patients will be offered 
psychosocial support by the case manager and some patients will have been 
prescribed medication by their GP. 
 
Antidepressants are very effective medications for depression. Many 
patients in primary care will be offered and will accept antidepressant 
medication. However, for a range of reasons, some patients will take a less 
than optimum dose and therefore get less benefit from their medication. It 
is the case manager‛s role to enable patients make better use of their 
medicines. Although the GP is in charge of prescribing medication, the case 
manager should assist the patient by reinforcing the information given to 
patients by their GP and by helping patients and GP problem solve any 
difficulties with medication tolerance. Where patients decide not to take - 
or to stop taking - medication, the case manager should support patients‛ use 
of alternative psychosocial strategies. 
Psychosocial support is less commonly available in primary care. In this trial 
of case management, it is provided by the case manager in the form of 
behavioural activation for all patients. Behavioural activation is an evidence-
based treatment that has been shown to have equivalent effects to more 
complex cognitive treatments of depression. It is simple to explain and use 
and is, therefore, an ideal psychosocial self-help intervention for use by case 
managers. Supported by patient information literature, case managers guide 
patients through a behavioural activation programme which increases the 
range and frequency of activities undertaken by patients in their daily lives.  
 
Instructions and patient education materials for both medication 
management and behavioural activation are provided in section C.  
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Section B 
 
 
 
Case Management: A 
Session by Session Guide 
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Case Management Session by Session Guide 
 
General Session Structure 
 
All case management sessions should adopt the following structure: 
 
1. Assessment 
2. Education 
3. Shared Decision Making
4. Action Following Contacts: Reporting and Supervision 
 
1. Assessment 
The depth of assessment depends at which stage patients are currently 
being cared for in the case management process. For example, the first 
contact requires a more in-depth assessment in order to plan a psychosocial 
support programme. Later contacts will have a more focussed assessment 
around progress towards patient goals. However, in all contacts there will be 
assessment of: 
• Patient symptom levels 
• Risk 
• Depression, using the PHQ 9 
• Motivation for engagement in treatment 
• Treatment concordance (pharmacological and/or psychosocial) 
• Response to interventions 
 
2. Education 
Again, the level of educational input will vary from session to session. It is 
likely that in the early contacts, educational input will be highest. However, 
education may be required at all stages to help patients take decisions about 
their treatment. For example, where a patient is considering an early 
termination of an antidepressant regime, education will be required on the 
mode of action of antidepressants and relapse rates to help the patient 
make an informed decision. Behavioural activation information is also likely to 
be given in more detail during the early contact sessions. 
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3. Shared Decision Making
Case managers should develop a collaborative relationship with patients. 
Patients are in charge of their own decisions. The case manager should 
always ensure these are made in an informed way. Case managers collaborate 
in these decisions by helping patients weigh up their options. Decisions will 
be about both medication issues and about behavioural activation activities.  
 
When patients have been prescribed medication by their GPs, case managers 
should ascertain how closely the patient wishes to follow the GP‛s 
prescription. Where a patient does not wish to adhere to the GP‛s 
prescription, the case manager should respect the patient‛s view even if they 
disagree, and help the patient to weigh up the pros and cons of their 
decision. Case managers must ensure patients‛ decisions are informed by 
accurate educational input on antidepressant action and respect and support 
decisions. Later, if appropriate, discussions about treatment decisions can be 
initiated by case managers, for example where symptoms and/or PHQ9 
scores do not improve. 
 
Decisions will also have to be made about behavioural activation targets and 
exercises. Negotiated targets and exercises to assist patients to regain 
their functioning should be realistic and achievable. Selection of activities 
should be based on patients‛ own identification of key deficits in their 
functional activities. 
 
Other decisions will be about the frequency of case manger/patient 
contacts, time of next contact etc. During all contacts, case managers need 
to finish the contact with a clear understanding of what the patient has 
decided to do between this and subsequent contacts and get feedback from 
patients on their shared understanding of the next steps. 
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4. Action Following Contacts
All contacts must be followed by feedback to the GP at levels 1-3 below: 
 
Level 1: A statement of the patient‛s main problem and treatment plan 
should be entered into record systems held at the practice level after the 
first patient contact using the guidelines in Section D.  Thereafter, a brief 
record of each contact should be entered into the general practice notes 
where the patient is progressing satisfactorily and/or willing to engage in 
the treatment plan.  
 
Level 2: Where the case manager wishes to alert the GP to changes that 
may need to be made to the treatment plan, for example in response to lack 
of progress or changes in patient preference, a specific note should be sent 
to the patient‛s GP. Where the case manager has suggested to the patient 
that s/he should arrange an appointment with the GP in the next few days, 
the case manager should always inform the GP before the patient makes an 
appointment. 
 
Level 3: Case managers should communicate in person by telephone to the GP 
when an urgent message needs to be passed on, for example where a patient 
is experiencing intolerable antidepressant side effects or where there is a 
significant worsening in a patient‛s mental health. No case manager should be 
managing patients at significant risk of suicide, self-harm or harm to others. 
Where patients express such ideas and where clear plans are evident, case 
managers should inform the GP in person immediately and make use of the 
local psychiatric service‛s arrangements for handling patients who present a 
risk to themselves or others. 
 
Case managers should always complete the patient contact log and session 
record as well as complying with the record keeping requirements of the 
services that employ them. 
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Supervision:
 
At each supervision session there will be a priority ordering of cases to be 
discussed: 
 
1. All new patients 
2. Patients who have reached a scheduled supervision review point after 
being in the trial for 4, 8 and 12 weeks 
3. Patients who are not improving as expected, for example where an 
adequate trial of antidepressant medication is not having a therapeutic 
effect or where patients are not benefiting from or engaging in the 
psychosocial self-help support programme 
4.  ‘Overdue‛ patients, i.e. where the case manager has not been able to 
make contact with patients as previously arranged 
5. All other patients
 
Supervisors will expect to base their supervision on reports of regular PHQ9 
scores, risk assessments, concordance information and treatment plans. 
Most supervision content will concern the process of decision making in 
overall case management, although some specific clinical supervision will be 
provided. 
 
Case managers should also be aware of how closely patients‛ medication 
regimes follow prescribing guidance. Where prescriptions do not follow 
accepted prescribing guidance, the case manager should discuss this with 
their supervisor. Action following this might include either the case manager 
or the supervisor communicating to the GP with suggestions. 
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Contact Session 1 
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Case Manager‛s Checklist for Session Number 1 
(photocopy additional copies as required) 
Tick when 
complete 
  
Introduction  
  
1. Assessment 
 person-centred, ‘here and now‛ problem assessment 
 
1.1 Assessment of Risk  
 thoughts, plans, actions and prevention 
 
1.2 Formal symptom assessment        Write score here 
 PHQ-9 
 
1.3 Medication review  
 attitude to medication and medication behaviour 
 
1.4 Medication side-effect assessment  
 unusual effects assessment 
 
  
2.0 Education  
 depression information  
 medication information  
 material on behavioural activation   
  
3.0 Shared Decision Making  
 agree action goals for medication and behavioural 
 activation 
 
 hand out medication and behavioural activation materials  
 negotiate the next contact session   
  
Record Keeping and Feedback to GP  
 complete patient contact log, session record and any 
 other records  
 
enter a short record of contact, problem statement and 
 action plan into the GP‛s record systems 
 make a special (level 2) or an urgent (level 3) 
 communication if indicated 
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Contact Session 1 
 
Introduction  
The case manager should introduce themselves by full name and job title, 
confirm the patient‛s full name, outline the case management role and the 
objectives of the interview, the confidentiality protocol for note taking and 
inform the patient that the contact should take no more than 30 minutes. 
 
Assessment 
1.1 Problem Assessment 
The case manager should conduct a person-centred, ‘here and now‛ problem 
assessment focussing on those aspects of the patient‛s problems that are 
interfering with their day to day activities and which are identified by the 
patient as priorities for change. 
 
1.2 Assessment of Risk 
The case manager should ensure they conduct a risk assessment to identify 
any risk thoughts, plans or actions and anything that is currently preventing 
the patient enact such plans if present. 
 
1.3 Formal symptom assessment  
The case manager should use the PHQ-9 to confirm symptoms and establish 
a baseline for symptom change over the next few weeks. 
 
1.4 Medication review 
If the patient is on antidepressants the case manager should assess the 
patient‛s attitude to their medication, ascertain if the patient has 
commenced the medication and find out to what extent the patient is taking 
the prescribed dose. 
 
1.5 Medication side-effect assessment 
The case manager should ask the patient about any unusual effects which 
might be attributed to their antidepressant medication. 
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Contact Session 1 Introduction: Example Script 
 
 
“Hello, my name is [case manager‛s name]. I am one of the [role title] 
working with Dr [GP Name]. Can I just confirm your full name? It‛s 
[patient‛s full name]. 
 
If you remember, you volunteered to be part of a research project 
investigating how to improve the way we organise treatment for depression. 
As part of that research study, my job is to contact you today and then 
regularly over the next three months to help you with your mood. I‛ll try to 
do this by supporting the treatment you are getting from Dr [GP Name]. I 
will also help you by giving you information about depression and your 
treatment and I will suggest other activities to help lift your mood. 
 
The purpose of today is for me to get a better understanding of your main 
difficulties. Dr [GP Name] has given me a short report but no details. I‛d 
like to ask you some questions about your main problems At the end of the 
interview we‛ll make a plan for the next few weeks to help you with your 
difficulties. We have about 40 minutes for the interview. 
 
After the interview, what I would normally do is let Dr [GP Name] know that 
we have been in contact with each other and give [him/her] a short report. 
From time to time I may discuss your treatment with Dr [GP Name]. Also, as 
part of the research, I have a supervisor whom I will report to so that I can 
make sure I am following the guidelines for this project Is this OK?” 
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Contact Session 1 Assessment Details: Example Questions 
 
 
1.1 Person-centred, ‘here and now‛ problem assessment 
• What are your main difficulties at the moment, those that prompted you 
to visit your GP recently? 
• How do these difficulties affect you physically? 
• How do they affect what you do with your time? 
• What thoughts do you have when you feel like this? 
• Are there any particular situations that trigger your feelings? 
• What impact is this having on your life? 
• Could you detail things that you have stopped doing because of the way 
you feel? 
 
1.2 Assessment of Risk 
• Do you have any thoughts of killing yourself? 
• Do you have any plans to kill yourself? 
• Have you made any preparations to kill yourself or have you tried to do it 
in the past? 
• Is there anything stopping you killing yourself? 
• Are you feeling as if you could hurt or harm anyone around you? 
• Are you finding it hard to look after yourself or anyone in your care such 
as children or older relatives? 
 
Other question areas 
• What makes the problem better or worse? 
• When did the problem start and how has it fluctuated over time? 
• Have you had any previous treatment for this problem now or in the past? 
• What is your current treatment? 
• What is your alcohol or drug consumption?
• What would you like to change about the problem (magic wand)? 
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Contact Session 1 Formal Symptom Assessment: The PHQ9 
 
 
1.3 Procedure for administering the PHQ9 
The PHQ9 (see section D) is a brief instrument which enables practitioners 
and patients to constantly monitor key symptoms of depression. It should be 
introduced in the following way. If possible, the patient should have a copy 
of the PHQ9 in front of them to help them answer the questions. 
Tell the patient you will be running through this questionnaire each time you 
talk to each other to give you both a measure of the patient‛s progress over 
time during the next few weeks that you will be in touch with them. 
 
“I would like to ask you some standard questions from a questionnaire. I will 
ask you about a series of common symptoms of depression. Could you tell me 
if you have been feeling these symptoms during the last two weeks: Not at 
all; Several days; More than half the days; or Nearly every day.” 
 
• Run through the questions in order. 
• Quickly add up the score using the system in section D. 
• Give the patient feedback on what the score means in terms of their 
depression severity. Always give this feedback to the patient. Be honest 
with the scoring and ask the patient, “How does this fit for you?” in 
terms of the way they are currently feeling. 
• Given that in the first interview, their score is likely to be high, remind 
the patient that this is a baseline to measure their progress against. 
• Make sure a spare copy of the PHQ9 is handed out/sent by post to the 
patient 
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Agree an overall problem statement with the patient 
that describes the patient‛s mood state, their 
symptoms and the impact of this mood state on their 
daily activities. For example: 
 
Your main problem is a lack of interest in undertaking previously enjoyed 
activities, lethargy, sleep problems, reduced activity and thoughts that 
you are a failure with the consequence that you are finding it difficult 
to work, socialise and keep on top of your housework. 
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Contact Session 1 Medication Review: Example Questions 
 
 
1.4 Medication Review 
• What medication did the GP prescribe? 
• Have you started taking it? 
• When and how often are you actually taking the tablets? 
• Do you know much about how these tablets work? 
• How do you feel about taking the medication? 
• Do you plan to continue to take them over the next few weeks? 
• Are you planning to take them regularly as advised by your GP? 
• Have you noticed any benefits yet? 
• How effective do you think these tablets are? 
 
1.5 Medication side-effect assessment 
• Have you noticed any unusual physical or mental feelings since you have 
been taking the tablets? 
• Could you describe these in detail? 
• What do you feel about these effects? 
• Do you know anything about side-effects these tablets might cause? 
 
 
 
A list of antidepressant side effects is given in Section C. 
Most side effects are temporary, mildly unpleasant but not 
dangerous. Consult Section D for a list of common side-
effects as well as a list of those for which it will be 
necessary to consult the GP. Very occasionally, patients may 
experience side-effects which require them to stop taking the 
medication. These are listed in Section C. Facts for patients 
are given in the educational section on the next pages. 
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Education 
 
The case manager should provide education to patients verbally using the 
information given on the next three pages. Wherever possible, this verbal 
information should be supplemented by written material given to, or posted 
out to, the patient. 
 
2.1 Depression 
Many patients request information about depression. There are many good 
information sources about depression. Section C provides several including an 
example published by the Mental Health Foundation. The case manager 
should provide the patient with these leaflets or other resources on 
depression.  
 
2.2 Medication 
If the patient is taking medication, the case manager should provide the 
patient with educational information on medication and reinforce information 
about antidepressants given to the patient by the GP. Facts about 
antidepressants are given in the next pages. Examples of medication 
information sheets which can be given to patients are provided in section C. 
 
2.3 Behavioural Activation
The case manager should also introduce material on behavioural activation 
and provide the patient with a rationale for its use. Facts about behavioural 
activation are given on the next page. Examples of behavioural activation 
information sheets which can be given to patients are provided in section C. 
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Contact Session 1 Education: Depression Information 
 
 
Basic facts about depression 
• Depression is not a sign of personal weakness  
• 15-20% of people will experience clinical depression at some time during 
their life. 
• The best research suggests that depression is caused by a combination 
of inherited or genetic factors and life events – just like high blood 
pressure or heart disease.  
• There is no one way people experience depression 
 
Common symptoms of depression  
 
Physical feelings such as: disturbed sleep including taking longer to get off 
to sleep and then waking up early; poor appetite and weight loss, or the 
reverse with comfort eating and weight gain; exhaustion; poor concentration  
 
Behaviours such as: staying at home and avoiding other people; loss of 
interest in life and inability to enjoy normal things; restlessness and 
agitation 
 
Thoughts such as: inadequacy; hopelessness and loss of self-confidence; 
thoughts or even plans of suicide  
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Contact Session 1 Education: Medication Information 
 
 
Basic facts about the effects of antidepressants 
• Antidepressant medication is, on average, effective – regardless of what 
seems to have caused depression for any particular person 
• Antidepressants help to relieve symptoms of depression such as 
depressed mood, loss of energy, appetite changes, sleep disturbance, loss 
of interest in things, trouble concentrating, and feelings of guilt or 
worthlessness. 
• Antidepressants will not change your personality or make you a different 
person. 
• Antidepressants will not change the important life problems you face, but 
they may help you deal with those problems more confidently and 
effectively. 
• Antidepressants may help you to feel less overwhelmed by life problems, 
but they don‛t create an artificial “high”. 
 
Facts about side-effects of antidepressants 
• Side effects are common, but these are usually mild and improve with 
time. 
• All known side effects go away after stopping medication (i.e. none are 
permanent). 
• Antidepressants are not addictive unlike other drugs which can produce 
dependence (e.g. alcohol, tranquilizers or sleeping pills). 
• Side effects are worst early on and usually improve whilst the benefits 
build slowly over a few weeks.   
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Contact Session 1 Education: Behavioural Activation  
 
 
How to Explain Behavioural Activation 
 
When we are depressed: 
• we feel physically unwell,  
• we have depressed thoughts  
• we change the way we behave.
 
We behave differently by: 
• often stopping doing the important life routines that make us 
comfortable in our surroundings. 
• withdrawing from doing pleasurable things that make us feel well, for 
example, talking to other people, going for a walk. 
• avoiding important and necessary things like paying bills. 
 
By withdrawing in this way, our feelings and thoughts also get worse because 
all our physical, thinking and doing symptoms of depression are linked. 
 
By setting goals of things we want to do we can ‘act our way out‛ of 
depression rather than wait until we are ready to ‘think our way out‛. 
 
Behavioural activation is a structured, active self-help intervention. It is 
focused on: 
 
• re-establishing our daily routines 
• increasing pleasurable activities 
• addressing necessary issues 
 
The purpose of this is to help us to regain functions which have been lost or 
reduced during depression.  
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How to Start Behavioural Activation 
 
1. The first step in behavioural activation is to make a diary of what you are 
doing now. 
 
2. The second step is to make lists of things that you would like to do, based 
on what you have stopped doing since you became depressed.  
• Some of these things will be just routine jobs which need to be done, 
such as housework or cooking. 
• Others things will be pleasurable activities such as going out and meeting 
people.  
• Some things will be important necessary activities that you are avoiding, 
such as paying bills or dealing with conflict. 
 
3. The third step is to order these separate lists into one big list, with the 
most difficult activities at the top of the list and some easier activities 
at the bottom, making sure you mix up routine, pleasurable and necessary 
activities. 
 
4. The forth step in behavioural activation is to use a diary sheet to plan out 
how to start doing these things, starting near the bottom of your list and 
working upwards. 
 
NB: When choosing activities it is very important to: 
 
• start small and help patients to choose things that they are likely to be 
successful at achieving 
 
• spell out exactly what the activity is, where it will be done, when it will be 
done, how it will be done, who it will be done with (if it includes other 
people) and what steps are needed to complete the activity. 
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3.0 Shared Decision Making
The case manager should agree action goals with the patient around: 
 
3.1 the use of Medication  
When patients have been prescribed medication by their GPs, case managers 
should ascertain how closely the patient wishes to follow the GP‛s 
prescription. Where a patient does not wish to adhere to the GP‛s 
prescription, the case manager should respect the patient‛s view even if they 
disagree, and help the patient to weigh up the pros and cons of their 
decision. Case managers must ensure patients‛ decisions are informed by 
accurate educational input on antidepressant action and respect and support 
decisions. Later, if appropriate, discussions about treatment decisions can be 
initiated by case managers, for example where symptoms and/or PHQ9 
scores do not improve. 
Case managers should also be aware of how closely the medication regime 
follows prescribing guidance. Where the prescription does not follow 
accepted prescribing guidance, the case manager should discuss this with 
their supervisor at the next supervision session and decide on a 
communication action plan to assist the GP in their prescribing. 
 
3.2 Behavioural Activation 
Decisions will have to be made about behavioural activation targets and 
exercises. In most instances at contact session 1, this will be reading the 
patient information leaflet in section C or keeping the diary. Activity diaries 
should be based on patients‛ own identification of key deficits in their 
functional activities. Some patients may wish to start using BA worksheets I 
and II to initiate activation activities. 
 
3.3 Arranging the Next Contact 
The case manager should negotiate the next contact session with the 
patient. This will normally be within a week of the initial session and be 
conducted by telephone. 
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Contact Session 1 Shared Decision Making 
 
 
3.1 Depression Action 
• Information on depression given verbally and handed out/sent by post 
 
3.2 Medication Action 
• Does the patient wish to take the medication? 
• Details negotiated regarding timing and dosage according to decision 
above 
• Information on antidepressant effects and side-effects given verbally 
and handed out/sent by post 
 
3.2 Behavioural Activation Action 
• Is there agreement to start a programme of behavioural activation? 
• Information on behavioural activation given verbally and handed out/sent 
by post 
• First stage diaries and/or worksheets handed out/sent by post for 
activity monitoring 
 
3.3 Next Contact Session 
• Agreement on next contact time, mode (telephone preferred) and place. 
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Action Following the Contact
 
Record Keeping  
The case manager should complete the contact log, session record and any 
other records required of the case manager‛s employing organisation.  
 
Feedback to GP 
Level 1, 2 or 3 feedback should be initiated. All patients require at least 
level 1 feedback (routine report in practice records). For patients with 
changed treatment preferences level 2 is required (special communication to 
GP). Level 3 feedback (personal contact with GP) should be used for patients 
who have severe side effects or present a risk. 
 
Supervision 
Case managers should report the outcome of contact session 1 to their 
supervisor in the next weekly supervision session using the format: 
 
 
• Gender, age, previous episodes, onset 
• Main problem statement 
• Risk assessment
• PHQ9 score 
• Treatment plan including medication and behavioural activation 
• Case Management Action 
 
 
Where case managers are concerned that the medication prescription by the 
GP does not follow prescribing guidelines, s/he should discuss this with the 
supervisor. Action following this might include either the case manager or 
the supervisor communicating to the GP with suggestions. 
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Contact Session 1 Action Following the Contact 
 
 
Record Keeping  
• complete patient contact log, session record and any other records 
required by the employing organisation 
 
Feedback to GP 
• enter a short (Level 1) record of contact, problem statement and action 
plan into the GP‛s record systems  
• make a special (Level 2) or an urgent (level 3) communication if indicated 
 
Supervision 
• report the outcome of contact session 1 in the next weekly supervision 
session 
• if medication prescription by the GP does not follow prescribing 
guidelines, discuss with supervisor 
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Contact Session 2 
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Case Manager‛s Checklist for Session Number 2 
(photocopy additional copies as required) 
Tick when 
complete 
  
Introduction  
  
1. Assessment 
 review and re-confirmation of problem statements 
 
1.1 Assessment of Risk  
 thoughts, plan, actions and prevention 
 
1.2 Formal symptom assessment         Write score here 
 PHQ-9 
 
1.3 Medication review  
 assessment of concordance 
 
1.4 Medication side-effect assessment  
 unusual effects assessment 
 
1.5 Review of Behavioural Activation Support Programme 
 diaries of negotiated behavioural activation  activities 
 
  
2.0 Education  
 Depression, medication and BA information  
  
3.0 Shared Decision Making  
 agree action goals for medication management  
 specific behavioural activation plans  
 negotiate the next contact session   
  
Record Keeping and Feedback to GP  
 complete patient contact log, session record and any 
 other records  
 
 enter a short record of contact, problem statement and 
 action plan into the GP‛s record systems 
 
 make a special (level 2) or an urgent (level 3) 
 communication if indicated 
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Introduction 
The case manager should confirm that they are speaking to the patient, 
remind the patient of who they are and describe the objectives and time 
scale for the contact. 
 
1. Assessment 
The case manager should remind the patient about the main problem 
statement agreed at the last contact and ascertain whether there has been 
any change in mood and problem impact since the last contact. This is not a 
new assessment but a review of previous information given. 
 
1.1 Assessment of Risk 
The case manager should ensure they conduct a risk assessment to identify 
any risk thoughts, plans or actions and anything that is currently preventing 
the patient enact such plans if present. 
 
1.2 Formal symptom assessment  
The case manager should use the PHQ-9 to re-measure symptoms and 
confirm the assessment information. 
 
1.3 Medication review 
If the patient is on antidepressants the case manager should assess if the 
patient is taking the prescribed dose and has experienced any benefits yet. 
 
1.4 Medication side-effect assessment 
The case manager should ask the patient about any unusual effects which 
might be attributed to their antidepressant medication. 
 
1.5 Review of Behavioural Activation Support Programme 
The case manager should discuss the previous behavioural activation 
activities negotiated during the last session. This may be reviewing a diary 
sheet or asking the patient if they have read educational material on 
behavioural activation. 
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Contact Session 2 Assessment Details: Example Procedure 
 
 
Assessment 
Each case management contact should build on the previous one, in essence a 
continuation of a conversation between the case manager and the patient. 
Continuation sessions should be short unless the patient‛s state has 
deteriorated markedly. Therefore, after the introduction: 
• Feedback previous summary statement of main problems.
• Ascertain from patient that this is still an accurate reflection of their 
difficulties – if not clarify and adjust the summary with the patient. 
 
Assessment of Risk 
It is always essential that case managers assess risk at each contact. This 
can be approached in the following way: 
 
“Last time we talked I mentioned that sometimes when people are depressed 
they can feel so despondent that they feel like taking their own lives. Can 
you tell me whether you have had any suicidal thoughts since we last talked. 
 
If an affirmative answer is given then the standard risk assessment 
questions must be run through, i.e. 
 
• Do you have any plans to kill yourself? 
• Have you made any preparations to kill yourself or have you tried to do it 
in the past? 
• Is there anything stopping you killing yourself? 
 
Additionally, harm to others, self- and other-neglect should be excluded. 
 
• Are you feeling as if you could hurt or harm anyone around you? 
• Are you finding it hard to look after yourself or anyone in your care such 
as children or older relatives? 
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Contact Session 2 Formal Symptom Assessment: The PHQ9 
 
 
Procedure for administering the PHQ9 
The PHQ9 (see section D) – the brief instrument which enables practitioners 
and patients to constantly monitor key symptoms of depression – should be 
rated again in the following way. The patient should have a copy of the PHQ9 
in front of them to help them answer the questions. 
Remind the patient that you will be running through this questionnaire each 
time you talk to each other to give you both a measure of the patient‛s 
progress over time. 
 
“I would like to ask you the same standard questions from the questionnaire 
we went through last time. I will ask you about a series of common symptoms 
of depression. Could you tell me if you have been feeling these symptoms 
during the last two weeks: Not at all; Several days; More than half the days; 
or Nearly every day.” 
 
• Run through the questions in order. 
• Quickly add up the score using the system in section D. 
• Give the patient feedback on what the score means in terms of their 
depression severity. Always give this feedback to the patient. Be honest 
with the scoring and ask the patient, “How does this fit for you?” in 
terms of the way they are currently feeling. Compare their current score 
to the baseline score rated in the last contact session.  
• If there is any improvement connect this to actions they have taken since 
the last session 
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Contact Session 2 Medication Review: Example Questions  
 
 
Medication Review 
The case manager needs to relate the next section to information gathered 
at the previous contact. Since side-effects of antidepressant typically 
appear during the first week to ten days of taking medication, this is likely 
to be a major feature in this section of the contact. Questions might 
include:
• Have you been taking your medication? 
• When and how often have you actually taken the tablets? 
• Have you noticed and benefits? 
• How do you feel about continuing to take the medication? 
 
Medication side-effect assessment 
• Have you noticed any unusual physical or mental feelings since you have 
been taking the tablets? 
• Could you describe these in detail? 
 
Information review 
• Did you read the information on antidepressants I gave/sent you? 
• What do you think about the information? 
• Do you have any questions for me about it? 
 
 
A list of antidepressant side effects is given in Section C. 
Most side effects are temporary, mildly unpleasant but not 
dangerous. Consult Section C for a list of common side-
effects as well as a list of those for which it will be 
necessary to consult the GP. Very occasionally, patients may 
experience side-effects which require them to stop taking the 
medication. These are listed in Section C. 
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Contact Session 2 Review of Behavioural Activation 
 
 
Information 
• Ask the patient if they have read the information you sent/gave them at 
the last contact session. 
• Ask the patient what they think about the material. 
• Ask the patient if they have made any attempts to list routine, 
pleasurable and necessary things that they would like to do that they 
have stopped doing since they became depressed. 
• Check if the patient has tried to put any of these things into a hierarchy 
or an ordered list. 
• Ask the patient if they have tried any of the activities. 
 
Diary 
• Ask the patient if they have filled in the diary sheet for the last week 
• If the sheet has been even partially filled in, go through it with them. 
• Make sure you praise and reinforce any attempt to make lists or order 
them. 
• If the patient has tried any activities make sure you encourage them and 
reinforce any progress. 
• Help the patient to connect any improvement with behavioural activation 
actions they have taken. 
 
Next Steps 
• Ask the patient if they are prepared to try some behavioural activation 
exercises 
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2.0 Education
The case manager should act on the information given in sections 1.1-1.5 of 
the assessment.  
 
2.1 Medication 
Further information on medication may be unnecessary if the patient is 
happy to take it as prescribed. However, if there are issues regarding 
medication, the case manager should reiterate the information about 
antidepressants given in the previous session and in the educational material 
sent to the patient. The case manager should ensure that the patient is fully 
informed about the action, effects and side effects of antidepressants. The 
case manager should also address pros and cons of medication concordance 
decisions plus discuss barriers to concordance where this has been 
identified as a problem in the assessment phase of the contact. 
2.2 Behavioural Activation 
The case manager should reiterate the rationale for behavioural activation 
and explore how prepared the patient is to embark on a personalised 
behavioural activation programme. 
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Contact Session 2 Education: Medication Information 
 
 
If patients are ambivalent about antidepressant medication, it may be 
necessary to again provide the information given in the previous contact: 
 
Basic facts about the effects of antidepressants 
• Antidepressant medication is, on average, effective – regardless of what 
seems to have caused depression for any particular person
• Antidepressants help to relieve symptoms of depression such as 
depressed mood, loss of energy, appetite changes, sleep disturbance, loss 
of interest in things, trouble concentrating, and feelings of guilt or 
worthlessness. 
• Antidepressants will not change your personality or make you a different 
person. 
• Antidepressants will not change the important life problems you face, but 
they may help you deal with those problems more confidently and 
effectively. 
• Antidepressants may help you to feel less overwhelmed by life problems, 
but they don‛t create an artificial “high”. 
 
Facts about side-effects of antidepressants 
• Side effects are common, but these are usually mild and improve with 
time. 
• All known side effects go away after stopping medication (i.e. none are 
permanent). 
• Antidepressants are not addictive unlike other drugs which can produce 
dependence (e.g. alcohol, tranquilizers or sleeping pills). 
• Side effects are worst early on and usually improve whilst the benefits 
build slowly over a few weeks.   
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Contact Session 2 Education: Behavioural Activation 
 
 
If it is necessary, briefly go through the rationale for Behavioural 
Activation, i.e. 
 
When we are depressed: 
• we feel physically unwell,  
• we have depressed thoughts 
• we change the way we behave. 
 
We behave differently by: 
• often stopping doing the important life routines that make us 
comfortable in our surroundings. 
• withdrawing from doing pleasurable things that make us feel well, for 
example, talking to other people, going for a walk. 
• avoiding important and necessary things like paying bills. 
 
By withdrawing in this way, our feelings and thoughts also get worse because 
all our physical, thinking and doing symptoms of depression are linked. 
 
By setting goals of things we want to do we can ‘act our way out‛ of 
depression rather than wait until we are ready to ‘think our way out‛. 
 
Explain the importance of the diary and BA worksheets I and II so that 
patients can plan their week and also keep a record to look back and see how 
they have done. 
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3.0 Shared Decision Making
The case manager should help the patient make decisions about a medication 
and behavioural activation treatment plan. Behavioural activation plans should 
be patient-centred, detailed and specific. Behavioural Activation 
Worksheets I and II and the Behavioural Activation Diary should be used 
and incorporated into behavioural activation treatment planning. 
 
The case manager should negotiate the next contact session with the 
patient. This will normally be within a week and be conducted by telephone. 
 
Record Keeping and Feedback to GP 
The case manager should complete the contact log, session record and any 
other records required of the case manager‛s employing organisation. The 
case manager should enter a level 1 record of contact into the GP‛s record 
systems and make any other contact at levels 2 or 3 as necessary.
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Contact Session 2 Shared Decision Making 
 
 
Medication Action 
• Does the patient wish to continue to take the medication? 
• Details negotiated regarding timing and dosage according to decision 
above 
• Any further information required on depression, antidepressant effects 
and side-effects given verbally and handed out/sent by post
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Behavioural Activation Action Plan 
 
Behavioural Activation Step 2:  
• if they have not yet thought of activities, help the patient to put their 
identified routine, pleasurable and necessary activities into a series of 
lists in BA Worksheet I.  
• If necessary, collaboratively fill in one or two activities in the three lists 
in worksheet I to encourage the patient. 
 
Behavioural Activation Step 3:  
• ask the patient to order these separate lists into one big list using BA 
Worksheet II, with the most difficult activities at the top of the list and 
some easier activities at the bottom, making sure patients mix up routine, 
pleasurable and necessary activities 
 
Behavioural Activation Step 4: 
• together, choose a few examples of these activities from the bottom of 
the list 
• help the patient schedule these activities into a new diary 
• try to schedule at least something once a day, more if the patient wishes 
it but do not insist on so many activities the patient will not be able to 
achieve them. 
 
NB: When choosing activities it is very important to: 
• start small and help patients to choose things that they are likely to be 
successful at achieving 
• spell out exactly what the activity is, where it will be done, when it will be 
done, how it will be done, who it will be done with (if it includes other 
people) and what steps are needed to complete the activity. 
 
Next Contact Session 
• Agreement on next contact time, mode (telephone preferred) and place. 
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Record Keeping and Feedback to GP 
The case manager should complete the contact log, session record and any 
other records required of the case manager‛s employing organisation. The 
case manager should enter a level 1 record of contact into the GP‛s record 
systems and make any other contact at levels 2 or 3 as necessary. 
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Contact Sessions 3-10 
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Case Manager‛s Checklist for Session Numbers  
3-10 (photocopy additional copies as required) 
Tick when 
complete 
  
Introduction  
  
1. Assessment 
 review and re-confirmation of problem statements 
 
1.1 Assessment of Risk  
 thoughts, plans, actions and prevention 
 
1.2 Formal symptom assessment         Write score here 
 PHQ-9 
 
1.3 Medication review  
 assessment of concordance 
 
1.4 Medication side-effect assessment  
 unusual effects assessment 
 
1.5 Review of Behavioural Activation Support Programme 
 diaries of negotiated behavioural activation  activities 
 
  
2.0 Education  
 Depression, medication and BA information  
  
3.0 Shared Decision Making  
 agree action goals for medication management  
 specific behavioural activation plans  
 negotiate the next contact session   
  
Record Keeping and Feedback to GP  
 complete patient contact log, session record and any 
 other records  
 
 enter a short record of contact, problem statement and 
 action plan into the GP‛s record systems 
 
 make a special (level 2) or an urgent (level 3) 
 communication if indicated 
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Contact Sessions 3-10 
 
Introduction 
The case manager should confirm that they are speaking to the patient, 
remind the patient of who they are and describe the objectives and time 
scale for the contact. 
 
1. Assessment 
The case manager should remind the patient about the main problem 
statement agreed at the last contact and ascertain whether there has been 
any change in mood and problem impact since the last contact. This is not a 
new assessment but a review of previous information given. 
 
1.1 Assessment of Risk 
The case manager should ensure they conduct a risk assessment to identify 
any risk thoughts, plans or actions and anything that is currently preventing 
the patient enact such plans if present. 
 
1.2 Formal symptom assessment  
The case manager should use the PHQ-9 to re-measure symptoms and 
confirm the assessment information. 
1.3 Medication review 
If the patient is on antidepressants the case manager should assess if the 
patient is taking the prescribed dose and has experienced any benefits yet. 
 
1.4 Medication side-effect assessment 
The case manager should ask the patient about any unusual effects which 
might be attributed to their antidepressant medication. 
 
1.5 Review of Behavioural Activation Support Programme 
The case manager should discuss the previous behavioural activation 
activities negotiated during the last session. This is likely to involve 
reviewing a diary sheet to assess concordance with negotiated activities. 
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Contact Sessions 3-10 Assessment Details: Example Procedure 
 
Assessment 
Each case management contact should build on the previous one, in essence a 
continuation of a conversation between the case manager and the patient. 
Continuation sessions should be short unless the patient‛s state has 
deteriorated markedly. Therefore, after the introduction: 
• Feedback previous summary statement of main problems. 
• Ascertain from patient that this is still an accurate reflection of their 
difficulties – if not clarify and adjust the summary with the patient. 
 
Assessment of Risk 
It is always essential that case managers assess risk at each contact. This 
can be approached in the following way: 
 
“When we have talked previously I have mentioned that sometimes when 
people are depressed they can feel so despondent that they feel like taking 
their own lives. Can you tell me whether you have had any suicidal thoughts 
since we last talked. 
 
If an affirmative answer is given then the standard risk assessment 
questions must be run through, i.e. 
 
• Do you have any plans to kill yourself? 
• Have you made any preparations to kill yourself or have you tried to do it 
in the past? 
• Is there anything stopping you killing yourself? 
 
Additionally, harm to others, self- and other-neglect should be excluded. 
 
• Are you feeling as if you could hurt or harm anyone around you? 
• Are you finding it hard to look after yourself or anyone in your care such 
as children or older relatives? 
 
  
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
130
The Universities of York, Manchester and Leeds 
The Treatment of Depression in General Practice 
A Randomised Controlled Trial 
 
Contact Sessions 3-10 Formal Symptom Assessment: PHQ9 
 
 
Procedure for administering the PHQ9 
The PHQ9 (see section D) – the brief instrument which enables practitioners 
and patients to constantly monitor key symptoms of depression – should be 
rated again in the following way. The patient should have a copy of the PHQ9 
in front of them to help them answer the questions. 
Remind the patient that you will be running through this questionnaire each 
time you talk to each other to give you both a measure of the patient‛s 
progress over time. 
 
“I would like to ask you the same standard questions from the questionnaire 
we go through each time. I will ask you about a series of common symptoms 
of depression. Could you tell me if you have been feeling these symptoms 
during the last two weeks: Not at all; Several days; More than half the days; 
or Nearly every day.” 
 
• Run through the questions in order. 
• Quickly add up the score using the system in section D. 
• Give the patient feedback on what the score means in terms of their 
depression severity. Always give this feedback to the patient. Be honest 
with the scoring and ask the patient, “How does this fit for you?” in 
terms of the way they are currently feeling. Compare their current score 
to the baseline and subsequent scores rated in previous contact sessions.  
• If there is any improvement connect this to actions they have taken since 
the last session 
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Contact Sessions 3-10: Medication Review: Example Questions  
 
 
Medication Review 
The case manager needs to relate the next section to information gathered 
at the previous contact. Questions might include: 
• Have you been taking your medication? 
• When and how often have you actually taken the tablets? 
• Have you noticed and benefits?
• How do you feel about continuing to take the medication? 
 
Medication side-effect assessment 
• Have you noticed any unusual physical or mental feelings since we last 
talked? 
• Could you describe these in detail? 
 
Information review 
• Do you need any further information or explanation on antidepressants? 
 
 
 
A list of antidepressant side effects is given in Section C. 
Most side effects are temporary, mildly unpleasant but not 
dangerous. Consult Section C for a list of common side-
effects as well as a list of those for which it will be 
necessary to consult the GP. Very occasionally, patients may 
experience side-effects which require them to stop taking the 
medication. These are listed in Section C. 
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Contact Sessions 3-10: Review of Behavioural Activation 
 
 
Diary 
• Ask the patient if they have filled in diary sheets for the period since 
the last contact.  
• In early sessions, BA worksheets I and II may have been the focus of 
activity between contacts, in which case ask about these – has the 
patient made any attempt to list routine, pleasurable and necessary
activities and have they tried to put any of these things into a hierarchy 
or an ordered list. 
• If the diaries and/or worksheets have been even partially filled in, go 
through them with patients. 
• Make sure you praise and reinforce any attempt to make lists, order 
them, complete diaries or try any activities. 
• Help the patient to connect any improvement with behavioural activation 
actions they have taken. 
• Try to elicit any barriers to behavioural activation, together with how the 
patient feels about the pros and cons of activating. 
 
Next Steps 
• Ask the patient if they are prepared to do some behavioural activation 
exercises 
 
 
  
DOI: 10.3310/hta20140 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 14
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Richards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
133
The Universities of York, Manchester and Leeds 
The Treatment of Depression in General Practice 
A Randomised Controlled Trial 
 
2.0 Education
The case manager should act on the information given in sections 1.1-1.5 of 
the assessment.  
 
2.1 Medication 
If there are issues regarding medication, the case manager should reiterate 
the information about antidepressants given in previous sessions and in the 
educational material sent to the patient. The case manager should ensure 
that the patient is fully informed about the action, effects and side effects 
of antidepressants. 
 
2.2 Behavioural Activation 
If necessary, the case manager should review the patient‛s understanding of 
behavioural activation programme, assess its success and refocus the 
patient‛s attention to educational material previously given out.
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Contact Sessions 3-10: Education: Medication Information 
 
During later sessions it is unlikely that patients will require much more 
information on antidepressants. However, it may be necessary to provide 
information about how long patients should stay taking antidepressants: 
 
Basic facts about the effects of antidepressants 
• Antidepressant medication is, on average, effective – regardless of what 
seems to have caused depression for any particular person
• Antidepressants help to relieve symptoms of depression such as 
depressed mood, loss of energy, appetite changes, sleep disturbance, loss 
of interest in things, trouble concentrating, and feelings of guilt or 
worthlessness. 
• Antidepressants will not change your personality or make you a different 
person. 
• Antidepressants will not change the important life problems you face, but 
they may help you deal with those problems more confidently and 
effectively. 
• Antidepressants may help you to feel less overwhelmed by life problems, 
but they don‛t create an artificial “high”. 
• Current recommendations suggest that in order to avoid a relapse it is 
beneficial for people to remain taking antidepressants for at least six 
months. 
 
Facts about side-effects of antidepressants 
• Side effects are common, but these are usually mild and improve with 
time. 
• All known side effects go away after stopping medication (i.e. none are 
permanent). 
• Antidepressants are not addictive unlike other drugs which can produce 
dependence (e.g. alcohol, tranquilizers or sleeping pills). 
• Side effects are worst early on and usually improve whilst the benefits 
build slowly over a few weeks.   
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Contact Sessions 3-10: Education: Behavioural Activation 
 
 
Although in later sessions it is unlikely, if it is necessary, briefly go through 
the rationale for Behavioural Activation, i.e. 
 
When we are depressed: 
• we feel physically unwell,  
• we have depressed thoughts 
• we change the way we behave. 
 
We behave differently by: 
• often stopping doing the important life routines that make us 
comfortable in our surroundings. 
• withdrawing from doing pleasurable things that make us feel well, for 
example, talking to other people, going for a walk. 
• avoiding important and necessary things like paying bills. 
 
By withdrawing in this way, our feelings and thoughts also get worse because 
all our physical, thinking and doing symptoms of depression are linked. 
 
By setting goals of things we want to do we can ‘act our way out‛ of 
depression rather than wait until we are ready to ‘think our way out‛. 
 
Explain the importance of the diary and BA worksheets I and II so that 
patients can plan their week and also keep a record to look back and see how 
they have done. 
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3.0 Shared Decision Making
The case manager should help the patient make further decisions about the 
medication and behavioural activation treatment plan. Behavioural activation 
plans should continue to be patient-centred, detailed and specific. They 
should also be progressive and forward looking as the patient becomes 
better able to determine their own activity programme. Diaries should be 
used and incorporated into behavioural activation treatment planning. 
 
The case manager should negotiate the next contact session with the 
patient. This will normally be within a week in the first month or so, 
becoming more spaced out in the second and third months. Most contacts will 
be conducted by telephone. 
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Contact Sessions 3-10: Shared Decision Making 
 
 
Medication Action 
• Does the patient wish to continue to take the medication? 
• Details negotiated regarding timing and dosage according to decision 
above 
• Any further information required on depression, antidepressant effects, 
ideal duration of treatment and side-effects given verbally and handed 
out/sent by post 
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Behavioural Activation Action Plan 
 
Behavioural Activation Step 4: 
• together, choose a few more examples of activities from the bottom of 
the list in BA Worksheet II 
• help the patient schedule these activities into a new diary 
• try to schedule at least something once a day, more if the patient wishes 
it but do not insist on so many activities the patient will not be able to 
achieve them. 
 
NB: when choosing activities it is very important to: 
• start small and help patients to choose things that they are likely to be 
successful at achieving 
• move on to bigger things when the patient feels able to 
• spell out exactly what the activity is, where it will be done, when it will be 
done, how it will be done, who it will be done with (if it includes other 
people) and what steps are needed to complete the activity. 
 
In addition it may be necessary to revisit steps 2 and 3, i.e. 
 
Behavioural Activation Step 2: 
• help the patient to put their identified routine, pleasurable and 
necessary activities into BA Worksheet I.  
• if necessary, collaboratively fill in one or two activities in the three lists 
in worksheet I to encourage the patient. 
 
Behavioural Activation Step 3:  
• ask the patient to order these separate lists into one big list using BA 
Worksheet II, with the most difficult activities at the top of the list and 
some easier activities at the bottom, making sure patients mix up routine, 
pleasurable and necessary activities 
 
Next Contact Session 
• Agreement on next contact time, mode (telephone preferred) and place. 
 
DOI: 10.3310/hta20140 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 14
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Richards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
139
The Universities of York, Manchester and Leeds 
The Treatment of Depression in General Practice 
A Randomised Controlled Trial 
 
 
Record Keeping and Feedback to GP 
The case manager should complete the contact log, session record and any 
other records required of the case manager‛s employing organisation. The 
case manager should enter a level 1 record of contact into the GP‛s record 
systems and make any other contact at levels 2 or 3 as necessary. 
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Section C 
 
 
 
Case Management 
Interventions and Patient 
Information Leaflets 
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Educating Patients about Depression 
 
The role of the case manager is to ensure that patients are well informed 
about their problems and about depression. This should be done both 
verbally and using back up written material. There are many good resources 
about depression to give to patients. Several key messages should be 
imparted:  
 
• Depression is not a sign of personal weakness  
• 15-20% of people will experience clinical depression at some time during 
their life. 
• The best research suggests that depression is caused by a combination 
of inherited or genetic factors and life events – just like high blood 
pressure or heart disease.  
• There is no one way people experience depression 
• Common symptoms include:  
 
Physical feelings such as: disturbed sleep including taking longer to get off 
to sleep and then waking up early; poor appetite and weight loss, or the 
reverse with comfort eating and weight gain; exhaustion; poor concentration  
 
Behaviours such as: staying at home and avoiding other people; loss of 
interest in life and inability to enjoy normal things; restlessness and 
agitation 
 
Thoughts such as: inadequacy; hopelessness and loss of self-confidence; 
thoughts or even plans of suicide 
 
At the end of this section are a number of patient information resources 
including authoritative information sources from independent bodies now 
follow. The booklet from the Mental Health Foundation (MHF) is a 
particularly good resource. The MHF have given us permission to photocopy 
this booklet for the purposes of this trial.  
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Medication Management 
 
The goal of medication management is to assist patients to make the best 
decision on antidepressant use by: 
• assessing attitudes to medication, medication use, clinical outcomes, 
medication effects and side effects 
• imparting education regarding appropriate use of antidepressants 
• negotiating shared decisions on patients‛ medication usage  
 
Case managers will provide information and will support patients‛ decision-
making. Case managers will not be making independent prescribing decisions 
(e.g. stopping medication, change in dosage).  Mostly, the case manager will 
support the patient in their decision to follow (or not) the medication 
recommendation made by the GP, providing information so that this decision 
is made in an informed manner. The only instance where a case manager 
should make a different direct recommendation to a patient on medication is 
if they identify possibly dangerous side effects. In these instances, case 
managers must: 
• advise the patient to temporarily discontinue medication 
• inform the GP of the possibility of dangerous side effects being present  
• strongly advise the patient to make an urgent appointment with their GP 
Where a patient decides not to follow the prescription made by the GP, case 
managers should ensure that the patient‛s decision is fully informed by 
information on the effects and side effects of antidepressants. The pros 
and cons of their decision and alternative strategies should also be explored. 
Further discussions between the patient and the GP should be encouraged 
and non-pharmacological psychosocial support offered in the form of 
behavioural activation by the case manager. 
 
Where a case manager is aware that a GP‛s prescription does not follow 
prescribing guidelines, this should be discussed with the case manager‛s 
supervisor and a joint plan devised to assist the GP and the patient make 
effective use of antidepressant medications. 
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Antidepressant Medication 
 
Antidepressants are prescribed by the GP to many patients with depression. 
They are highly effective. Modern antidepressants from the Selective 
Serotonin Reuptake Inhibitor (SSRI) and Selective Noradrenalin reuptake 
Inhibitor (SNRI) classes are now more widely used than earlier 
antidepressants such as the tricyclics. However, older tricyclic 
antidepressants are still prescribed where clinically indicated. 
 
The role of the case manager is to enable the patient to maximise the 
benefits of taking antidepressants. Many patients take antidepressants at a 
less than optimum dose through misguided beliefs about addiction or mode 
of action. For example, it is necessary to take antidepressants for a number 
of weeks at a therapeutic dose before beneficial effects are observed by 
patients. Unfortunately, unpleasant side effects often appear before these 
beneficial effects. This combination of delayed action and immediate side 
effects causes many patients to reconsider or stop taking their 
antidepressants. Other patients may take antidepressants sporadically when 
they are feeling particularly low, in the belief that they have an immediate 
effect. Finally, current recommendations are that patients should continue 
to take antidepressants for six months following remission of symptoms. 
Many patients stop taking their medication before this period has elapsed, 
increasing their chances of relapse. 
 
It is important to state that case managers are there to help patients make 
informed decisions about taking antidepressant medication. Where that 
decision is not to take medication, patients‛ decisions are to be respected 
and supported. Later, if appropriate, case managers can initiate further 
discussions about medication decisions made by patients, if for example 
symptoms and/or PHQ9 scores do not improve. 
 
Medication management is, therefore, essential to help patients get the 
most benefit from their prescriptions. A combination of education, 
medication effect and side effect monitoring in collaboration with patients 
can improve concordance and mental health outcomes.  
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Common antidepressant side-effects and actions 
Side effect What happens What to do about it 
COMMON 
Nausea and 
vomiting 
Feeling sick and being 
sick. 
Take your medicine after food. If you are 
sick for more than a day, contact your 
doctor. This tends to wear off after a 
few days or a week or so.  
Insomnia Not being able to get 
to sleep at night. 
Discuss with your doctor. He or she may 
change the time of your dose, or reduce 
the dose a little to start with. 
Sexual 
dysfunction 
Finding it hard to have 
an orgasm. No desire 
for sex. 
Discuss with your doctor. See also a 
separate question in this section.  
LESS COMMON 
Drowsiness Feeling sleepy or 
sluggish. It can last for 
a few hours after 
taking your dose. 
Don't drive or use machinery. Ask your 
doctor if you can take your SSRI at a 
different time of day. 
Headache Your head is pounding 
and painful. 
Try aspirin or paracetamol. Your 
pharmacist will be able to advise if these 
are safe to take with any other drugs you 
may be taking.  
Loss of 
appetite 
Not feeling hungry. You 
may lose weight. 
If this is a problem, contact your doctor 
or chemist for advice. 
Diarrhoea Going to the toilet 
more than usual and 
passing loose, watery 
stools. 
Drink plenty of water. Get advice from 
your pharmacist. If it lasts for more than 
a day, contact your doctor. 
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Common antidepressant side-effects and actions - continued 
UNCOMMON 
Restlessness 
or anxiety 
Being more on edge. 
You may sweat a lot 
more. 
Try and relax by taking deep breaths. 
Wear loose fitting clothes. This often 
happens early on in treatment and should 
gradually ease off over several weeks. A 
lower starting dose may help sometimes. 
RARE 
Rashes and 
pruritis 
Rashes anywhere on 
the skin. These may be 
itchy.
Stop taking and contact your doctor now. 
Dry mouth Not much saliva or spit. Suck sugar-free boiled sweets. If it is 
bad, your doctor may be able to give you a 
mouth spray. 
Skin rashes  Blotches seen 
anywhere. 
Stop taking and contact your doctor now. 
This is a particular problem with 
fluoxetine (Prozac) 
Tremors and 
dystonias 
Feeling shaky. You may 
get a twitch or feel 
stiff. 
It is not dangerous. If it troubles you, 
contact your doctor. 
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Side Effects Which Give Cause For Concern 
 
 
Below is a list of side effects which should be regarded as of 
considerable concern. They are rare. For most of these 
symptoms, patients should be advised to stop their medication 
and discuss with the GP as soon as possible. 
 
Skin rash – Can be caused by any medication.  This is usually not caused by a 
true allergy, but is usually reason for switching medication.  
 
Akathisia - Subjective symptoms of tension, panic, irritability and 
impatience together with movements usually taking the form of shuffling of 
feet while sitting and pacing or rocking while standing. Fidgety leg 
movements may occur while lying down. 
 
Priapism (prolonged or painful erections) – Can occur with Trazodone.   
 
Jaundice (yellow skin or eyes) – Can indicate liver inflammation (hepatitis) 
caused by medication.   
 
Manic/Hypomanic symptoms (speeded up, “racy”, elevated mood, 
excessive energy, grandiosity) – Antidepressant medications can 
precipitate mania (especially in those with family history of bipolar 
disorder).   
 
Palpitations/Irregular heartbeat – While antidepressants can cause 
irregular heartbeat, this symptoms will usually be due to anxiety.  Should 
discuss with GP as soon as possible. 
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Problem Solving Medication Management Difficulties 
 
Patients may stop taking medication completely or take less than the 
prescribed dose for a range of reasons. Here are some possibilities: 
 
• ‘ineffective/not-helpful‛‛ 
• ‘no longer necessary‛ 
• ‘side effects‛ 
• ‘concerned about safety‛ 
• ‘concerned about addiction‛ 
• ‘believes not appropriate - just a crutch‛ 
• ‘family oppose it, others will find out‛ 
• ‘forgot to renew prescription‛ 
 
It is important to: 
 
Assess the true reasons for medication non-concordance 
Provide education about the way antidepressants work and their side 
effects 
Come to a shared decision about what to do next. 
 
Several examples of education materials for patients are provided later in 
this section. These should be used to help patients come to an informed 
decision.  
 
The next page highlights key messages about antidepressants and side 
effects which case managers may find useful in coming to a shared decision 
with patients. 
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Antidepressant Medication: Key Messages 
 
 
Basic facts about the effects of antidepressants 
• Antidepressant medication is, on average, effective – regardless of what 
seems to have caused depression for any particular person 
• Antidepressants help to relieve symptoms of depression such as 
depressed mood, loss of energy, appetite changes, sleep disturbance, loss 
of interest in things, trouble concentrating, and feelings of guilt or 
worthlessness. 
• Antidepressants will not change your personality or make you a different 
person. 
• Antidepressants will not change the important life problems you face, but 
they may help you deal with those problems more confidently and 
effectively. 
• Antidepressants may help you to feel less overwhelmed by life problems, 
but they don‛t create an artificial “high”. 
• Current recommendations suggest that in order to avoid a relapse it is 
beneficial for people to remain taking antidepressants for at least six 
months. 
 
Facts about side-effects of antidepressants 
• Side effects are common, but these are usually mild and improve with 
time. 
• All known side effects go away after stopping medication (i.e. none are 
permanent). 
• Antidepressants are not addictive unlike other drugs which can produce 
dependence (e.g. alcohol, tranquilizers or sleeping pills). 
• Side effects are worst early on and usually improve whilst the benefits 
build slowly over a few weeks.   
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Behavioural Activation 1 
 
When we are depressed we feel physically unwell, we have negative thoughts 
and we change the way we behave. These feelings, thoughts and behaviours 
are all linked. We end up in a vicious circle where the worse we feel 
physically, the more we think depressed thoughts and the more we withdraw 
from doing the normal things we used to do. The more we withdraw, the 
more we feel physically unwell and the more depressed our thoughts become. 
 
• Some of these things we avoid are just routine activities such as cleaning 
the house, doing the ironing, washing up. Other routines are disrupted 
such as the time we go to bed or get up, when we eat and how we cook for 
ourselves. These are the important life routines that make us 
comfortable in our surroundings 
• Other activities that get disrupted are things we do for pleasure such as 
seeing our friends, enjoying a day out with our families or playing games 
with our children. There are the things that often make us feel well. 
• A third area where we avoid activities is in important necessary things 
such as paying bills or confronting difficult situations at work. 
 
Behavioural activation is a structured, active self-help intervention. It is 
focused on activities to help patients:
• re-establish their daily routines 
• increase pleasurable positively reinforcing external activities 
• address necessary issues such as unpaid bills 
 
Behavioural activation is about helping patients to ‘act their way out‛ of 
depression rather than wait until they are ready to ‘think their way out‛. 
 
The case manager‛s role is to support and coach patients in using a range of 
materials including diaries and information sheets. Case managers are not 
therapists and the patient retains control of all activities they undertake 
through a guided support programme from the case manager. 
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Behavioural Activation 2 
 
How to Start Behavioural Activation 
 
1. The first step in behavioural activation is to make a diary of what people 
are doing now. 
 
2. The second step is to think about things that people would like to do, 
based on what they have stopped doing since they became depressed.  
• Some of these things will be just routine jobs which need to be done, 
such as housework or cooking. 
• Others things will be pleasurable activities such as going out and meeting 
people.  
• Some things will be important necessary activities that people are 
avoiding, such as paying bills or dealing with conflict. 
 
3. The third step is to make a list of these different things, with the most 
difficult activities at the top of the list and some easier activities at the 
bottom, making sure people mix up routine, pleasurable and necessary 
activities. 
 
4. The forth step in behavioural activation is to use a diary sheet to plan out 
how to start doing these things, starting near the bottom of people‛s list 
and working upwards.  
 
NB: When choosing activities it is very important to: 
 
• start small and help people to choose things that they are likely to be 
successful at achieving 
 
• spell out exactly what the activity is, where it will be done, when it will be 
done, how it will be done, who it will be done with (if it includes other 
people) and what steps are needed to complete the activity. 
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Enhanced Care for 
Depression  
 
 
Patient Information 
Leaflets 
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Help from your mental health worker 
 
As part of the research trial, your mental health worker, who has had special 
training in helping people to manage depression, will support you during the 
next three months. S/he will do this in several different ways: 
 
· Contact you by telephone at regular intervals and at a time arranged 
between you and her/him. 
 
· Explain about depression and give you information, including leaflets and 
booklets to read and information on where to get other information. 
 
· Help you make the best use of any medication that your GP has 
prescribed by giving you information on the medicine, including 
information on any possible side effects. 
 
· Plan an individual programme of support and self-help activities with you 
to help you overcome many of your symptoms of depression.  
 
· Work closely with your GP and anyone else involved in your care and 
treatment.  
Please do not be afraid to ask your mental health worker any questions about 
the system of care we are testing in this research trial. They will try to 
answer your queries as best they can and if necessary will forward your 
questions to one of the researchers. 
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Depression 
What is Depression? 
 
In our lives we use the word 'depression' to describe feelings of low mood 
which all of us feel from time to time. However, the word is also used to 
describe a medical illness. When we talk about depression in this medical way 
it describes a feeling of persistent sadness, involving feelings of 
helplessness and hopelessness. Depression also affects our bodies and our 
thoughts and includes feelings of physic illness and of not being able to think 
clearly.  
 
Depression is a very common problem. Very many adults will at some time 
experience symptoms of depression. Feeling sad or fed up is a normal 
reaction to experiences that are upsetting, stressful or difficult. Those 
feelings will usually pass with time. However, if you are suffering depression, 
you are not 'just' sad or upset. You have an illness which means that intense 
feeling of persistent sadness, helplessness and hopelessness are 
accompanied by physical effects such as sleeplessness, a loss of energy, or 
physical aches and pains. 
 
How Does Depression Affect People? 
When people are depressed they may find it difficult to do even simple 
things. People stop doing their normal activities such as household routines, 
getting up at certain times of the day, cooking and eating meals. People also 
cut themselves off from other people. They may also become inactive, just 
doing nothing for long periods of time. 
 
  
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
156
The Universities of York, Manchester and Leeds 
The Treatment of Depression in General Practice 
A Randomised Controlled Trial 
 
Common Symptoms of Depression
 
There is no specific way a person who is depressed feels. However, many 
people have a range of physical and mental symptoms which affect the way 
they feel, do and think. Some symptoms are listed below. 
 
Physical feelings such as: disturbed sleep including taking longer to get off 
to sleep and then waking up early; poor appetite and weight loss, or the 
reverse with comfort eating and weight gain; exhaustion; poor concentration  
 
Behaviours such as: staying at home and avoiding other people; loss of 
interest in life and inability to enjoy normal things; restlessness and 
agitation 
 
Thoughts such as: inadequacy; hopelessness and loss of self-confidence; 
thoughts or even plans of suicide 
 
 
Depression: the Good News 
 
The good news about depression is that the vast majority of people recover 
from their depression. Treatments are available which are effective. These 
include drug treatments and self-help. Your mental health worker will help 
you get the best out of whatever treatment you have decided to take. S/he 
will be able to answer your questions about medication and self-help and will 
support you during your illness. Your mental health worker will also talk to 
your GP to keep your GP informed as to how you are progressing.  
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Behavioural Activation 1 
 
When we are depressed we feel physically unwell, we have negative thoughts 
and we change the way we behave. These feelings, thoughts and behaviours 
are all linked. We end up in a vicious circle where the worse we feel 
physically, the more we think depressed thoughts and the more we withdraw 
from doing the normal things we used to do. The more we withdraw, the 
more we feel physically unwell and the more depressed our thoughts become. 
 
On the next page is an example of the vicious circle of depression: ‘George‛ 
 
• Some of these things we avoid are just routine activities such as cleaning 
the house, doing the ironing, washing up. Other routines are disrupted 
such as the time we go to bed or get up, when we eat and how we cook for 
ourselves. These are the important life routines that make us 
comfortable in our surroundings 
• Other activities that get disrupted are things we do for pleasure such as 
seeing our friends, enjoying a day out with our families or playing games 
with our children. There are the things that often make us feel well. 
• A third area where we avoid activities is in important necessary things 
such as paying bills or confronting difficult situations at work. 
Behavioural activation is a structured, active self-help intervention. It is 
focused on activities to help us: 
• re-establish our daily routines 
• increase pleasurable activities 
• address necessary issues such as unpaid bills 
 
Many people think that it is necessary to feel completely physically well 
before starting to do things again. However, research evidence suggests 
that gradually starting to do more of the things we have been avoiding again 
can be a very effective way of self-help for depression. 
 
Behavioural activation is about helping us to ‘act our way out‛ of depression 
rather than wait until we are ready to ‘think our way out‛. 
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George had been feeling anxious and depressed since he had been made 
redundant. He had lost his confidence and had a low self-esteem. He had 
thoughts that he was no good and could do nothing right. He felt tired and 
lethargic all the time, lost interest in hobbies and interests, and had poor 
concentration. He became unmotivated and stopped going out or meeting 
friends or doing the things he had previously enjoyed. He became more and 
more withdrawn. The more he had these thoughts, physical symptoms and 
behaviour the more depressed and anxious he became. This ‘vicious circle‛ of 
thoughts, physical symptoms and changes in behaviour maintain George‛s  
depression. 
 
  
Behaviour 
Unmotivated, stops 
meeting friends and 
going out, becomes 
 
Physical symptoms 
Poor concentration, 
tired, lethargic, loss 
of interest 
Thoughts 
I cannot do 
anything right, 
everything I do 
withdrawn
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Behavioural Activation 2 
 
The goal of behavioural activation is to enable you to recommence some of 
the behaviours which are typically reduced in depression. The purpose of 
this is to help you to regain some of your lost or reduced activities.  
 
Behavioural Activation – The Four Steps 
 
1. The first step in behavioural activation is to make a diary of what you are 
doing now. 
 
2. The second step is to make three lists of the things that you would like 
to do, based on what you have stopped doing since you became depressed.  
 
• One list will be just routine jobs which need to be done, such as 
housework or cooking. 
• The second list will be pleasurable activities such as going out and 
meeting people.  
• The final list will be important necessary activities that you are avoiding, 
such as paying bills or dealing with conflict. 
 
3. The third step is to combine these different things into a final big list, 
with the most difficult activities at the top of the list and some easier 
activities at the bottom, making sure you mix up routine, pleasurable and 
necessary activities. 
 
4. The forth step in behavioural activation is to use a diary sheet to plan out 
how to start doing these things, starting near the bottom of your list and 
working upwards.  
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Behavioural Activation 3 
 
Step 1 
 
Take a blank diary sheet.
 
Each day, fill in what you are doing. Be specific and try to fill in each square. 
Even if you think you are doing nothing, this is very helpful information 
 
Discuss this list with your depression specialist mental health worker. His or 
her role is to support and coach you in using the diaries and information 
sheets. You are in control of all activities you plan to undertake, though you 
will get guidance and support from the depression specialist mental health 
worker. 
 
Step 2 
 
Think about things that you would like to do, based on what you have written 
down in your first diary. Identify things that you have stopped doing since 
you became depressed.  
 
• Some of these things will be just routine jobs which need to be done, 
such as housework or cooking. 
• Others things will be pleasurable activities such as going out and meeting 
people.  
• Some things will be important necessary activities that you are avoiding, 
such as paying bills or dealing with conflict. 
 
Use the Worksheet I to list all these activities. Put them down in any 
order you like, as you think of them 
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Behavioural Activation 4 
 
Step 3 
 
Using Worksheet II, organise all these different things into a list, with 
the most difficult activities at the top of the list and some easier activities 
at the bottom. 
 
Make sure you mix up routine, pleasurable and necessary activities so that 
there is a mixture of different types of activities at the bottom, middle and 
top of the list. 
 
Step 4 
 
Use another clean diary sheet to plan out how to start doing these things. 
Take some examples of routine, pleasurable and necessary activities from 
near the bottom of your list and plan to do them. Write down at certain 
times exactly what you will do. 
Spell out exactly what the activity is, where it will be done, when it will be 
done, how it will be done, who it will be done with (if it includes other people) 
and what steps are needed to complete the activity. 
 
Try to schedule at least something once a day, more if you wish it but do not 
plan on so many activities that you will not be able to achieve them. 
Remember to start small and work up to big. 
 
Try it for a week or two! 
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Behavioural Activation 5 
 
What‛s Next? 
 
Once you have tried to do some of the activities you have listed, discuss 
your progress with your mental health worker. He or she will encourage you 
and give you advice. As you accomplish some activities on your list move on up 
the list to other more difficult activities. Some activities will give you 
pleasure but it is more likely you will begin top feel a sense of 
accomplishment for more successfully completed activities (no one feels 
pleasure at paying a bill!) 
 
Dealing with Setbacks 
 
Remember that depression affects how you feel, what you do and what you 
think. It is unlikely you will be 100% successful. Some days will be better 
than others. If you do not do what you had planned one day, leave it for 
another day and try again. Complete success is not necessary. The best thing 
you can do is to keep trying. Compare what you are doing with how you were a 
few weeks earlier (try comparing your new diary with old ones). If you are 
really struggling, choose some activities from nearer the bottom of your list, 
or something different. 
 
Finally, discuss your progress with your mental health worker. He or she will 
advise you and support you. 
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Behavioural Activation 
 
 
Patient Worksheets and 
Diaries 
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Section D 
 
 
 
Resource Materials in  
Case Management 
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PHQ-9 monitoring tool 
 
Patient Name  Date   
1. Over the last 1-2 weeks, how often have you been bothered by any of the following problems?  
Read each item carefully, and circle your response. 
a. Little interest or pleasure in doing things 
 Not at all Several days More than half the days Nearly every day 
b. Feeling down, depressed, or hopeless 
 Not at all Several days More than half the days Nearly every day 
c. Trouble falling asleep, staying asleep, or sleeping too much 
 Not at all Several days More than half the days Nearly every day 
d. Feeling tired or having little energy 
 Not at all Several days More than half the days Nearly every day 
e. Poor appetite or overeating 
 Not at all Several days More than half the days Nearly every day 
f. Feeling bad about yourself, feeling that you are a failure, or feeling that you have let 
yourself or your family down 
 Not at all Several days More than half the days Nearly every day 
g. Trouble concentrating on things such as reading the newspaper or watching television 
 Not at all Several days More than half the days Nearly every day 
h. Moving or speaking so slowly that other people could have noticed. Or being so fidgety or 
restless that you have been moving around a lot more than usual 
 Not at all Several days More than half the days Nearly every day 
i. Thinking that you would be better off dead or that you want to hurt yourself in some way 
 Not at all Several days More than half the days Nearly every day 
2. If you ticked off any problem on this questionnaire so far, how difficult have these problems 
made it for you to do your work, take care of things at home, or get along with other people?  
 Not Difficult at All Somewhat Difficult Very Difficult  Extremely Difficult 
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Scoring the PHQ-9 
 
The PHQ-9 is a useful monitoring tool to ensure case managers have an 
objective measure of a patient‛s mood as well as information gleaned from 
their assessment contacts. It can be quickly totalled to give confirm mental 
health state and give patients weekly feedback on the outcomes of their 
treatment. 
 
Of the 9 items in question 1 count one point for each item ticked ‘several 
days‛, two points for each ticked ‘half the days‛ and three points for those 
ticked ‘nearly every day‛. Sum the total for a severity score. 
 
SCORE SEVERITY
<10 Mild depression 
10-14 Moderate depression 
15-19 Moderate to severe 
depression 
>20 Severe depression 
 
Definition of improvement 
 
Improved  A reduction of 2 or more points on the baseline score 
 
Not improved Drop of 1 point or no change or increase 
 
Definition of remission 
 
If patients have a score of less than 5 they are considered to be in 
remission.
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Session Record; Summary of Contact
 
Patient    Date    Session no 
 
Assessment (depression, risk, medication, side effects, behavioural 
activation) 
 
          PHQ9 Score 
 
 
 
 
 
 
Education
 
 
 
 
 
 
 
 
Shared Decision Making 
 
 
 
 
 
 
 
Action Following Contact (Level of GP feedback – 1,2,3) 
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Suggested Brief Reporting Format for GP Records  
Following Session 1 
 
Date and Time of Contact with Patient _____________________ 
 
Main Problem Statement (single sentence summarising the patient‛s 
triggers, autonomic, behavioural and cognitive symptoms, impact on 
life). Risk category. 
 
E.g. Jean Smith, part of case management research trial. Main 
problem is a lack of interest in undertaking previously enjoyed 
activities, lethargy, sleep problems, reduced activity and thoughts 
that she is a failure with the consequence that she is finding it 
difficult to work, socialise and keep on top of her housework. Not at 
risk of suicide. 
 
Case Management Plan (outline of contacts planned with patient) 
 
E.g. Mrs Smith agreed to be contacted weekly to review her progress 
with fluoxetine and to commence a programme of behavioural 
activation. Information on depression, antidepressants and 
behavioural activation given to Jean. 
 
Name of Case Manager _______________________ 
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Suggested Brief Monthly Reporting Format for GP Records  
 
Number of Contacts with Patient in Last Month _________________ 
 
Progress report (brief outline of progress) 
 
E.g. Mrs Smith experienced initial mild nausea which abated after 10 
days. Her mood is slightly improved and she continues to take her 
fluoxetine as prescribed. She has started on a behavioural activation 
programme and is beginning to re-establish her daily routine. She is 
not at risk. 
 
Future Plans 
 
E.g. Mrs Smith will continue to be contacted weekly for the next two 
weeks to review her progress, her concordance with her fluoxetine 
and to support her behavioural activation programme. 
 
Name of Case Manager _______________________ 
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Preparing for Supervision.  Date…………………… 
 
In preparation for your supervision session, make a note of patients in the 
following five categories. Include the detail mentioned to assist you and the 
supervisor deal with your caseload effectively and efficiently. Use your 
session records and patient contact log to organise yourself prior to 
supervision and to refer to during supervision. 
 
1. New Patients: (gender, age, previous episodes, onset, main problem 
statement, risk, PHQ9 score, treatment, case management action so far). 
 Number of patients for discussion…………………………………………. 
2. Patients at 4, 8 or 12 weeks (review point, gender, age, episode, 
treatment summary, initial PHQ 9 score, risk, case management action, 
progress including PHQ 9 scores). 
 Number of patients for discussion…………………………………………. 
3. Patients who are not improving as expected, (time in study, gender, age, 
episode, treatment summary, initial PHQ 9 score, risk, case management 
action, progress including PHQ 9 scores). 
 Number of patients for discussion…………………………………………. 
4. Overdue patients (time in study, gender, age, episode, treatment 
summary, initial PHQ 9 score, risk, case management action including 
number of attempts made to contact patient).
 Number of patients for discussion…………………………………………. 
5. All other patients (current caseload numbers, number of patients in 
caseload additional to those already discussed in this supervision session, 
any other problems).  
 Number of patients for discussion…………………………………………. 
  
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
174
The Universities of York, Manchester and Leeds 
The Treatment of Depression in General Practice 
A Randomised Controlled Trial 
 
Organising Information For Supervision
1. New Patients
• Gender, age, previous episodes, onset 
• Main problem statement, risk 
• PHQ9 score 
• Treatment plan including medication and behavioural activation 
• Case Management Action 
 
2. Patients at 4, 8 or 12 weeks 
• Review point, gender, age, episode 
• Treatment summary 
• Initial PHQ 9 score, risk 
• Action so far by case manager 
• Progress including PHQ 9 scores 
3. Patients who are not improving as expected 
• Time in study, gender, age, episode 
• Treatment summary 
• Initial PHQ 9 score, risk 
• Action so far by case manager 
• Progress including PHQ 9 scores 
4. Overdue patients 
• Time in study, gender, age, episode 
• Treatment summary 
• Initial PHQ 9 score, risk 
• Action including number of attempts made to contact patient 
5. All other patients 
• Current caseload numbers 
• Number of patients in caseload additional to those already discussed in 
this supervision session 
 
Plus…… any other problems not covered above. 
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Appendix 2 Consolidated Standards of Reporting
Trials checklist
TABLE 27 Consolidated Standards of Reporting Trials 2010 checklist of information to include when reporting a
randomised triala
Section/topic
Item
number Checklist item
Reported on
page number
Title and abstract
1a Identification as a randomised trial in the title vii
1b Structured summary of trial design, methods, results and
conclusions (for specific guidance see CONSORT for abstracts)
vi–vii
Introduction
Background
and objectives
2a Scientific background and explanation of rationale 1–3
2b Specific objectives or hypotheses 5
Methods
Trial design 3a Description of trial design (such as parallel, factorial) including
allocation ratio
5
3b Important changes to methods after trial commencement (such as
eligibility criteria), with reasons
NA
Participants 4a Eligibility criteria for participants 5–6
4b Settings and locations where the data were collected 7
Interventions 5 The interventions for each group with sufficient details to allow
replication, including how and when they were actually
administered
7–10
Outcomes 6a Completely defined pre-specified primary and secondary outcome
measures, including how and when they were assessed
10
6b Any changes to trial outcomes after the trial commenced,
with reasons
NA
Sample size 7a How the sample size was determined 11
7b When applicable, explanation of any interim analyses and
stopping guidelines
NA
Randomisation
Sequence
generation
8a Method used to generate the random allocation sequence 6
8b Type of randomisation; details of any restriction (such as blocking
and block size)
6
Allocation
concealment
mechanism
9 Mechanism used to implement the random allocation sequence
(such as sequentially numbered containers), describing any steps
taken to conceal the sequence until interventions were assigned
6
Implementation 10 Who generated the random allocation sequence, who enrolled
participants and who assigned participants to interventions
6
Blinding 11a If done, who was blinded after assignment to interventions (for
example, participants, care providers, those assessing outcomes)
and how
6
11b If relevant, description of the similarity of interventions NA
continued
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TABLE 27 Consolidated Standards of Reporting Trials 2010 checklist of information to include when reporting a
randomised triala (continued )
Section/topic
Item
number Checklist item
Reported on
page number
Statistical methods 12a Statistical methods used to compare groups for primary and
secondary outcomes
11–13
12b Methods for additional analyses, such as subgroup analyses and
adjusted analyses
11–13
Results
Participant flow
(a diagram is
strongly
recommended)
13a For each group, the numbers of participants who were randomly
assigned, received intended treatment and were analysed for the
primary outcome
15–16
13b For each group, losses and exclusions after randomisation, together
with reasons
16
Recruitment 14a Dates defining the periods of recruitment and follow-up 7
14b Why the trial ended or was stopped NA
Baseline data 15 A table showing baseline demographic and clinical characteristics
for each group
17–18
Numbers analysed 16 For each group, number of participants (denominator) included in
each analysis and whether the analysis was by original assigned
groups
16
Outcomes and
estimation
17a For each primary and secondary outcome, results for each group
and the estimated effect size and its precision (such as 95%
confidence interval)
20–23
17b For binary outcomes, presentation of both absolute and relative
effect sizes is recommended
NA
Ancillary analyses 18 Results of any other analyses performed, including subgroup
analyses and adjusted analyses, distinguishing pre-specified from
exploratory analyses
20–23
Harms 19 All important harms or unintended effects in each group
(for specific guidance see CONSORT for harms)
NA
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision
and, if relevant, multiplicity of analyses
65–66
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 66–68
Interpretation 22 Interpretation consistent with results, balancing benefits and harms
and considering other relevant evidence
66–68
Other information
Registration 23 Registration number and name of trial registry viii
Protocol 24 Where the full trial protocol can be accessed, if available 71
Funding 25 Sources of funding and other support (such as supply of drugs),
role of funders
viii
NA, not applicable.
a We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration
Document for important clarifications on all of the items. If relevant, we also recommend reading the CONSORT
Statement extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments,
herbal interventions and pragmatic trials. Additional extensions are forthcoming; for those and for up-to-date references
relevant to this checklist, see www.consort-statement.org.
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Appendix 3 Consolidated Standards of Reporting
Trials abstract checklist
Item Description Reported on line number
Title Identification of the study as randomised vii
Authorsa Contact details for the corresponding author vii
Trial design Description of the trial design (e.g. parallel, cluster,
non-inferiority)
vii
Methods
Participants Eligibility criteria for participants and the settings where the
data were collected
vii
Interventions Interventions intended for each group viii
Objective Specific objective or hypothesis vii
Outcome Clearly defined primary outcome for this report viii
Randomisation How participants were allocated to interventions vii
Blinding (masking) Whether or not participants, care givers and those assessing
the outcomes were blinded to group assignment
viii
Results
Numbers randomised Number of participants randomised to each group viii
Recruitment Trial status NA
Numbers analysed Number of participants analysed in each group viii
Outcome For the primary outcome, a result for each group and the
estimated effect size and its precision
viii
Harms Important adverse events or side effects NA
Conclusions General interpretation of the results viii
Trial registration Registration number and name of trial register viii
Funding Source of funding viii
NA, not applicable.
a This item is specific to conference abstracts.
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Appendix 4 The CollAborative DEpression Trial
ethics documents
GP Headed paper 
 
Dear Patient 
 
Treatment of depression in primary care 
 
At this surgery we have decided to take part in a research study being co-ordinated at SITE DETAILS 
which may be of interest to you.  A new treatment is being tested called Collaborative Care for 
depression and is explained in the leaflet that comes with this letter.  Please take the time to read this 
and consider if participating in this research would be right for you. 
 
As stated in the information sheet, if you are interested in participating in the study please complete the 
“permission for researcher to contact” form and send it free post to the address given. If you have any 
questions, or are interested in finding out more about the study please ring the research team on the 
number listed.  
 
In the next week or so you may receive a call from the surgery to check that you have received this 
letter and to ask if you are interested.  To help the surgery please let the practice know if your telephone 
number has changed. 
 
If you are certain that you do not want to take part in the research you may return the slip at the bottom 
of this letter to the surgery and you will not be contacted again. 
 
Thank you for taking the time to read this letter. 
 
Yours sincerely, 
 
 
 
Surgery GP’s name 
 
 
---------------------------------------------------------------------------------------------- 
 
 
I DO NOT want to take part in this study and DO NOT want a follow-up call 
 
Name: 
 
Signature: 
 
Please return to GP SURGERY ADMINISTRATOR NAME, at SURGERY NAME 
(CADET:  Collaborative Depression Trial) 
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Collaborative Depression Trial (CADET) 
Treatment of Depression in General Practice 
 
We are looking at a new treatment called collaborative care which has been shown to be very helpful in the 
treatment of depression.  We are writing to you because your GP surgery has agreed to help us with this and 
you have visited your GP reporting symptoms experienced by many people with depression.  This letter asks 
you to consider taking part in the research study. 
 
What is the treatment that is being tested? 
The new treatment is called Collaborative Care for Depression. People receiving Collaborative Care are 
allocated a case manager who is a health worker specially trained to help people with depression, they will 
help to organise your care and give you advice on overcoming depression.  You will still carry on seeing your  
GP to help you deal with your depression but you will also regularly speak to this case manager.  The case 
manager will have more time to discuss the management of your care and will offer advice about medication 
and explain some things you can do to start to make you feel better.  The case manager will see you face to 
face initially, at a time and place to suit you, and the meeting will usually take about 40 minutes.  After this 
first meeting, you will usually speak to the case manager over the telephone, but there is the opportunity for 
more face to face meetings if you wish.  They will arrange to call you at regular times to support you in your 
treatment.  These calls take about 15 minutes, and will be booked at times that you find easiest.  Usually, they  
will call you once a week for the first month and then once a fortnight for the next three months, but how 
often they call is totally up to you.  You will have contact with the case manager for four months. 
 
What will happen to me if I take part? 
This study is a randomised controlled trial. Sometimes, because we do not know which way of treating 
patients is best, we need to make comparisons. We are asking people from a number of different GP surgeries 
in the area if they would like to take part.  Every patient who takes part in the study will continue to have their 
treatment managed by their GP, but people from half of the GP surgeries will also receive Collaborative 
Care.  What we do is compare the progress and experiences of patients who received collaborative care with 
those who didn’t.  The decision about whether a surgery will offer collaborative care is made totally by 
chance, and you will not know which group your GP surgery is in until you decide to take part in the study.  
So it is important to note that half of the people who agree to take part will be receiving exactly the same 
treatment as they would be if they chose not to take part in the study, that is, they will not be receiving 
Collaborative Care.   
 
We would also want to meet you to ask you some questions about how you are feeling and we will ask you to  
fill out some short questionnaires.  We try to see everyone three times, once when they agree to take part and 
then four and twelve months later.  These meetings will take between 45 and 90 minutes.   
 
Will my taking part in this study be kept confidential? 
All information collected about you during the course of the research will be kept strictly confidential.   
 
How do I find out more? 
This is a very short summary about the study, if you would like to find out more then you can return the 
‘permission for researcher to contact’ form or call site researcher on xxxxx.  Someone working on the study 
will then send you more information about this study and arrange a time to meet you to answer any questions 
that you may have.   
 
Thank you for reading this and for considering taking part in this study. 
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Permission for researcher to contact 
 
Patient’s GP Surgery name: 
 
 
I confirm that I have read and understand the summary sheet for the above study and am happy for a 
researcher to contact me to discuss whether or not I would like to take part. 
 
I understand that my participation is voluntary and that I am free to withdraw at any time without giving any 
reason, without my medical care or legal rights being affected. 
 
 
Name          __________________________________________________________ 
 
Address      __________________________________________________________ 
 
____________________________________________________________________ 
 
Signature    __________________________________________________________ 
 
Telephone contact details   Day        ______________________________ 
 Evening  ______________________________ 
 Mobile   ______________________________ 
 
Email address___________________________________________________________ 
 
 
Return in enclosed pre-paid envelope to: 
Relevant site details here – including phone number 
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Participant Information Leaflet 
  
 
 
 
 
 
 
 
Collaborative Depression Trial (CADET) 
 
Treatment of Depression in General Practice 
 
 
You are being invited to take part in a research study.  Before you decide whether you want 
to take part or not it is important for you to understand why the research is being done and 
what it will involve.  Please take time to read the following information carefully and discuss 
it with others if you wish.  Ask us if there is anything that is not clear or if you would like 
more information.  Take time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
 
Depression causes misery to many people and is a major health problem in the UK. Although 
effective treatments are available, many people do not have access to them and we are always 
looking for treatments that are easier and quicker for patients to receive.  New ways of 
organising treatment have been developed in the United States but we do not know if they are 
better than usual care in the UK. Therefore, this study will investigate a way of organising the 
way we deliver treatment for depression. This is called ‘collaborative care for depression’ and 
it is being compared with the usual care given by GPs.  
 
Why have I been chosen? 
 
Your GP surgery is taking part in this trial and you have recently visited you GP reporting 
symptoms experienced by many people with depression.  This letter asks you to consider 
taking part in this research study. 
 
Do I have to take part? 
 
It is entirely up to you to decide whether or not to take part.  If you do decide to take part you 
will be asked to sign a consent form.  You will still be still free to withdraw at any time and 
without giving a reason.  A decision to withdraw at any time, or a decision not to take part, 
will not affect the standard of care you receive in any way. 
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What is the treatment that is being tested? 
 
The new treatment is called Collaborative Care for Depression. People receiving 
Collaborative Care are assigned a case manager who is a health worker specially trained to 
help people with depression.  Case managers help to organise the person’s care and will give 
them advice on overcoming depression. For example, the case manager may advise about 
medication or explain some very simple ways that a person can help themselves to start to 
feel better.  Case managers see people face to face initially, at a time and place to suit them, 
and the meeting will usually take about 40 minutes.  After this first meeting, they will 
telephone the person at regular times to support them in their treatment, these calls take about 
15 minutes, and will be booked at times to suit the patient.  Usually, the case manager will 
call once a week for the first month and then once a fortnight for the next three months, but 
how often they call is totally up to the patient.  Patients have contact with the case manger for 
four months. 
 
What will happen to me if I take part? 
 
This study is a randomised controlled trial. Sometimes, because we do not know which way 
of treating patients is best, we need to make comparisons. We are asking people from a 
number of different GP surgeries in the area if they would like to take part.  Every patient 
who takes part in the study will continue to have their treatment managed by their GP, but 
people from half of the GP surgeries will also receive Collaborative Care.  What we do is 
compare the progress and experiences of patients who received collaborative care with those 
who didn’t.  The decision about whether a surgery will offer collaborative care is made 
totally by chance, and you will not know which group your GP surgery is in until you decide 
to take part in the study.  So it is important to note that half of the people who agree to take 
part will be receiving exactly the same treatment as they would be if they chose not to take 
part in the study, that is, they will not be receiving Collaborative Care.   
 
What information do you need from me? 
 
If you agree to take part in the research the first thing we will want to do is to find out about 
you. We will need to ask about your current and past mental health as well as your life more 
generally.  We have already arranged to meet with you at site details, if you are happy to take 
part in this study we will ask you some questions about how you have been feeling recently 
and there will be a few questionnaires that we would like you to fill out.  You will also have 
an opportunity to ask any questions you may have about the study.  This meeting will take 
about 90 minutes.   
 
We would then arrange to see you in four and twelve months time.  These meetings will be a 
little shorter as they only involve you filling out some questionnaires.  We expect these 
meetings to take about 45 minutes.  We also need to collect some information from your 
medical records. The research study will last for two-and-a-half years, but your involvement 
will only be for twelve months.    
 
We are also interested in finding out what it was like to be part of this study and will be 
giving a small number of you the opportunity to describe your experiences of the treatment 
and the ways in which you think it could be improved.  To do this, we will ask some of you 
to agree to a longer interview of about 60 minutes.  If you agree, we would like to tape record 
this interview.  The tapes will be given a code and securely stored for a maximum of 20 years 
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before being destroyed.  We will also make typed copies of the taped conversations. We will 
ensure all information in these copies is anonymous by removing all named references to you 
or your family and friends from the copies.   
 
We want to make sure that all patients are offered the best service possible, so in a bid to 
maintain quality we would like to tape record some of the contact sessions with the case 
managers.  This is so that we can check the quality of the advice given to you by the case 
manager.  The tapes will be given a code and securely stored for a maximum of 20 years 
before being destroyed.  We will also make typed copies of the taped conversations. We will 
ensure all information in these copies is anonymous by removing all named references to you 
or your family and friends from the copies.  However, if you would rather they weren’t taped, 
you can refuse. This will not affect your care at all and you can still take part in the study. 
 
Will I have to do anything differently? 
 
There are no restrictions in your lifestyle from taking part in this research. You should 
continue to follow the advice of your GP. 
 
Are there any side effects, disadvantages and risks of taking part? 
 
We are not aware of any side effects, disadvantages or risks to you of taking part in this 
research. 
 
What are the possible benefits of taking part? 
 
We hope that both the new treatment and usual care from your GP will help you. The 
information we get from this study may help us to treat future patients with depression better. 
 
What happens when the research study stops? 
 
Throughout the study and afterwards, your GP will continue to treat you as s/he feels is best 
for you and with your agreement. 
 
What if something goes wrong? 
 
We do not expect any harm coming to you from being in this study. However, if you wish to 
complain, or have any concerns about any aspect of the way you have been approached or 
treated during the course of this study, the normal National Health Service complaints 
mechanisms are available to you. 
 
Will my taking part in this study be kept confidential? 
 
All information collected about you during the course of the research will be kept strictly 
confidential.  Any information about you that is collected from the questionnaires or 
interviews will have your name and address removed so that you cannot be recognised from 
it. As your GP is involved in your treatment, s/he will be informed of your progress as part of 
the research study, with your permission.  Should your condition worsen to a point where it is  
felt by either a researcher or the case manager that you may be a danger to yourself or others, 
your GP will be informed of this, with or without your permission.  However, this is the only 
time we would ever break confidentially.  
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What will happen to the results of the research study? 
 
We will publish the results of this research study widely. As well as producing a research 
report and writing articles for health professionals to read, you will be given a summary of 
the findings on request at the end of the trial in 2012. To request the study summary and 
articles please contact Prof. David Richards, whose details are at the end of this information 
leaflet.  We will also ensure patient organisations such as Depression Alliance are informed 
of the results of the trial. You will not be personally identified in any publications from this 
trial. 
 
Who is organising and funding the research? 
 
The Medical Research Council has funded this research study. Your GP is not being paid any 
extra money for being involved in the study. 
  
Who has reviewed the study? 
 
This research study has been reviewed and approved by the South West Research Ethics 
Committee. 
 
Next Steps 
 
An appointment has been arranged for you to come and see site details and during this 
meeting you will have the chance to ask any questions you have.  If you are still happy to 
take part in the study we will ask you to sign a form to say so and then get you to fill out 
some questionnaires about yourself. 
 
If you need further information to help you decide, please contact Professor Dave Richards at 
the address below.  
 
Thank you for reading this and for considering taking part in this study. 
 
Contact for Further Information 
 
If you need further information about this study please contact: 
 
David Richards 
Professor of Mental Health Services Research 
School of Psychology 
University of Exeter 
 
Office: XXXX  
Email:  XXXX  
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CONSENT FORM       Patient Identification  
Number for this trial: 
 
   
Site Details 
 
 Please initial box 
1.  I confirm that I have read and understand the information sheet 
dated .........................  (version ............) for the above study and have had the 
opportunity to ask questions. 
 
2.  I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights 
being affected. 
 
3.  I agree to take part in the above study. 
 
 
 
4.  I agree to my GP being informed of my participation in this study. 
 
 
 
5.  I understand that research staff will contact my GP or specialist if they feel 
that my condition has deteriorated and further action is needed  
 
 
In addition to the above, I would also be prepared to consent to the following; 
 
6.  I understand that sections of any of my medical notes may be looked at by 
research staff.  I give permission for these individuals to have access to my 
records. 
 
7. If my surgery is one where collaborative care is offered, I am willing to have 
some of my sessions with the health worker tape recorded. 
 
8. I am willing to be interviewed about my experiences of taking part in the 
study and for this interview to be tape recorded. 
 
 
When you have initialled all the boxes above, please complete below, including the date yourself: 
  
Name of Patient _____________________________________________________                    __ 
 
 
Signature ____________________________________           _____ Date____________________ 
 
 
Name of Person taking consent _____________________________________________________ 
 
 
Signature ____________________________________           _____ Date____________________ 
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Multi-Centre Randomised Controlled Trial of Collaborative 
Care for Depression 
  
Serious Adverse Event 
 
A Serious Adverse Event (SAE) is defined in accordance with ICH/GCP as “Any 
untoward medical occurrence that:  
· Is fatal or life threatening  
· Requires hospitalisation or prolongs existing hospitalisation  
· Results in significant or permanent disability or incapacity  
· Is a new primary cancer  
· Is a congenital anomaly or birth defect  
· May jeopardise the patient and may require medical or surgical intervention to 
prevent one of the outcomes listed above”  
 
Even in a clinical trial of a non-investigational medicinal product (non-CTIMP) like 
CADET the study investigator should report any SAE that is both related to the 
research procedures and is unexpected. An immediate report (within 24 hours) 
must be made orally or in writing to the Research Sponsor (University of Exeter). The 
immediate report must be followed by a detailed written report on the event. This 
report must also be sent to our main REC (South West REC) within 15 days of the CI 
becoming aware of the event. 
 
If you are alerted to an SAE that is both related to CADET research procedures and is 
unexpected, please telephone the CADET coordinating centre immediately, and fax 
the CADET disclosure/adverse event recording form to XXXX, so that both 
the Sponsor and the Main REC can be notified within the relevant time period. 
 
Recording adverse events 
 
1 At both 4 and 12 month assessments serious adverse events that might have occurred 
since the previous visit should be elicited from the participant. If a participant (or a 
patient’s GP or next of kin) discloses a serious adverse event please document it using 
the CADET disclosure/adverse event recording form. As CADET is a non-CTIMP we 
are not required to log all non-serious adverse events, however the CADET 
disclosure/adverse event recording form allows researchers to record other adverse 
events when it is not immediately clear that it falls into the “Serious Adverse Event” 
category, or which causes concern. 
2 General completion guidelines: 
3 Ask patient the date and start and stop time of event.  If the patient cannot 
remember, then as near as possible. Document the outcome of the event and any 
actions taken. Confirm it with your site lead and have them countersign it. 
4  
Please note that ALL instances where the risk protocol is enacted must be recorded in 
the usual manner on the CADET Risk Form and countersigned by the site lead or their 
nominated deputy. 
DOI: 10.3310/hta20140 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 14
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Richards et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
189
CADET Disclosure/Adverse Event Recording Form 
 
Date of Incident: Patient ID: Patient Initials: Sex: 
Details of disclosure 
 
 
 
 
 
 
 
 
 
 
Outcome: 
 
 
 
 
Please indicate type (tick all that apply): 
Self harm:  Hospitalisation or prolongation of 
hospitalisation 
 
Life threatening  Persistent or significant disability or 
incapacity 
 
Death:  
 
Other  
 
ADDITIONAL RELEVANT INFORMATION 
 
 
 
 
 
 
 
Action taken by research team (if any) 
 
 
 
 
Name of Researcher 
(BLOCK CAPITALS)  
 
Date 
 
 
 
Signature 
Name of  PI 
(BLOCK CAPITALS)  
 
Date 
 
 
 
Signature 
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Report of Serious Adverse Event (SAE) 
 
The Chief Investigator should report any SAE that is both related to the research 
procedures and is unexpected. Report the SAE to the sponsor within 24 hours and 
send the Report to the Research Ethics Committee that gave you favourable opinion 
of the research within 15 days of the CI becoming aware of the event. 
 
1. Details of Chief Investigator 
Name Prof David A Richards 
Address Mood Disorders Centre 
School of Psychology 
Washington Singer Laboratories 
University of Exeter 
Telephone  
Email   
Fax   
 
2. Details of study 
 
Full Title of Study Multi-Centre Randomised Controlled 
Trial of Collaborative Care for 
Depression 
Name of Main REC South West Research Ethics Committee 
Main REC reference 09/H0206/1 
Research Sponsor University of Exeter 
Sponsor’s reference for this report (if 
applicable) 
 
 
3. Type of Event 
Please categorise this event, ticking all appropriate options 
Death ⁪ Life Threatening ⁪ Hospitalisation or 
prolongation of 
hospitalisation ⁪ 
Persistent or significant 
disability or incapacity ⁪ 
Congenital anomaly or 
birth defect ⁪ 
Other ⁪ 
 
4. Circumstances of the event 
 
Date of SAE  
Location  
Describe the circumstances of the event  
 
 
 
(attach copy of detailed report if 
necessary) 
 
XXXX
XXXX
XXXX 
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What is your assessment of the 
implications, if any, for the safety of 
study participants and how will these be 
addressed? 
 
 
5. Declaration 
 
Signature of Chief Investigator  
Print Name  
Date of submission  
 
6. Acknowledgement of receipt by main 
The South West Research Ethics Committee acknowledges receipt of the above 
 
Signed  
Name  
Position on REC  
Date  
 
Signed original to be sent back to Chief Investigator (or other person submitting the 
report). Copy to be kept for information by main REC
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